Aspects of The Short Term Oral Toxicity of Citral in Two Strains of Rat. by Jackson, Graham Maudslay.
Aspects of the Short Term Oral Toxicity 
of Citral in Two Strains of Rat.
by Graham Maudslay Jackson, BSc., MSc., GIBiol
Thesis submitted to the University of Surrey 
for the degree of Doctor of Philosophy.
November 1985
ProQuest Number: 27598761
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com p le te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest
ProQuest 27598761
Published by ProQuest LLO (2019). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLO.
ProQuest LLO.
789 East Eisenhower Parkway 
P.Q. Box 1346 
Ann Arbor, Ml 48106- 1346
Summary
The short-term oral toxicity of the food and 
cosmetics additive, citral was studied in Wistar albino 
and Long Evans hooded rats with special emphasis on the 
effects upon blood coagulation and hepatic enzymes.
The maximum tolerated, non-lethal dose was found to 
be 2.4 g/kg by the dietary and the gastric intubation 
routes of administration. Citral was found to produce a 
slight prolongation of the thrombotest clotting time in 
hooded but not albino rats. Citral also produced 
dose-related hepatomegaly by initial hyperplasia followed 
by hypertrophy. Histopathologically, citral caused
periportal accumulation of lipid and centrilobular 
depletion of glycogen.
Co-administration of citral and warfarin produced 
30% mortality in the hooded rats with no effect in the 
albino rats. Pretreatment with citral increased the 
metabolism of warfarin, especially in albino rats. It is 
suggested that albino rats have a higher control level of 
cytochrome P-450 than hooded rats, but that it is more 
inducible in hooded rats.
Due to structural analogy to fatty acids and the 
hepatic lipid accumulation, proliferation of hepatic 
peroxisomes and mitochondria with induction of 
p-oxidation was studied in both strains of rat following
citral aaministration. Citral did indeed induce
peroxisomal p-oxidation with proliferation of 
peroxisomes, smooth endoplasmic reticulum and 
mitochondria; however, there was no hypolipidaemic 
activity. It is thought that citral may be unique in 
this respect. It is suggested that the p-oxidation is 
important in the metabolism of citral and other 
peroxisome-proliferating compounds. Citral also caused 
induction of CsO and ^ - 1 -oxidation; this may also be 
important with regard to citral metabolism.
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Glossary
The following abbreviations were used in this thesis
ADI Allowable Daily Intake
BSA Bovine Serum Albumin
CAS Chemical Abstracts Services
CRF Code of Federal Regulations
ED5 Q Median Effective Dose
FDA Food and Drug Administration
FEMA Flavour Extract Manufacturers Association
GRAS Generally Regarded as Safe
HSA Human Serum Albumin
iu International Units
JECFA Joint Expert Committee on Food Additives
LD50 Median Lethal Dose
MS Mass Spectroscopy
PAGE Polyacrylamide Gel Electrophoresis 
PCA Perchloric Acid
PSI Pounds per Square inch (Ib/in^)
RBC Red Blood Cell
RBP Retinol Binding Protein
RSA Rat Serum Albumin
SDS Sodium Dodecyl Sulphate
All other abbreviations used were standard.
Statistics
All data presented in this thesis were subjected to 
statistical analysis by Students' t-test using the 
formula
t = %1 - %2
y(SEM2 + SEm 2)
with ( n]^ + n2 - 2 ) degrees of freedom
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Section I
General Introduction
Chapter 1
The acyclic monoterpenoid, citral, has been in 
commercial use since the early 1900's. It is an 
important food and cosmetics additive with a strong lemon 
aroma and was given GRAS status by FEMA (1965) (number 
2303). It is approved by the FDA for food use (GRAS 21, 
CRF 182.60) and was listed by the Council of Europe 
(1974) with an ADI of 5 mg/kg. The Food Chemical Codex 
(1972) published a monograph on citral and the JECFA 
(1980) allocated a group ADI of 0-0.5 mg/kg to citral and 
some structurally related terpenoid flavours. The Food 
Additives and Contaminants Committee (1976) concluded 
that citral was acceptable for use as a food flavouring 
at levels up to 50 ppm whilst noting that the 
toxicologically acceptable level could be higher. The 
CAS Registry Number is 5392-40-5.
As a monoterpenoid, citral has 10 carbon atoms and 
is found naturally, principally in the volatile or 
essential oils of plants and trees. Like all terpenoid 
compounds, it is formed from a common 5 carbon atom 
isoprene unit. The synthesis, toxicity and biological 
activity of citral are reported in this introduction.
1.1 Terpenoids
Fundamental investigations by Tiemann and Semmler in 
Germany and Barbier and co-workers in France between 
1890-1900 involving chemical analysis of plant and animal 
material revealed the occurrence of a large number of 
compounds with a molecular structure which could be 
constructed from isoprene or isopentane units. This type 
of structure appears frequently- in volatile oils of 
plants, the so called "essential oils". The occurrence 
of this type of compound in oil of terpentine impressed 
upon them the name of "terpenes".
The terpenes nearly always obey the Isoprene Rule of 
Wallach (1887) - certain substances are constructed of
isoprene skeletons and therefore probably arise by the 
natural polymerization of isoprene. Such compounds were 
then called isoprenoid (figure 1 .1 ).
There are eight terpene classes (table 1.1). The 
simpler mono-(Cio) sesqui-(Cp5 ) terpenoids are found
principally in the volatile or essential oils of plants 
and trees. Diterpenoids (C2 0 ) and triterpenoids (C3 0 ) 
occur most notably in plant and tree gums and resins. 
Figure 1.2 represents the biosynthesis of terpenes and it 
shows the relationship between the different classes from 
a common C 5 isoprene stucture.
1.2 Monoterpenoids
The main source of monoterpenes is the essential
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Table 1.1
The Terpenoid Classes (from Haagen-Smit and Nimmo, 1963)
NUMBER OF CARBON ATOMS TERPENOID CLASS
Hemiterpenes
10 Monoterpenes
15 Sesquiterpenes
20 Diterpenes
25 Sesterterpenes
30 Triterpenes
40 Tetraterpenes
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oils obtained from plants by steam distillation followed 
by extraction with low boiling point solvents, fats or by 
pressing. A large percentage of many oils consists of 
hydrocarbons and oxygen-containing derivatives which can 
be constructed from two isoprene units and, with 
monoterpenes, the so-called "head-to-tail" arrangement of 
isoprene units predominates.
The structure of geraniol was discovered in 1890 by 
Semmler, although it was first separated in it's pure 
state by Jacobsen in 1871 from Turkish geranium oil. The 
series of structures related to geranial through 
dehydrations, hydrogenation and the introduction of 
oxygen, form the acyclic monoterpenes. Examples are the 
olefin myrcene, the alchol citronellol and the aldehyde 
citral. The double bond between carbon atoms 2 and 3 of 
geraniol makes the existence of cis - and trans-isomers 
possible. However, the trans-isomer predominates as it 
does with most other <=<, p - unsaturated aldehydes because 
the resonance energy of the tT- electron is larger in the 
trans - than in the cis - isomer, so making the trans­
isomer more stable (Schauenstein et al., 1977). The 
relative ease of ring formation allows one to distinguish 
between these forms, which have been called nerol and 
geraniol according to the origin from oil of neroli 
(first isolated by Hesse and Zeitschel in 1902) or oil of 
geranium respectively.
The work presented here is concerned with the
toxicity of the acylic monoterpene aldehyde, citral, 
which has been described as the most important member of 
the aliphatic terpenes (Simonsen, 1947).
1.3 Citral
Citral, or cis - and trans - 3,7 - dimethyl - 2,6 - 
octadien - 1 - al, is a mixture of two isomers, geranial 
and neral in the proportion of 6 6 % geranial (trans­
isomer) to 34% neral (cis-isomer). The structure, 
discovered in 1895 by Tiemann and Semmler, is represented 
in figure 1.3 with the physical/chemical properties 
summarised in table 1 .2 .
1.3.1 Occurrence
Citral was first isolated by Bertram in 1888 from 
the oil of Backhousia citriodora in amounts of between 
95-97%. It has also been found in lemongrass oil 
(Cymbopogon flexuosus [Nees.] Stapf.) in amounts of up to 
75%, C .citratus, Litsea citrata ( 90%), L. cubeba.
Blume. (^ 70%), Lindera citriodora (^ 65%), Calypranthes 
parriculata ( 62%), Leptospermum liversidgei var. A.
leaves (/^  70-80%) and Ocimum gratissimum (/-^ 6 6 % ). It is 
also present in lime (6 - 9%), lemon (2 - 5%) and Citrus 
aurantifolia leaves (petitgrain, 36%), (Fenaroli's
Handbook of Flavour Ingredients, 1975).
1.3.2. Preparation and Uses
Citral is produced either synthetically by chemical 
means (Saucey et al., 1959; Rabinowitz et al. , 1974;
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Table 1.2
A Summary of the Physical and Chemical Properties 
of Citral (adapted from several sources, see below).
Physical/Chemical Propterties Citral
Appearance Mobile, pale yellow liquid
Molecular weight 152.24
Boiling point 103-104*C at 12mm Hg from 
lemon
106-107°C at 12mm Hg from 
lemongrass
Specific gravity 0.885 - 0.891 at 25°C
Refractive index 1.486 - 1.489 at 20°C
Solubility Soluble in fixed oils, 
mineral oil, propylene 
glycol and most organic 
solvents. It is sparingly 
soluble in water and 
insoluble in glycerin.
Organoleptic characteristics Strong, lemon-like odour, 
characterstic, bittersweet 
taste.
Assay for food use Not less than 96% of CigH^^O
Adapted from Food Chemicals Codex, 1972; Fenarolis' 
Handbook of Flavour Ingredients, 1975; Opdyke 1979; 
Steltenkamp et al. , 1980 and the Encyclopedia of the
Terpenoids, 1982.
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Table 1. 3a
Fragrance uses of Citral (after Opdyke, 1979)
Soap Detergent Creams Perfume
Usual 0 . 0 2 0 . 0 0 2 0.005 0 . 2
Maximum 0 . 2 0 . 0 2 0 . 2 0 . 8
The figures represent the concentration of citral in the 
final product (percent).
Table 1.3b
Consumable uses of Citral (From Fenarolis' Handbook of 
Flavour Ingredients, 1975).
Foodstuff Citral Concentration - ppm
Non-alcohlic beverages 9.2
Ice cream etc. 23.0
Confectionery 41.0
Baked goods 43.0
Chewing gum 170.0
10
Pauling et al., 1976; Suzuki et al., 1983; Alexakis 
et al., 1984) or is obtained from natural sources. The 
products from the different sources are used 
interchangeably in the fragrance industry and 
specifications do not distinguish between them.
It is one of the most important raw materials of the 
essential oil, flavour and cosmetics industry. Citral is 
used extensively for the compounding of synthetic 
flavours, for the scenting of soaps and toiletries and 
for the preparation of numerous perfume compositions 
(table 1.3). Use in frangrances in the USA was 
approximately 34,000 kg/yr (Opdyke, 1979).
Large quantities of citral serve as the starting 
material for the manufacture of ionones and methyl 
ionones, vitamin A and other polyene compounds (Levi and 
Laughton,1959).
1.3.3 Acute Toxicity
The oral LD5 0 for rats was reported as being 4.96 
g/kg b.w. with depression followed by death within 4 
hours - 4 days (Jenner et al., 1964). The acute toxicity 
appears to be species dependent, and in addition, the 
route of administration of citral is important when 
considering acute toxicity data. The oral LD50 for mice 
has been reported as 150 mg/kg b.w. (Boyland 1940) with 
an intraper itoneal LD5 0 in mice reported as being 440 
mg/kg b.w. (Zollner and Esterbauer, 1973). However, Le
11
Bourhis and Soenen (1973) gave a maximun non-lethal oral 
dose of citral of 900 mg/kg b.w. for mice; it is unusual 
for the oral toxicity to be greater than via the 
intraperitoneal route and suggests a large strain 
difference between the mice used by Boyland (1940) and Le 
Bourhis and Soenen (1973). The latter workers also 
reported a maximum non-lethal dose of 250 mg/kg by the 
intraperitoneal route of administration of citral. This 
is in the same order of magnitude and tends to agree with 
the LD5 0 value quoted by Zollner and Esterbauer (1973). 
The dermal LD5 Q in rabbits was reported as 2.25 g/kg 
b.w. (1.39 - 3.11 g/kg) (Moreno, 1974), a figure that is 
less than half of the reported oral LD5Q for rats. This 
suggests that rabbits are more susceptible to the toxic 
effects of citral than rats. Indeed, Leach and Lloyd 
(1956a) reported increased ocular tension in rabbits 
given a single subcutaneous dose of 5pg citral/kg and 
in monkeys receiving oral doses of 0.7 jug/kg b.w./day 
for two weeks.
1.3.4 Short Term Toxicity
Administration of citral and geraniol in the diet at 
concentrations of 10,000, 2,500 or 1,000 ppm for 13 weeks 
to rats produced no macroscopic effects (Hagan et al. , 
1967). In a 12 week feeding study, no adverse effects 
were reported in male and female rats fed 50 mg/kg b.w. 
citral per day (Wood, 1981, cites Oser, 1967). No data 
for chronic toxicity of citral has been published.
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1.3.5 Reproduction and Teratogenicity
Citral administered at 300 mg/kg intraperitoneally 
or 460 mg/kg b.w. topically for 60 or 100 days reduced 
the number of normal follicles in female rats (Toaff ^  
al. , 1979). In addition, the reproductive performance
was reduced with a reduction in implantation numbers and 
an increase in post-implantation foetal wastage.
Several studies have examined the malformations 
occurring following citral administration (30 ug/egg or 
at a concentration of 0.05M) into the suproblastodermic 
space of chick embryos on day 3 of incubation. On day 6 
of incubation, the allantoic fluid of malformed embryos 
was more acidic compared to controls; by day 1 2 , normal 
values were recorded again. Electron microscopy
detected phocomelia and amelic legs on day 1 2 suggesting 
that citral interfered with myofibrilogenesis of striated 
muscle during the early gestation period. Morphological 
changes in the ectoderm and mesoderm of micromelic and 
amelic limbs after 24, 48 and 72 hours were related to
the severity of the malformation (Opdyke, 1979 cites 
Abramovici, 1973; Abramovici et al., 1973; Rachmuth et 
al. , 1974; Sporn et al., 1975). At a concentration of
0.05M, citral injected into eggs on day 3 produced 
various solitary limb and multiple malformations, 
principally micromelia, phocomelia and olig-odactylia. 
These became apparent after 36 hours in 74 out of 123 
embryos. Localization of the malformation near the site 
of administration suggested a local irritant effect
13
(Abramovici, 1972). No data is available on teratogenic 
effects of citral in mammalian species.
1.3.6 Metabolism of Citral
Studies on the absorption, distribution and 
excretion of C^ '^ C] citral in the rat and mouse gave no 
evidence for long-term storage of citral in the body and 
thusy any hazards associated with tissue accumulation 
after prolonged exposure would be expected to be minimal 
(Phillips et al., 1976; JECFA, 1980). In rats, single 
oral doses of 5, 770 and 960 mg/kg b.w. were largely
excreted within 72 hours mainly in the urine ( ^  0.5% as 
unchanged citral) but also to a significant extent in the 
faeces and via the lungs. Retention of radioactivity was 
more prolonged in the liver (1.5 - 2.0% after 24 hours) 
compared to the rest of the body, except for the 
gastro-intestinal tract. Autoradiographic studies in 
mice following a single dose of 1 0 0 mg/kg b.w. indicated 
rapid absorption and uniform distribution throughout the 
body by 1 2 hours with most radioactivity being excreted 
within 120 hours, mainly in the urine. This indicates 
slower excretion of citral by the mouse compared to the 
rat with consequential differences in the toxic response, 
the mouse being more susceptible than the rat. The 
studies suggested that biliary excretion might be 
involved in the metabolism of citral. JECFA (1980), 
however, reported that there was little enterohepatic 
circulation with citral, except at high doses. Linalool, 
although structually related to citral, more readily
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forms the glucuronide and thus enterohepatic circulation 
occurs to a greater extent (Parke et al., 1974a).
Induction of enzymes by citral has been studied in 
vivo and such studies have suggested possible routes and 
mechanisms for citral metabolism. The mixed function
oxidase system, and more especially cytochrome P-450, has 
been implicated as a mediator in the metabolism of
citral.
By either intraperitoneal injection or admixture 
with the diet, administration of citral to rats for 3
days at 150 mg/kg b.w. resulted in a 25% increase in the
activities of biphenyl 4-hydroxylase, glucuronyl 
transferase and 4-nitrobenzoate reductase and in 
cytochrome P-450 in liver homogenates (Parke and Rahman, 
1969). Geraniol, the alcohol of the trans-isomer of 
citral, administered to rats at 600 mg/kg b.w. for 6 days 
by daily gastric intubation, resulted in a 38% increase 
in the activity of cytochrome P-450 and a similar 
increase in geraniol hydroxylase activity in liver 
microsomes (Chadha and Madyastha, 1984). Linalool 
induced cytochrome P-450 by 50% after administration to 
rats for 3 days at 600 mg/kg b.w. by gastric intubation 
(Chadha and Madyastha, 1984). The degree of cytochrome 
P-450 induction was the same as that reported by Parke e_t 
al. , (1974b), who administered linalool to rats at a dose 
of 500 mg/kg for 30 days.
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Licht and Coscia (1978), demonstrated
CO -hydroxylation of geraniol and nerol by a rabbit liver 
microsomal system containing cytochrome P-450. Kuhn and 
Livada (1933) suggested that citral suffered AT -p- 
saturation by asymmetric hydrogenation together with W- 
-oxidation in vivo. Hildebrandt (1901) and Williams 
(1959) identified two metabolites of citral, 2,6-dimethyl 
-2,6 -octadiendioic acid (Hildebrandt acid) and 2,6- 
dimethyl-2-octendioic acid (Dihydro-Hildebrandt acid). 
Chadha and Madyastha (1984) proposed a possible metabolic 
pathway for geraniol (figure 1.4). The reactions 
involved in the metabolism of geraniol include allylic 
oxidation (Asano and Yamakawa, 1950) and hydration of the 
2,3-double bonds. One route of metabolism suggests that 
geranic acid is a metabolite; however this has been 
identified as one of the acidic substances formed when 
citral spontaneously oxidises in air and as being 
responsible for the unpleasant odour of deteriorated 
citral; the other compound was 3,7-dimethyl-7-hydroxy-2- 
octenoic acid (Kimura et al., 1983a and b). This
suggests that the Hildebrandt acid is a more likely 
metabolic end product of geraniol and citral detoxi­
fication. In contrast, microbial degradation of geraniol 
is via p-oxidation (Seubert and Fan, 1964), with dimethyl 
-, acrylyl-CoA as the end product. To support this, 
Loomis (1967) reported that the C = C double bond o< to a 
carbonyl as found in citral, is also found in fumarate 
and acyl intermediates of fatty acid synthesis and 
P-oxidation (Loomis, 1967).
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1.3.7 Pharmacology
When citral was administered in an aqueous solution
II
containing 1% Tween 20 to mice, beha^oural (escape 
response) effects resulting gave EDgg values of 25-100 
mg/kg b.w. intraperitoneally and 400 mg/kg orally; the 
anticonvulsant ED50 values were 1 0 0 mg/kg b.w. intra­
peritoneally and 800 mg/kg b.w. orally (Le Bourhis and 
Soenen, 1973). Wood (1962) reported that citral did not 
prevent diet - induced hypercholesterolaemia in chicks 
and subsequently, Herzmann (1966) found that citral 
administered orally at 1 0 0 mg/kg b.w. for 1 week and then
at 200 mg/kg for 7 weeks to chicks fed an atherogenic
diet produced an increase in the aortic concentration of 
cholesterol greater than that in animals fed only the 
atherogenic diet. In addition, it has been shown that 
linalool does not inhibit cholesterol biosynthesis (Isler 
et al. , 1959).
At a concentration of 1.2mM, citral, in an in vitro 
system, produced 100% haemolysis of erythrocytes (Tamir 
et al., 1984). These workers suggested two possible 
mechanisms; either by a free radical mechanism, by
glutathione depletion or by a non-specific steroid 
terpenoid interaction with the erythrocyte membrane.
As outlined in section 1.3.3, increased ocular 
tension has been reported in rabbits and monkeys
following oral administration of citral at extremely low 
levels (1-5 pg/kg b.w.); damage to vascular endothelia
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was also reported (Leach and Lloyd, 1956a). Citral was 
considered to act as a vitamin A competitor in 
endothelial cells and a possible role of citral in 
glaucoma and cardiovascular disease in man was suggested 
(Leach and Lloyd, 1956b). These results were not, 
however confirmed by Laughton et al. , (1962) and in the
light of other toxicological data available, it would be 
unlikely that such a low dose would produce any effects 
in either species. A species specific response may 
explain the findings, especially since Leach and Lloyd 
(1956b) did not specify the species of monkey or the 
strain of rabbit used in their work. In addition, Redger 
et al., ( 1959) reported that citral was not a vitamin A 
inhibitor in glaucoma, an effect also suggested by Leach 
and Lloyd. Thus, although this work suggested some 
toxicological effects of citral relevant to man, the 
results should be treated with some caution.
1.3.8 Antagonism with Vitamin A
Differentiation was reported to be stimulated in 
cultured mucous cells with inhibition of ciliated cell 
differentiation at a citral concentration of 0.2-1.0mM 
(Aydelotte, 1963a). At 2.0-3.0mM, tracheal epithelium 
became stratified and occasionally keratinized. With the 
addition of vitamin A alcohol to the citral, the effects 
of vitamin A were inhibited and the effects of citral 
reduced. Citral, at a concentration of 0.2-0.3 mM, plus 
vitamin A, alone, or in combination, also altered the 
pattern of differentiation of chick - embryo oesophageal
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and corneal epithelium (Aydelotte, 1963b), supporting the 
original proposition of Leach and Lloyd (1956b) that 
citral may be an antagonist of vitamin A. In contrast, 
Abramovici (1972) found no antagonism between citral and 
vitamin A in chick embryos, indicating that the mode of 
action of citral was independent of that of vitamin A.
In studies on suckling - hamster trachea in organ 
culture (Crocker and Sanders, 1970), citral (2 or 4 mM) 
inhibited ciliary differentiation, but it did not produce 
squamous metaplasia. The incidence of squamous
metaplasia induced by benzo [a] pyrene may have been 
increased by the addition of citral. These workers 
proposed that citral produced tissue damage by 
interfering with vitamin A associated processes or by 
peroxidative destruction of vitamin A.
In whole skin slices of guinea pig ear, vitamin A 
increased the incorporation of C^^S] sulphate in muco­
polysaccharides and citral at a concentration of 100 mM, 
inhibited the effect of vitamin A (Barker et al., 1964).
Citral has a high affinity for REP (Hase et al. ,
1976) and thus it may prevent vitamin A binding so 
increasing the concentration of free vitamin A 
circulating in blood, and it is the free vitamin A that 
leads to hypervitaminosis A. In addition, it has been 
reported that citral causes dehelicization of albumin and 
alters peptide maps in both alcoholic and aqueous media
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(Bagdasar'yan and Troitskii, 1971); this may alter 
binding to albumin and so indirectly affect the free 
circulating vitamin A levels.
1.3.9 Sensitization and the Allergic Response
Experimental sensitization to citral has been 
successful in man (Steltenkamp et al., 1980), but 
unsuccessful with lemongrass oil (natural citral and 
limonene in the ratio of 4:1) (Opdyke, 1976). 
Steltenkamp et al., (1980) reported that citral could not
be identified as being responsible for any elicited or 
induced reaction in patch tests with consumer products or 
fragrance blends containing citral.
In citral sensitized animals, more [14^] label was 
found in the soluble skin protein extracts when citral 
and limonene were applied to the skin; with citral and 
limonene sensitized animals, the same trend was found 
(Barbier and Benezra, 1983). The authors suggested that 
limonene may alleviate the allergic reaction to citral, a 
conclusion that is supported by Opdyke (1976). In guinea 
pig tests using the Beuhler method, the sensitization 
reaction was not inhibited in the presence of d-limonene 
(Suskind and Majeti, 1976).
1.3.10 Cytotoxicity of Citral
The anticancer activity of citral was first studied 
by Boyland and co-workers, (Boyland and Mawson, 1938; 
Boyland, 1940). The authors showed that citral retarded
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the growth of spontaneous tumours and of inoculated 
tumours in mice. The corresponding monocarboxylic and 
dicarboxylic acids were inactive which indicated that the 
CŸ ,p-unsaturated aldehyde grouping was responsible for 
the carcinostatic action. Citral was also quite active 
towards tumours in man. Carcinoma of the stomach 
responded best to treatment with citral (Osato, 1965). 
Of the other tumours treated (uterus, pancreas, liver or 
lung carcinoma) only lung cancer responded significantly 
to citral treatment.
Field and Roe (1965) investigated forestomach tumour 
promotion by citral-containing citrus oils in mice. With 
benzo [a] pyrene and 7,1 2-dimethylbenz [a] anthracene 
administered by a single oral dose of 12.5 or 50 jjg and 
1 0 0 or 2 0 0 ug respectively, lime oil and orange oil only 
gave rise to a few tumours, so suggesting that these 
oils, and citral, were not tumour - promoting agents. 
This contrasts with the results of Crocker and Sanders, 
(1970) who reported an increase in metaplasia (see 
section 1.3.8). In addition, Abramovici et al., (1982) 
reported that 185 pg/kg citral administered topically for 
3 months to rats produced sebaceous gland lobules and 
hyperplasia together with prostate gland hyperplasia. 
The authors suggested that the mechanism of hyperplasia 
was hormonal and not a direct effect of the citral. 
Table 1.4 summarises the types of tumours treated with 
citral.
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Table 1.4
A Summary of the Types of Tumour Treated with Citral 
(adapted from Schauenstein et al, 1977).
Tumour Treated Species Reference
Spontaneous breast Mouse Boyland and Mawson, 1938
Ehrlich Carcinoma solid Mouse Dittmar, 1940
Methylcholanthrene - 
induced tumours and 
inoculated tumours Mouse Boyland, 1940
Stomach, colon, lung 
cancers Man Osato, 1950
Yoshida sarcoma Mouse Osato et al., 1953
Bladder carcinoma Man Morrow, 1960
Adenocarcinoma Mouse Osato et al., 1961
HeLa cells Culture Zolotovich et al., 1969
P 815Y mast-cell Culture Thomas and Pasternak, 
1969 and Toaff et al., 
1979
Sarcoma 180
................ ........
Mouse Iriye et al., 1984
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The regression, and the inhibition of the growth of 
tumours may possibily be connected with capillary damage 
caused by citral (Schauenstein et al., 1977); the newly 
formed capillary system of the tumours may be especially 
sensitive to cytotoxic agents. Leach and Lloyd (1956b) 
found that citral caused damage to endothelial tissue, 
although simultaneous application of vitamin A prevented 
such damage. According to Herzmann (1966), citral can 
competitively displace vitamin A, which is necessary for 
metabolism in the vessels, and can thus act as an 
antivitamin A compound, as suggested in section 1.3.8.
1.3.11 The Antimicrobial Action of Citral
Citral shows a marked bactericidal activity (Cole ^t 
al., 1975) associated with low toxicity towards mammals. 
Osnos (1964) recommended citral for the prophylaxis and 
therapy of postnatal infections. Citral, and other 
terpene aldehydes present in grasses, have been reported 
to inhibit the growth of microbes in the stomachs of 
ruminants, and this may prejudice full utilization of 
their foodstuffs (Oh et al., 1967). The activity of 98% 
pure citral (125, 250 and 550 ppm concentrations) against 
gram positive bacteria, yeasts and moulds was attributed 
to an impurity since the isomers separately, and in a 
50:50 mixture were inactive against all bacteria tested 
and were less active than citral against some yeasts and 
moulds (Stevens et al., 1971). Metabolism of citral by 
bacteria has been reported (Joglekar and Dhavlikar, 1969; 
Banthorpe et al., 1983). Like other aldehydes, citral
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has been found to inactivate vesicular stomatitis virus 
in vitro (Kremzner and Harter, 1970).
1.3.12 Citral as a Semiocheraical
The transfer of information between living creatures 
can take place in various ways, and compunds of low 
molecular weight can be involved. Law and Regnier (1971) 
termed such substances "semiochemicals", these being 
substances which are secreted by an individual or a 
species and which contain specific information for 
another individual. Little is known about the
biosynthesis of these compounds, but it is known that 
citral is synthesised from acetate by the ant 
Acanthomyops (Happ and Meinwald, 1965). Citral has been 
identified as an alarm pheromone in ants (Formicinae), 
bees and wasps (Hymenoptera). The two isomers, geranial 
and neral, are also recruiting pheromones in the honey 
bee (Apis mellifera) (Law and Regnier, 1971). Citral has 
also been identified in the American cockroach, the 
rove-beetle, three Pieris species (butterflies), the 
silkworm larva (Bombyx mori) and two species of moth, 
Antheraea polyphemus and Galleria mellonella, (Opdyke, 
1979). The roles of citral in these species are in 
recruiting, as an alarm pheromone, an attractant during 
searching (honey bee) and as a defence chemical (rove 
beetle).
1.4 Aims of the Work
The aim of the current work was to compare and
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contrast the effects of citral, following short term 
administration to two strains of rat, with particular 
emphasis on the differences between the two strains.
Specific approaches to the work were:
1. An investigation of the effect of route of 
administration upon the thrombotest clotting time in two 
strains of rat. To determine the dose of citral that 
maximally prolonged the clotting time without causing 
mortality and to establish the histopathological changes 
associated with citral administration.
2. To study the interaction between citral and
warfarin, a known vitamin K antagonist, in the two 
strains of rat using both in vivo and in vitro 
techniques.
3. To investigate the possible interaction of citral
and vitamin A and to gauge the effects by studying the 
thrombotest clotting times, the vitamin A levels, 
histopathology and the effect upon hepatic mixed function 
oxidase enzyme activities.
4. To compare the effects of citral upon enzymes
important in fat metabolism, plasma and serum chemistry
and the hepatic mixed function oxidase enzymes in two
strains of rat. In addition, the dose and time
relationships of citral administration and enzyme changes
were studied in Wistar albino rats in order to elucidate
the mechanism of citral toxicity.
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Section II
Effects of Citral on Blood Coagulation
Chapter 2
Introduction
Blood Coagulation. The Role of Vitamin K
and the Significance of Vitamin A.
Although coagulation can be observed at a site of 
injury, or if blood comes into contact with a foreign 
surface, it is a complex reaction, the nature of which is 
not fully understood. It depends on the presence in the 
blood of platelets, of ionised calcium and a number of 
coagulation factors synthesised in the liver. Four of 
these factors are vitamin K-dependent (see section 
2.2.2).
Thus, any impairment of vitamin K synthesis, 
metabolism or recirculation will result in impairment of 
blood coagulation due to reduced synthesis of the vitamin 
K-dependent clotting factors. The aim of this
introduction is to give a brief outline of the clotting 
process and the elements which alter vitamin K synthesis 
or impair blood coagulation by vitamin K-related 
mechanisims. In addition, vitamin A is discussed at some 
length since antagonism between citral and vitamin A has 
been demonstrated (see Chapter 1, section 1.3.8) and 
hypervitaminosis A has been shown to cause impaired blood 
coagulation (see section 2.3.4).
2.1 Blood Coagulation - Haemostasis
Haemostasis is accomplished by a combination of 
vasoconstriction of the injured vessel at the site of 
injury, platelet aggregation to form a "plug" and 
triggering of the coagulation process which results 
ultimately in the formation of a fibrin clot. A key step 
is the generation of thrombin from prothrombin (factor
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II) by the action of activated factor X (factor Xa ) , a 
^-carboxylated, 2-chain glycoprotein. These two
proteins depend on vitamin K for their synthesis, as do 
factors VII and IX (Suttie, 1978). The role of vitamin K 
is discussed in more detail in section 2.2.3. The 
conversion of fibrinogen to fibrin occurs in three 
stages, the initial stage being mediated by thrombin:
1. Partial proteolysis of fibrinogen - thrombin 
hydrolyses four peptide bonds of fibrinogen so releasing 
two peptides leaving the fibrin monomer.
2. Fibrin monomer aggregation - fibrin monomers 
undergo polymerization.
3. Formation of stabilised fibrin - this occurs in 
the presence of Ca+^ ions and is achieved by cross-links 
between chains of different fibrin molecules. Removal
of free calcium from blood (for example, by adding
oxalate or citrate) will thus inhibit thrombin and clot 
formation. The complex of prothrombin and calcium ions 
is the only form of prothrombin that can be activated to 
form thrombin (Ganrot and Nilehn, 1968).
In the cascade model (figure 2.1) for coagulation, 
prothrombin activation may be triggered by two
alternative pathways involving stepwise activation of 
precursors in plasma and relying on two separate
initiation phenomena for activation. One of these
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Figure 2.1
The Cascade Mechanism of Blood Coagulation
Intrinsic System
Surface Contact
XII Xlla
XI -*^ XIa
IX
Extrinsic System 
VII
IXa
Ca++ PL
Tissue Factor III
vint -.-Ua— VIII
r
( iXa  + Vlllt + Ca"^  + Pl ) (Vlla+Tissue Factor)
PL- Phospholipid
II - Prothrombin
lia- Thrombi n
I - Fibrinogen
Im- Fibrin
Ip - Stabilized Fibrin 
a— Act ive
t- Thrombin Activat ed
(lXa + Vt + Ca+'^+ PL)
11 a
Im
Xllla
Ip
From Houghie and Baugh (1980), adapted from schemes of 
Davie and Ratnoft and Biggs and McFarlane.
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involves a substance known as "tissue factor" and is 
released from cells following injury.
2.1.2 Tissue Factor
This is a lipoprotein complex (thromboplastin) that 
is a specific initiator of blood coagulation. It is 
produced as a result of a signal for cell adhesion. 
Zacharski et al., (1981) suggested that the signal may be 
mediated through the microtubular system of the cell. 
Tissue factor in cell membranes renders it readily 
available for complexing with plasma coagulation factor 
VII (Zeldis et al., 1972). Jensen et al., (1976) 
implicated tissue factor in the haemostatic process which 
stops haemorrhage from skin incisions. Zacharski and 
Rosenstein (1979) suggested that tissue factor was 
vitamin K-dependent since its . activity was diminished 
following administration of warfarin. However, Stenflo 
(1977) and Netsestuen (1978) demonsti^ted that it was not 
modified following anticoagulant administration.
2.1.3 Factors Concerned with Prothrombin Activation
i. Antihaemophilic factors - there are three
types of haemophilia. A, B and C; these represent 
deficient or defective antihaemophilic globulin (factor 
VIII), Christmas factor (factor IX) and plasma tissue 
factor antecedent (factor XI) respectively.
ii. Accelerator globulin - present in plasma as 
an inactive precursor, proaccelerin (factor V).
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iii. Proconvertin (factor VII) is stable. There 
are two theories as to the mode of action:
a) prothrombin interacts with tissue factor in the 
presence of Ca++ ions so forming thrombin, or
b) a substance acts with tissue factor to speed up 
prothrombin conversion. Proconvertin levels are
increased following administration of vitamin K.
iv. Platelets - these were first studied in 1882 
by Hayem and Bizzozero; working independently, they 
observed platelet adhesion around cut vessels. These are 
derived from megakaryocytes mainly in the bone marrow 
(Mustard and Packham, 1970), but also in other tissues, 
the spleen for example.
Physiologically, the platelet helps maintain the 
integrity of the vascular system by interacting with the 
vessel wall and other blood elements, especially the 
procoagulant plasma proteins of the fibrin clotting 
mechanism by release of the activator thrombokinase. The 
platelet alsp plays a key role in a number of 
physiological and pathological processes including 
haemostasis, inflammation, immunologic responses,
complement activation, atheroma and thrombosis.
In the platelet release system. White (1972) 
implicated the surface-connected canalicular system in
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the release of substances from the platelet. A similar 
system was reported in mast cells (Kessler and Kuhn, 
1975). However, Warren and Vales (1972), suggested that 
substance release was via the vesicle separation 
following the platelet interaction with subendothelial 
structures. Calcium is necessary for such platelet 
aggregation, although excess calcium has been reported to 
inhibit ADP-induced platelet aggregation (Born and Cross, 
1964). Several compounds inhibit platelet aggregation, 
for example adenosine (Born et al., 1964), EDTA (Born and 
Cross, 1963 and others) and antihistamines (O'Brien, 
1961; Herrman and Frank, 1966). In contrast, adrenalin 
and noradrenalin both cause platelet aggregation 
(O'Brien, 196 3).
2.1.4 Summary of the Blood Clotting Mechanism
Evidence for the "cascade" system is incomplete. It 
is known that activation of the Hageman Factor (XII) is 
the first event. Factor VII has been used to monitor 
changes in the levels of vitamin K-dependent factors due 
to its short half-life (Spurling et al., 1974) which has 
been reported to be 6 hours in man (Koller et al., 
1951). The half-life of factor VII is unsown in rats, 
but with factors II, IX and X the half-life is much less 
than in man suggesting that factor VII will also have a 
shorter half-life than in man (Vainieri and Wingard,
1977).
Ca++ ions and protease enzymes are also needed.
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Generally, each inactive plasma zymogen of the cascade in 
the intrinsic system is present at a higher concentration 
than the preceeding one. Thus, following activation of 
the Hageman Factor, there is an amplification of the
response.
2.2 Vitamin K
Vitamin K was defined by Dam in 1935 (Dam, 1935a and 
1935b), when he observed haemorrhage in chicks fed a 
sterol-free diet. In 1936, Schonheyder traced the 
coagulation defect to lack of prothrombin. Both
phylloquinone (from alfalfa) and menaquinone are the
important forms of vitamin K in blood coagulation (see 
figure 2.2), Vitamin K is widely distributed in natural 
foods, usually, however, at low concentrations. ' In
general, the vitamin K contents of spinach, kale, 
broccoli and cabbage is greater than in other vegetables 
(Parish, 1980).
2.2.1 Uptake and Absorption of Vitamin K
Vitamin K is absorbed from the intestine into the 
lymphatic system and requires bile and pancreatic juice 
to allow maximum absorption (Almquist, 1975; Hollander, 
1981). However, the different forms of vitamin K are 
absorbed at different sites in the gastrointestinal tract 
and by different mechanisms.
Phylloquinone is specifically concentrated and 
retained in the liver, while menaquinone is poorly
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Figure 2.2
The Structures of Phylloquinone (Vitamin ) and
Menaquinone (Vitamin K2 ).
O
CH
a) Phylloquinone, 2-methyl-3-phyty1-1,4-naphthoquinone
From Sommer and Kofler (1956) after MacCorquodale et a l ., 
(1939) and Binkley et al., (1940).
O
CH
b) Menaquinone, 2-methyl-3-al1 trans- 
farnesylyeranylyeranyl-1,4-naphthoquinone.
From Pennock (1966) after Isler et al., (1958)
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retained; it has a wide distribution through tissues and 
is rapidly excreted. The inability to rapidly develop 
vitamin K deficiency in most species results from the 
difficulty in preventing any absorption of the vitamin 
from the diet or from intestinal synthesis by the gut 
microflora rather than from significant storage of the 
vitamin (Suttie, 1978).
2.2.2 Vitamin K Deficiency
In summary, vitamin K deficiency may be due to one 
of four mechanisms.
i. Inhibition of intestinal synthesis by
sterilization with antibacterial agents (Thompson and 
Hilferty, 1949; Hooper et al., 1980; Maclennan et al.,
1983),
ii. Reduced absorption (Snell, 1939; Suzuki ^  
al. , 1979 and 1983 ; Takahashi and Hiruga, 1979),
iii. Disorders of liver parenchymal cells leading 
to inadequate utilization (Deutsch, 1965),
iv. Competitive antagonism - this may occur when 
a compound has a similar structure to vitamin K; for 
example, coumarins (Campbell and Link, 1941; O'Reilly, 
1976; Park et al., 1979a and 1979b; Leek and Park, 1981; 
Park and Leek, 1982). A free hydroxyl group augments the 
vitamin K - like activity. In addition, six membered
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heterocyclic rings also augment anticoagulant activity 
(Bababunmi et al., 1980).
Such vitamin K deficiency is marked by a diminished 
plasma "prothrombin" concentration which leads to a 
prolonged clotting time (Mameesh and Connor Johnson, 
1959). Johnson et al., (1972) demonstrated that the 
actual amount of active prothrombin (factor II) protein 
present was lowered in the blood of vitamin K-deficient 
and warfarin - treated rats. The activities of the other 
vitamin K-dependent clotting factors VII, IX and X are 
all mutually lowered to a similar degree (Hemker et al., 
1963 and others). This is so for chronic hepatic damage 
and vitamin K-deficiency.
2.2.3 The Vitamin K-Dependent Carboxylation Reaction
During prothrombin biosynthesis, glutamyl residues 
in prothrombin precursor proteins are carboxylated to 
/-carboxyglutamyl residues by a vitamin K-dependent 
carboxylase (Jones et al., 1977; Larson and Suttie, 1978; 
Blanchard et al., 1981; Shah and Suttie, 1983). Vitamin 
K is needed in an enzyme reaction which carboxylates 
glutamyl residues in a hepatic microsomal protein 
precursor of plasma prothrombin to form the ^-carboxyl- 
glutamic acid (Gla) residues (Sadowski et al., 1976).
The activity of the vitamin K-dependent carboxylase 
is increased during periods when vitamin K action is 
blocked (Carlisle et al., 1979). The location of the
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carboxylation has been reported to be on the lumen side 
of the rough endoplasmic reticulum (Carlisle et al., 
1979; Carlisle and Suttie, 1980). Vitamin K-dependent 
carboxylase is not restricted to the liver, but is also 
present in the lung, kidney, spleen and testis (Buchthal 
and Bell, 1983; Vermeer, 1984).
The significance of the Gla residues in blood 
coagulation is that the vitamin K-dependent clotting 
factors are bound .to a phospholipid surface during the 
conversion from the proenzyme to the active form. This 
binding occurs via Ca++ ions. This specific binding is 
mediated by the Gla residues (Uotila and Suttie, 1982) 
and is essential for their biological role (Magnusson e_t 
al. , 1974 ; Esmon et al., 1975; Suttie, 1978 and 1980).
2.2.4 The Metabolism of Vitamin K
Following anticoagulant administration, Matschiner 
and Bell (1970) reported accumulation of a metabolite of 
vitamin K^ ; this was identified as vitamin K^ epoxide. 
It has since been shown that during the carboxylation 
reaction, vitamin Kj is oxidised to the biologically 
inactive epoxide metabolite (Willingham and Matschiner, 
1974; Willingham et al., 1976; Sadowski et al., 1977). 
Subsequently, this metabolite is reduced back to vitamin 
K% by an enzyme, phylloquinone epoxide reductase (Bell 
and Matschiner, 1972; Willingham and Matschiner, 1974; 
Silverman, 1980). This is summarised in figure 2.3. It 
has been proposed that oral anticoagulants exert their
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Figure 2.3
Vitamin K
Microsomes.
Related Metabolic Activity in Rat Liver
0X0.
GlaGiu
OH
OH
NAD(P)
NAD(P)H
DTTH
DTT
WARF
WARF
DTT
DTTH
1, Carboxylase; 2, KO-Reductase ; 3, K-Reductase.
Cross pathways with WARF are those that are sensitive to 
the action of coumarin anticoagulants. The figure 
indicates that the epoxide (c) is reduced by a warfarin - 
sensitive pathway that uses dithiothreitoi (DTT) as a 
reducing agent and that the quinone form (b) of the 
vitamin can be reduced to the hydroquinone (a) by either 
a warfarin - sensitive DTT-driven pathway or by a 
pyridine nucleotide - linked dehydrogenase. Gla-Glutamic 
acid and Glu-Gammacarboxyglutamic acid.
Adapted from Suttie, 1980, Uotila and Suttie, 1982 and 
Ve rinee r , 19 8 4.
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hypoprothrombinaemic effect by inhibition of the epoxide 
reductase leading to an accumulation of vitamin K\ 
epoxide (Bell and Matschiner, 1972; Bell et al., 1972; 
Caldwell et al., 1974; Matschiner et al., 1974; Whitlon 
et al., 1978). However, more recently, Carlisle and 
Blaschke (1981) and Bechtold et al., (1983) studied the 
pharmacokinetics of vitamin K% and vitamin K%2,3 
epoxide in dogs and man following administration of anti­
coagulants and suggested that this simple model of 
interconversion between vitamin K% and vitamin Kp2,3 -
epoxide was not sufficient to explain their results.
It has been suggested that vitamin K% epoxide is 
biosynthesized as a means of intracellular storage of an 
inactive form of the vitamin (Suttie et al., 1978). This 
would give a ready supply of percursor to the cell for 
immediate utilization and may explain the time delay 
between the onset of vitamin K-deficiency and the 
impaired coagulation that has been reported by several 
authors (Greaves, 1939; Elliott et al., 1940; Mellette 
and Leone, 1960; Colucci et al., 1983; Shah et al.,
1984).
Finally, figure 2.4 summarizes the total metabolism 
of vitamin K as proposed by Bell (1978) and Park and Leek 
(1982). This figure illustrates how the carboxylase and 
the epoxide cycle fits in with the overall metabolism. 
It shows that the epoxide formation is a vital step of 
the functioning of vitamin K.
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Figure 2.4
The Metabolism of Vitamin K
PrecursorsVitamin K KH
CarboxylaseEpoxidase
Epoxide
Reductase
,VII,iX,XKOW-Oxidation.
— in mitochondria
B-Oxidation-I
Metabolism ?Reduction
Conjugation ( glucuron ides) Conjugation
Excre ion Excretion
Adapted from Beil, 1978 and Park and Leek, 1982
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2.2.5 The Mode of Action of Vitamin K
Uotila and Suttie (1982) suggested that vitamin K 
was involved in the labilization of the hydrogen in the 
# -position of the Glu residue, so allowing carbon
dioxide to attack the position. Friedman et al., (1979), 
reported evidence in favour of this. However, the 
mechanism is still not clearly understood. It is
currently thought that there is an oxygenated
intermediate (the hydroperoxide has been suggested) in 
the conversion of vitamin Kj to the epoxide via the
carboxylation reaction. However, it is not known whether 
formation of carbanion or radical formation is involved 
in the mechanism. Recently however, a semiquinone 
radical intermediate has been implicated (Canfield and 
Ramelow, 198 4).
2.3 Vitamin A
Vitamin A was first described as "fat soluble A" by 
McCollum and Davis in 1915, although in 1913 they
reported that there was a lipid soluble substance in 
certain foods that promoted growth of rats. The role in 
the retina was described in 1935 by Wald; more recently 
the molecular action of vitamin A has been investigated 
by two main groups of workers (Ong and Chytil, 1978;
Chytil and Ong, 1979, Deluca, 1979; Deluca et al., 1979; 
Omori and Chytil, 1982).
Vitamin A is a generic term for any compound that
qualitatively shows the same biological activity as
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retinol (Goodman 1979; 1984). Vitamin A activity in
mammals is exhibited by  ^ p_ and ÿ -carotenes by
retinol and retinol2 and by number of other carotenoids 
such as cryptoxanthin. Vitamin A itself, or retinol 
(C2 0H2 9OH) is the isoprenoid polyene alcohol, 3,7- 
dimethyl-9-(2'6 '6 '-trimethyl-1'-cyclohexen-1'-y)-2, 4, 6 , 
8 -non-atetraene-l-ol; also called axerophthol, the 
antixerophthalmic vitamin and the anti infective vitamin 
(Bauernfeind, 1983). The structure was discovered by
Karrer and co-workers in 1931.
CH CH =CH C H = C H - C = C H — CHOH 
2
Vitamin A
With it's trimethylcyclohexenyl ring and a 
methylated side chain containing four conjugated double 
bonds, vitamin A can exist in different isomeric forms 
(16 cis-trans isomers in total), each with different 
biological activity. The all trans forms have the 
greatest biological activity (Thompson et al. , 1965).
The natural occurrence of the vitamin is confined to 
mammals, birds and marine fish life. However, in
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freshwater fish a form of vitamin A known as A 2 (C2 0H 2 8O) 
has been found, but it has less biological activity than 
vitamin A, (Bauernfeind, 1983). In species where
synthesis occurs, the process involves the same units 
utilized in sterol synthesis, that is, mevalonic acid, 
dimethyl pyrophosphate, isopentenyl pyrophosphate and 
geranyl pyrophosphate. Two moles of geranyl
pyrophosphate condense to form geranylgeranyl 
pyrophosphate and two moles of the latter condense to 
form phytoene. Stepwise formation of four additional 
double bonds yields lycopene and ring formation yields 
the common carotenes. There are alternative pathways in 
which ring formation may precede some of the desaturation 
steps. Commercial production by chemical synthesis 
favours p-ionone as an intermediate; this can be obtained 
in several ways (figure 2.5). Variations in the 
industrial process depend upon the manner in which the 
Ci3 p-ionone molecule is expanded to retinol.
2-3.1 Absorption, Uptake and Transport of Vitamin A
Uptake of vitamin A is the same in the proximal and 
distal parts of the intestine. It is a passive process 
with no energy needed and is carrier mediated (Hollander, 
1981). Absorption of retinol is rapid into lymph 
(Drummond et al., 1935). Absorption is increased if the 
bile salt concentration is increased, if the hydrogen ion 
concentration is increased or if bile acids are present 
(Hollander, 1980). However, retinol absorption into 
lymph falls if the bile salt concentration is low or if
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Figure 2.5
Synthesis ot the 0-Ionone Intermediate used in the 
Commercial Synthesis of Vitamin A.
From Bauernfeind, 1983.
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there are long-chain fatty acids or retinoic acid 
present.
Carotenoid vitamin A is converted into retinol 
before it can be absorbed. The conversion takes place 
mainly in the intestinal mucosa during absorption by 
symmetric or asymmetric fission and/or terminal oxidation 
to produce retinol which is subsequently reduced to 
retinol. Orally administered retinol is emulsified in 
the small intestine and is transported by the lymph in 
the ester form (Eden and Sellers, 1950). Storage in the 
liver is mainly in the trans form as retinyl palmitate 
(Aguilar and Parrish, 1971) in parenchymal cells, Ito 
cells and fibroblasts (Vajta et al., 1982a and 1982b).
From the liver, vitamin A is mobilized and
transported in plasma as the alcohol, retinol, bound to a 
specific transport protein, retinol-binding protein 
(RBP), (Ong et al., 1976); the binding is of high 
affinity (Ong and Chytil, 1978). Mobilization of vitamin 
A from the liver is highly regulated by factors that 
control the rates of RBP production and secretion.
Delivery to extra-hepatic tissues involves specific cell 
surface reception for RBP (Smith and Goodman, 1979;
Goodman, 1980). In contrast, unregulated and non­
specific delivery of vitamin A to biological membranes 
may lead to vitamin A toxicity.
RBP is synthesised in hepatic parenchymal cells, the
45
same cells are also sites for lipid storage. Kent e^ 
al., (1976), suggested that ingestion of large amounts of 
vitamin A may stimulate proliferation of fibroblasts and 
Ito cells and cause hepatic disorders. This has recently 
been confirmed by Forouhar et al., (1984). In addition, 
hepatic disease causes a reduction in plasma RBP. 
Retinol deficiency blocks RBP secretion, resulting in 
lowered plasma RBP levels and increased hepatic RBP 
levels (Smith and Goodman, 1979). These changes and the 
fact that plasma vitamin A turnover is greater with 
vitamin A sufficient rats than deficient rats leg Lewis 
et al., (1981) to suggest a three pool kinetic model for 
vitamin A with recirculation between the liver, plasma, 
intestinal fluid and tissues.
2.3.2 Metabolism of Vitamin A
The liver is the major site of formation of retinol 
from carotene and the intestinal mucosa is the major site 
for conversion of p-carotene to retinyl esters. However, 
the cleavage enzyme is also present in the liver of some 
species (Olson, 1967).
Vitamin A is metabolised to the aldehyde before it 
can carry out it's visual function, and other forms of 
vitamin A may well be formed according to the function. 
For example, retinol forms retinal which in turn forms 
retinoic acid (Dunagin et al., 1964; Emerick et al., 
1967) and the retinoic acid is more active than retinol 
in the stimulation of growth and in differentiation of
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epithelial tissue. However, retinoic acid cannot support 
the visual or reproductive functions.
Retinol and retinoic acid may be metabolised further 
by the same or similar major pathways. Retinol becomes 
oxidized to the carboxyl state before any degradation of 
the isoprenoid side chain occurs (Roberts and Deluca, 
1967). Retinoic acid is metabolised rapidly to more 
polar compounds (Frolik et al., 1979; Roberts et al., 
1979) and is excreted largely in the urine and bile 
(Yatzidis et al., 1979; Goodman, 1980).
Further metabolism of retinoic acid is unknown apart 
from the formation of retinoyl p-glucuronide (Dunagin e^ 
al. , 1965) and a biologically inactive metabolite,
5-epoxy-retinoic acid (McCormick et al., 1978), although 
McCormick et al., (1978) also reported the formation of 
another metabolite derived from the epoxy-metabolite, 5, 
8 -oxyretinoic acid.
2.3.3 The Functions of Vitamin A
The first major functional breakthrough was when 
Wald demonstrated the importance of retinaldehyde in
vision. Retinol is needed to maintain the visual process
'r'' '
since it is the precursor for the 1 1-cis-retinal 
prosthetic group of the visual pigment (transmembrane 
glycoprotein). Bleaching converts the 11-cis-retinal 
prosthetic group of visual pigments to the all-trans 
isomer which is reduced to all-trans retinol by an
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NÀDP-dependent, membrane - bound retinol dehydrogenase 
(Olson et al., 1983).
In addition to the visual function, vitamin A has 
been shown to be important in growth and differentiation. 
Two hypotheses have been put forward to explain the role:
a. vitamin A, in combination with specific 
cellular binding proteins, may directly influence the 
genome (Chytil and Ong, 1979),
b. the vitamin may be directly involved as a sugar 
transporting agent in the synthesis of specific
glycoproteins.
With regard to the role in glycoprotein activity, 
vitamin A may function in the phosphorylated form as a 
carrier of specific mannosyl residues. Deluca et al., 
(1979) suggested that retinoids may have a role in 
glycosylation of cell surface glycoproteins. Excess 
vitami^ A stimulates the incorporation of mannose into 
glycoproteins by enhancing the synthesis of lipid 
intermediates involved in specific mannosyl transfer 
reactions. This glycosylation function of vitamin A may 
be responsible for some of the effects of excess and 
deficiency of this nutrient (Hassell et al., 1978). 
Bollag (1983) suggested that the effect of vitamin A on 
glycosyltransfer reactions may also be responsible for 
several of its properties.
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Localization of vitamin A in the testes has 
suggested a role of vitamin A in spermogenesis (Ong ejt 
al., 1976; Rajguru et al., 1983). It has been shown that 
retinoic acid cannot replace retinol in the reproductive 
function (Deluca, 1979; Goodman, 1980), although the 
molecular mechanisms underlying these biological effects 
are unknown. It is likely, however, that retinoids 
affect gene expression of target cells (Omori and Chytil, 
1982; Sporn and Roberts, 1983). The other suggested mode 
of action of vitamin A is that retinol may act as a 
coenzyme in membrane - mediated synthesis of 
glycoproteins (Deluca, 1977).
2.3.4 Vitamin A Toxicity
i. Hypervitaminosis A
This has been reviewed by Clark (1971) and Olson 
(1983). Vitamin A toxicity occurs in vivo when the level 
of vitamin A in the body is such that retinol circulates 
in plasma, and is presented to membranes, in a form other 
than bound to RBP (Mallia et al., 1975; Smith and 
Goodman, 1976). At this point, large amounts of vitamin 
A combine with membrane lipoprotein and then with 
exogenous protein to lyse erythrocytes (Dingle et al., 
1962; Lucy and Dingle, 1962a and 1962b). Vitamin K has 
been shown to inhibit the haemolytic effect of retinol 
(Callari et al., 1978). In addition, there are
alterations to metabolism (Dingle et al., 1961; Singh ^  
al., 1978) and degradation of the cartilage matrix (Fell 
et al., 19 61).
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It has been reported that excess vitamin A in the 
rat leads to haemorrhage and hypoprothrombinaemia which 
can be prevented by administration of vitamin K (Light ^  
al. , 1944 ; Walker et al., 1947; Wostman and iK'night,
1969). The effect was reported to be more pronounced in 
male than female rats (Matschiner and Doisy, 1962). In 
addition. Quick and Stefanini (1948) indicated that 
excess vitamin A may interfere with vitamin K synthesis 
by gut microflora. Antagonism between vitamins A and K 
has been reported with vitamin A at a level of more than 
ten times the optimum (Wostman and Knight, 1965).
However, chronic hypervitaminosis A results in a 
cirrhotic - like liver syndrome including portal
hypertension. With excess vitamin A, fatty livers result
with perisinusoidal fibrosis (Forouhar et al., 1984) and 
one reason for the non-specific bleeding may be impaired 
vitamin K metabolism and/or synthesis (Deutsch, 1965). 
In addition. Spit (1983) reported an increase in size and 
number of lipid droplets in alveolar fibroblasts.
Teratogenic effects have been reported with vitamin 
A toxicity in the mouse, rat, hamster and guinea pig. 
Malformations include cleft palate, fused ribs, spina
bifida, meningocele, hydronephrosis and heart and 
genitourinary abnormalities (Nolan, 1969). In young
animals, bone growth may be severely or permanently 
retarded, while exostoses are the main skeletal lesions 
in mature animals (Clark, 1971).
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ii. Hypovitaminosis A
Vitamin A deficiency may be caused by several 
different means. For example, administration of
oestradiol reduces renal vitamin A (Moore et al., 1951) 
and high levels of achiote suppress hepatic vitamin A 
(Preston and Matos, 1981). Administration of compounds 
that induce the mixed-function oxidase system such as 
dioxon, phénobarbital or phenytoin also reduce the 
hepatic vitamin A levels (Tuchweber et al., 1976; 
Thunberg and Hakansson, 1983; Leo et al., 1984).
Vitamin A deficiency has been reported to affect 
metabolism and metabolising enzymes. Dogra et al., 
(1982) reported that vitamin A deficiency reduced hepatic 
and pulmonary glutathione and pulmonary glutathione-S- 
transferase. Cytochrome P-450 has also been shown to be 
reduced (Becking, 1973 ; Colby et al., 19 75; Toma'sèij and 
Olson, 1983; Tom et al., 1984 ). Colby et a 1 . , (1975)
suggested that the nature of the cytochrome P-450 may be 
altered.
The general effects of vitamin A deficiency are that 
young animals fail to grow, epithelial cells undergo 
keratinizing metaplasia, renal medullary cells cornify, 
there are changes in the eye with xerophthalmia, there is 
increased susceptibility to respiratory tract infection, 
ducts of glands become blocked resulting in gland 
atrophy, germinal epithelium may atrophise with delayed 
spermeation (Huang and Marshall, 1983) and there may be
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cornification of cells from vaginal smears. The effects 
of these changes to man have recently been reviewed by 
Goodman (1984).
2.3.5 Vitamin A and Cancer
Retinoids have been shown to suppress in vitro
expression of the malignant phenotype irrespective of
whether it was caused by chemical carcinogens, radiation
or viral transforming factors. Retinoids also protect
inhibitors from the promoting effects of phorbol esters
(Span and Newton, 1979). 13-cis-retinoic acid has been
shown to arrest neoplastic progression in the bladder
with N-methyl-N nitroso-urea (Sporn et al., 1977; Squire 
and
et al., 1977)  ^ N-butyl-N-(4-hydroxybutyl) nitrosamine 
(Grubbs, 1977; Becci et al., 1978).
The mechanism is not understood although it may 
involve glycoprotein synthesis in epidermal cells (Adamo 
et al., 1979b). This suggestion arose from studies that 
demonstrated that retinoic acid - treated cells 
(Balb/3Tl2-3 cells) showed increased adhesion (Adamo et 
al., 1979a). 13-cis-retinoic acid is currently being
employed in chemoprevention in humans, although newer, 
highly active retinoids are also being tested (Goodman, 
1984) .
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Chapter 3
The Effect of Short-Term Administration of
Citral to Rats Upon Blood Coagulation
and Histopathology.
A Comparative Study.
Introduction
Although citral is generally regarded as safe (FEMA, 
196 5) and is approved for food use by the FDA (GRAS 21, 
CRF 182.60), research has shown that citral affects 
haemostasis with apparent effects both on plasma clotting 
factors and the vascular endothelium.
Flude (1977) reported testicular haemorrhage in male 
Long Evans hooded rats fed a diet containing 2% citral. 
Testicular haemorrhage in the rat, associated with other 
tissue bleeding, is normally symptomatic of vitamin K 
deficiency. Subsequent work revealed prolonged
thrombotest clotting times in hooded rats fed a diet 
containing 2% citral for 28 days (Wood, 1981). No 
haemorrhage was reported however and Wistar albino rats 
treated in a similar way showed no alteration in the 
thrombotest clotting time.
More recently, citral has been reported to cause 
haemolysis of erythrocytes in vitro (Tamir et al., 
1984). Two mechanisms were suggested; firstly, an 
interaction between citral and glutathione leading to 
free radical production and secondly a non-specific 
steroid-terpenoid interaction in the membrane of the 
erythrocyte. However, hypervitaminosis A has been 
reported to cause haemorrhage (Light et al., 1944; Walker 
et al. , 1947; Wostman and Knight, 1965). Toxicity occurs 
when the level of vitamin A in the body is such that free 
retinol circulates. Large amounts of vitamin A then
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combine with membrane lipoprotein and exogenous protein 
to cause red cell lysis (Dingle et al. , 1962; Lucy and
Dingle, 1962 a and b). Thus, vitamin A antagonism may be 
involved in citral toxicity.
In addition to the effects upon the blood itself, 
citral has been reported to cause damage to vascular 
endothelia in monkeys receiving 0.7 - 1.7 ug citral/kg/ 
day for 14 days (Leach and Lloyd, 1956b). However, the 
doses at which effects were reported are approximately 
1 0 , 0 0 0  times lower than those at which any other effects 
have been reported, and so the validity of the work must 
be questioned.
The findings suggest that the strain of experimental 
animal used may be important when considering citral 
toxicity. The mechanism of action of citral is unknown, 
however, interference with vitamin A and/or vitamin K 
metabolism may be involved. Several possible mechanisms 
of action have been proposed (Wood, 1981).
1. Citral may interfere with the intestinal flora, so 
inhibiting production of vitamin K.
2. Citral may compete with other fat soluble compounds 
such as vitamin K, for émulsification by bile salts in 
the gut, so reducing the amount available for absorption.
3. There may be an imbalance of fat storage and
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metabolism in the liver leading to impaired protein 
synthesis, especially vitamin K dependent clotting 
factors.
4. Citral may act as a vitamin A antagonist and/or 
combine with RBP so increasing the amount of free vitamin 
A circulating. Thus, as outlined above, RBC lysis may 
result with hypoprothrombinaemia and consequentially 
altered blood coagulation.
In the present work, the aim was to investigate the 
strain differences in the toxicity of citral and to 
elucidate the mechanism of action initially by examining 
the effects following administration by two routes and at 
different dose levels. The former may be important when 
considering citral toxicity since one possible mechanism 
of action is a disturbance of fat metabolism which can be 
brought about by an altered food consumption pattern and 
effects on the gut microflora.
Materials and Methods
3.2.1 Chemicals
The following chemicals/reagents were obtained from 
suppliers as listed below.
Citral - BDH Ltd., Poole, Dorset, U.K. and 
Aldrich Chemical Co. Ltd., Gillingham, Dorset, U.K.
Cornoil - "Mazola", CPC (U.K.) Ltd., Esher, Surrey.
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. Thrombotest reagent - Nygaard Ltd., Birmingham, U.K.
Diagen Normal Control Plasma - Diagnostic Reagents 
Ltd., Thame, Oxon, U.K.
Diethylene Glycol Succinate (DEGS) - Phase 
Separations Ltd., Queensferry, Clwyd, N. Wales.
All other chemicals used were of analytical grade 
from BDH Ltd., Poole Dorset, U.K. All solvents were 
obtained from May and Baker Ltd., Dagenham, Essex, U.K.
3.2.2 Histology
All chemicals and stains for histology were obtained 
from R. A. Lamb Ltd., London, U.K. The glass slides and 
cover slips were obtained from Chance Propper Ltd., 
Smethwick, W. Midlands, U.K.
3.2.3 Gas Liquid Chromatography
The purity of the citral used during this work was 
initially checked using a Pye 104 mark 2 analytical Gas 
Chromatograph (Pye Ltd., Cambridge, U.K.) with a flame 
ionisation detector. Separations were achieved on an 
1/8" internal diameter 3 feet glass column (University of 
Surrey glass blowers) packed with 6 % (w/v) DEGS.
The oven temperature used was 140°C with the 
air/hydrogen mixture set at 10 psi and the nitrogen at 20 
psi. 1 pi of a 1 % (v/v) solution of citral in chloroform 
was injected onto the column for detection.
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3.2.4 Mass Spectroscopy
The impurities in the citral samples were further 
analysed by mass spectroscopy. This analysis was carried 
out by Mr M Yeadon at the Home Office Central Research 
Establishment (HOCRE) using a VG Analytical 7070H double 
focussing mass spectrometer (VG Analytical Ltd., 
Altrincham, U.K.). A 10% (v/v) solution of citral in
carbon tetrachloride was used. 0 . 1 jjI of the solution 
(containing 10 pg of citral) was injected onto a 25 m 
SE30 capillary column with temperature programming of 50 
- 200°C at 10°C min"l. The VG 707OH used chemical or 
electron impact ionisation with Nier-Johnson (or 
conventional) geometry. Total ion current chromatographs 
were produced.
3.2.5 Animals
Male Wistar albino and Long Evans hooded rats 
weighing 150 ± 20g were obtained from the University of 
Surrey breeding unit.
3.2.6 Animal Housing
The rats were housed 10 per cage in polypropylene 
cages with stainless steel lids using sawdust as litter. 
Food and water were allowed ad libitum. The rats were 
housed in rooms containing no other species and were 
maintained at a temperature of 21 ± 2°C and a relative 
humidity of 50 ± 3%. The animal rooms were subjected to 
an artificially controlled 1 2 hour light/dark cycle with 
the light phase being from 0700 to 1900 hours GMT.
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3.2.7 Animal Diet
Rats were either fed an expanded pelleted diet LAD - 
1 (for the gastric intubation studies) or a powdered diet 
(with citral mixed in the diet). Both were obtained from 
Scientific Feeds, Croydon, Surrey, U.K.
3.2.8 Administration of Citral
i. Citral was administered in the diet, at 
concentrations of 0.5, 1.0, 2.0 or 4.0% (w/w) . The
citral was dissolved in cornoil and then mixed with the
diet for 15 minutes in a single cone mixer. The diet was
made up weekly and stored in opaque sealed glass jars 
since losses of 58% citral have been reported from 
laboratory animal diets in open feed pots during a seven 
day period (Jones et al., 1962).
ii. When citral was administered to rats by oral 
intubation, three solutions of citral in cornoil were 
prepared at different concentrations. These were
administered to the test groups as outlined in table 3.1 
on a body weight basis.
In total, 4 pilot studies were carried out to 
compare strains, route of administration and dose of
citral. Each pilot study consisted of 4 dose groups 
receiving citral with 1 0 rats per group and a control 
group of 20 rats receiving cornoil alone (table 3.1).
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3.2.9 Thrombtest Clotting Time Determinations
Commercially available "thrombotest" is a modified 
one-stage prothrombin time reagent and the assay was 
carried out according to the method of Spurling (1974).
The reagent was reconstituted in 11.0 ml of sterile 
3.2mM calcium chloride. Following addition of the 
calcium chloride, the reagent was allowed to equilibrate 
for 2 - 3  minutes prior to thorough mixing. Aliquots of
250 pi were then pipetted into LP3 tubes, stoppered and
stored at -20°C for a maximum of 2 months.
The reconstituted reagent was defrosted and then 
left to equilibrate in a waterbath at 37 ± 0.5°C for at 
least 3 minutes but no longer than 60 minutes.
Each animal was restrained for blood sampling. 
Vasodilation was achieved by warming the tail in water at 
approximately 40°C. Two duplicate 5 jul blood samples 
were taken from a superficial venesection and pipetted
into two LP3 tubes containing 250 pi of the thrombotest 
reagent at 37°C, so achieving a dilution of 1:51. As
blood samples were released into the reagent, stop clocks 
were started and the tubes gently tapped to mix the blood 
and reagent. After 30s, the tubes were tilted to check 
for signs of clotting. This procedure was repeated at 5s 
intervals until clot formation was observed as judged by 
the first appearance of gelation. At this point, the 
stop clocks were stopped and the times recorded. Plastic
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tubes and pipette tips were used throughout to minimise 
contact activation. Normal control plasma was employed 
as a standard to correct for inter assay variation.
When the thrombotest could not be carried out on 
fresh blood, 3.8% (w/v) tri-sodium citrate was employed
as an anticoagulant, mixed with blood in a ratio of 1:9.
3.2.10 The Autopsy
After recording the final body weights, animals were 
killed by cervical dislocation. A mid-line ventral 
incision was made and the abdominal viscera were visually 
checked for abnormalities; any changes, compared to 
controls, were noted.
The livers were excised and weighed with slices 
taken for histological examination (see section 3.2.11). 
In addition to the liver, the stomach, duodenum, d'leum, 
kidneys, thymus, heart and lungs were also prepared for 
histological examination. All tissues were fixed for at 
least 7 days in 1 0 % (w/v) saline - phosphate buffered
formalin, pH 7.4. The rest of the carcass was checked 
for any gross abnormalities.
3.2.11 Histology
Following fixation, tissue samples were prepared for 
wax embedding by processing overnight in a histokinette 
(Type E7326, American Optical Co., Slough, Bucks, U.K.). 
Tissue slices were then embedded in fibrowax (registered
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trade name) and 6 pm sections were then cut using an 
American Optical Co. microtome, mounted on glass slides 
and allowed to dry. A routine haematoxylin and eosin 
method (Culling, 1974) was used to stain the sections. 
The stained sections were mounted in D.P.X.
Results
3.3.1 Purity of Citral
Figure 3.1 shows a gas chromatogram of 1 pi of a 1% 
solution of citral in chloroform. The trace indicated 
the presence of two major peaks with a number of much 
smaller peaks. These smaller peaks comprise
approximatley 5% of the total area under the curve. The 
major peaks are the two isomers of citral, namely neral 
and geranial.
Further analysis of the citral using mass 
spectroscopy showed a total of 10 peaks (figure 3.2). 
The two major peaks were the two isomers. Using the MS 
library at HOCRE, a tentative identification of all the 
peaks was possible; these are summarised in table 3.2. 
The other compounds present are byproducts of citral 
synthesis.
3.3.2 Comparison Between Routes of Administration of 
Citral to Rats and the Effect of Dose Level
The body weight gain and food consumption were both 
decreased with increasing dose level of citral; this was
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Figure 3.1
Gas Chromatographic Analysis of Citral
9 8 3 2 06 5 47 1
Time (min)
A gas chromatograph of ip 1 of a 1% (w/v) solution of
citral in chloroform. This was injected onto as 5% DEGS
packed 3 ft. glass column with an oven temperature of
14 0"C. Air and nitrogen were set at 10 and 2 0 psi
respectively. A - impurity
B - neral 
C- geranial
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Table 3.2
Analysis of the Components of Citral by GC/MS.
COMPONENT COMPOUND (FULL CHEMICAL NAME)
A
B
D
E
H
3 - methyl, 2 - Cyclohexan - 1 - one. 
cis - undec - 3 - ene.
3.7 - dimethyl, trans - 2,6 octadien - 1 - ol, 
(geraniol).
trans, trans - 2,4 - decandienal. 
trans, cis - 2,4 - decandienal.
2 . 8 - dimethyl - 1 , 8 - nonadiene.
3.7 - dimethyl, cis - 2,6 octadienal,
(neral).
3.7 dimethyl, trans - 2,6 - octadienal,
(geranial).
4, 6 , 8 - trimethyl - 1 - nonene.
6 - methyl - trans - undec - 3 - ene.
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so for both routes of citral administration (figures 3.3,
3.4 and 3.5). At the top dose level in the gastric 
intubation studies, the rats of both strains greatly 
reduced food consumption and as a result, the studies 
were terminated. Thus, 2.4 g/kg citral was the maximum 
tolerated, non-lethal dose. Dietary administration of 
citral decreased body weight to a greater extent than 
with daily gastric intubation (figure 3.3). The reduced 
body weight gain can largely be attributed to the reduced 
food intake (figure 3.5) although the food conversion 
decreases with increasing level of citral (see figure 
3.4a). The two routes of administration affected the 
strains differently. With gastric intubation, the hooded 
rats showed a.. greater; body weight gain than the albino 
rats. Following dietary administration, the converse was 
apparent with the albino rats generally showing a greater 
body weight gain.
The different routes of administration of citral 
resulted in different levels of intake of citral due to 
the lower food consumption associated with dietary 
administration of citral (figure 3.6). With gastric 
intubation, all animals received a daily body weight 
adjusted dose of citral. With dietary administration, 
the level of citral intake depended upon food 
consumption. It was only at the two high dose levels 
where food consumption was significantly lower than 
controls where the difference between gastric intubation 
and dietary citral intake became significant, with
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Figure 3.3
The Effect of Citral Administration upon Body Weight 
gain.
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The figures are the mean % of the control values i SEM 
with 10 animals per group following dietary and gastric 
intubation administration of citral for .14 days to Wistar 
albino (Ao) and Long Evans hooded (a^ b ) rats respectively. 
With citral at a level of l.2g/kg (oral) (1% dietary) or 
greater, body wtMghf gain for i)o t h .strains was 
significantly Iowe r (P< 0.001) than control animals.
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Figure 3.4
The Relationship between Food Consumption and Body Weight 
Gain (A) and the Food Conversion (B) for Dietary 
Administration of Citral.
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(A) The figures are the mean values per cage of 10
animals from Wistar albino (1) and Long Evans hooded (2) 
rats with no SEM.
(B) The mean ± SEM of 10 animals per group for dietary 
administration of citral with food conversion for Wistar 
albino ( a ) and Long Evans hooded { a ) rats.
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Figure 3.5
The Effect of Dietary Administration of Citral to Wistar 
albino (A) and Long Evans hooded rats (B) upon food 
consumption.
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The figures are the mean per cage of 10 animals with 
dietary citral at levels of 0.5 (n ), 1.0 (□ ) ,  2.0 ( a  )
and 4.0% ( a ) (w/v) .
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Figure 3.6
A Comparison Between Dietary and Gastric Intubation 
Routes of Administration of Citral with regard to Daily 
Intake of Citral.
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The figures are the mean ± SEM of 10 animals per group 
and compare Wistar albino ( # ) with Long Evans hooded 
rats ( B ) with dietary citral administration and daily 
weight adjusted gastric intubation administration of 
citral (a ).
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dietary administration resulting in a reduced citral 
intake.
Citral administration to both strains of rat and by 
both routes of administration caused dose-related 
hepatomegaly, (figure 3.7). Administration of citral by 
gastric intubation produced larger livers compared with 
dietary administration with the results expressed as 
percent of body weight and as absolute wet weights of the 
livers. No time dependency can be ascribed since all 
animals were administered citral for 14 days. The albino 
rats showed a greater degree of liver enlargement 
than the hooded rats. However, at this time it is not 
known whether the initial réponse was hyperplasia or 
hypertrophy.
3.3.3 The Effects of Citral upon Thrombotest Clotting 
Time
The hooded rats showed a prolonged clotting time 
following citral administration by both routes. In 
contrast, the albino rats showed no change in clotting 
time (figures 3.8 and 3.9). With the hooded rats, the 
prolonged clotting times were not dose related and 
occurred to a greater degree with dietary administration, 
although the difference between the two routes of citral 
administration was not significant. The latency period 
between the start of citral administration and the onset 
of prolongation of clotting was greater with dietary 
administration than with gastric intubation. The
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Figure 3.7
The Effect of Citral Administration to Wistar albino and 
Long Evans hooded rats upon the Absolute (A) and Relative 
(B) liver weight.
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The figures presented are the mean t SEM with 10 animals 
per group for Wistar albino and Long Evans hooded rats 
administered citral in the diet ( a  , a ) and by daily 
gastric intubation { □ , ■ ) respectively.
* P < 0.05, ** P < 0.01 and *** P < 0.001 compared to
controls.
Figure 3.8
The Effect of Daily Gastric Intubation Administration of 
Citral to (A) Wistar albino and (B) Long Evans hooded 
rats upon the Thrombotest Clotting time.
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The figures presented are the mean ± SEM with 5 
determinations per time point. Citral was administered 
at 0.6 ( B ), 1.2 ( □ ), 2.4 ( a ) or 4.8 ( a ) g/kg body
weight. The controls ( O ) received the cornoil vehicle 
alone. * P< 0.05, * * P< 0.01. All times above 53.5s are 
significantly greater (P < 0.001) than the control
clotting times.
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Figure 3.9
The Rifzect of Dietary Administration of Citral to (A) 
Wistar albino and (B) Long Evans hooded rats upon the 
Thrombotest Clotting Time.
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The figures presented are the mean ± SEM with 5 
determinations per time point. Citral was administered 
at 0.5 (b), 1.0 ( □ ) ,  2.0 ( a )  or 4.0 ( a ) % (w/w) in
the diet. The controls ( O ) received the cornoil vehicle 
in the diet. * P < 0.05, * * P < 0.01. All times above 
56.0s are significantly greater (P< 0.001) than control 
clotting times.
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prolongation of clotting times recorded were only 1 0 s 
maximally (a 2 0 % increase in clotting time compared to 
the controls). This compares with a 3s range in control 
clotting times with the hooded rats and a 1 0 s range with 
the albino rats.
3.3.4 Histopathology
Neither of the strains of rat, by either route of 
citral administration, showed any significant 
pathological changes in the microscopic appearance of the 
organs examined at any dose level. All test groups were 
compared to controls treated with cornoil. The only
minor change was the presence of so called "plant cells" 
in the livers of rats treated with 2.4 g/kg citral. This 
was apparent in both strains and by both routes of 
administration (figure 3.10). These plant cells occurred 
in centrilobular areas in particular and they represent 
excess glycogen deposition in hepatocytes.
Discussion
A purity of 95% is claimed by the manufacturers of 
citral, Aldrich Chemical Co. Ltd. The GC/MS analysis 
confirmed this and it provided a tentative identification 
of all the impurities. The data presented indicates that 
the sample comprised principally the two isomers of 
citral, geranial and neral, with eight other natural 
compounds comprising 5% of the total. Terpenoids almost 
invariably occur as a complex mixture in plants, and a
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Figure 3.10
Photographs of formalin - fixed, paraffin wax - embedded 
liver sections stained with haemotoxylin and eosin.
..V
(A) Section taken from the liver of a control Long
Evans hooded rat (x 400).
(B) Section taken from the liver of a Long Evans hooded 
rat treated orally with 2.4g/kg citral for 10 days 
(X 400). Note the plant cells (pc). Livers of Wistar 
albino rats showed a similar change.
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single essential oil may thus be expected to contain
several dozen other terpenoids (Templeton, 1969). The
low concentration of these other compounds would tend to
suggest that any toxicity could be attributed to the
citral and not the impurities.
In all studies, 2.4 g/kg citral was the maximum dose 
that did not cause mortality. 4.8 g/kg citral caused
between 0-80% mortality within 4 days. This was not
unexpected since the reported oral LD 5 0 for rats is 4.96 
g/kg (Jenner et al., 1964). The low body weight gain 
compared to controls at the high levels of citral
administration in all studies is mainly as a result of 
reduced food intake. However, the food conversion also 
decreased with increasing dose level of citral, and it is 
these two factors together that resulted in the lower 
body weight gain. These figures are in agreement with 
those of Wood (1981). Citral, at a dietary level of
0.5%, resulted in only a slight depression in food 
consumption compared to controls. This supports the 
results of Flude (1977), who reported that citral at 0.2% 
and 0 .0 2 % in the diet had no effect upon food 
consumption. Reduction in food consumption will also 
result in a reduced intake of citral by dietary
administration.
Low food intake is an important factor since it 
has been reported to increase circulating free fatty 
acids (Masoro, 1968) with parallel effects upon lipid
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metabolism (Cornelius, 1970; Ishii et al., 1980), stored 
glycogen levels and sex dependent hepatic enzymes 
capable of breaking down incoming nutrients and 
xenobiotics including fat - solùible vitamins- (Kato and 
Gillette, 1965). This in turn will affect synthesis of 
proteins, lipids and lipoproteins resulting in altered 
transport of cholesterol and triglycerides in the body 
(Lehninger, 1977). Use of a pair-feeding protocol with 
high levels of dietary citral would eliminate any effects 
due to lower food consumption since the control groups 
would receive the same amount of food as the test groups 
consumed.
Compared with the gastric intubation, where the
daily intake of citral was in a single dose on a body
weight basis, dietary administration resulted in variable
daily intake over a period of time. This may be
important with regard to the pharmacokinetics of citral.
Phillips et al. , (1976) administered a single oral dose
to rats and reported almost complete excretion within 72
hours. No such data is available for dietary
food
administration. This, coupled with the low^ intake and 
the reported losses of citral from the diet (Jones et 
al. , 1962 ) suggest that gastric intubation is the most
consistent route of citral administration.
The greater degree of hepatomegaly following 
gastric intubation is most probably due to the greater 
relative dose of citral. The difference between the
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albino and hooded rats suggests a difference in the 
taj
ada^ion by the liver to citral administration. This in 
turn may be related to the metabolizing abilities of the 
strains of rat from different genetic pools (Evans e_t 
al.y 1960). The expression of the liver weight as a 
percentage of body weight may lead to inaccurate 
conclusions since the relative liver weights will appear
greater as the body weight decreases. The absolute liver
;|e
weights do, however, generally confirm the hepatomgaly.
A
A strain difference was also evident with the 
thrombotest clotting times, where only the hooded rats 
showed any prolongation compared to the control values. 
The increase was not dose - related and it was only a 20%
increase compared to the control value at any one time.
Elliot et al., ( 1940) reported the prothrombin time for 
120 control rats. They showed a range from 43s to 106s 
in the prothrombin time (a 250% range) with a mean of 
69.8 ± 0.9 (SEM) seconds. This suggests that intra­
specific variation is an important factor with regard to 
data interpretation. Colucci et al., (1983) reported an 
increase of 700% in the thrombotest clotting time of 
rats following a 15 day period of feeding a vitamin K 
deficient diet. This suggests that complete vitamin K 
deficiency is unlikely to be the cause of the
prolongation of clotting time in the hooded rats.
The true vitamin K requirement, that is, the amount 
that must be absorbed to prevent prolongation of
80
prothrombin time, is influenced by many factors with 
strain, sex, age and environmental temperature being the 
most important (Mellette and Leone, 1960; Johnson et al., 
1960; Metta and Johnson, 1960; Mills et al., 1964). The 
only variable in these studies was the strain of rat and 
it has previously been shown that Sprague - Dawley and 
Charles River rats are more sensitive to dietary 
deprivation of vitamin K than are Texas A and M, Holtzman 
and St. Louis University strains (Mellette and Leone, 
1960 ). The Long Evans hooded rats used here of the 
University of Surrey strain are Charles River derived and 
so genetic variation is a likely explanation for the 
clotting defect. A similar genetic difference between 
strains has been reported with rabbits (Hawkey, 1975).
The route of administration had no effect upon the 
degree of prolongation of thrombotest clotting time; the 
time of onset of the prolongation did vary however. With 
gastric intubation, the prolongation occurred 1 - 2  days 
after the start of citral administration. This compares 
with 5 days following the start of dietary administ­
ration. This may be due to the relative difference in 
citral intake by the two routes of administration, or the 
increased gastric irritation associated with short-term 
gastric intubation (Carmichael, 1985) and the reported 
transient changes in the gut microflora (Gustafsson, 
1948; Osnos, 1964). Citral has been shown to inhibit the 
growth of microbes in the stomachs of ruminants, so 
prejudicing full utilization of their foodstuffs (Oh e^
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al. , 1967). This may also be the case with rodents with 
an effect both upon vitamin K synthesis and food 
utilization. The decreased food conversion, a direct 
measure of food utilization, with increasing dose of 
citral does suggest an effect of citral upon nutrient 
absorbtion and the gut microflora, with the hooded rats 
responding to a greater extent than the albino rats.
Although vitamin K is synthesised in the gut, it is 
not directly absorbed and coprophagy is necessary for 
its' full utilization (Barnes and Fiala, 1958). Indeed, 
it had been previously shown th,at an ether extract of 
faeces fed to vitamin K deficient chicks protected them 
from vitamin K deficiency (Greaves, 1939). It was noted 
during the course of this work that the rats, especially 
in the higher dose groups of citral administration, 
developed diarrhoea, resulting in a reduced degree of 
coprophagy. Thus, if the coprophagy is reduced to the 
same extent in each dose group, then any prolongation of 
thrombotest clotting time would occur in a non-dose- 
related manner. It was not possible to gauge the amount 
of coprophagy that occurred, however this does not 
explain the strain difference since it occurred in both 
strains. The absorption of vitamin K from the gut is 
bile dependent (Butt and Snell, 1941) and it has been 
suggested that biliary excretion is important in the 
metabolism of citral (Phillips et al., 1976). Such 
biliary excretion may interfere with full absorption of 
the vitamin K from the gut; this implies a genetically
based difference in the metabolism of citral in the two 
strains of rat used here.
In addition to vitamin K deficiencies,vitamin A has 
been implicated in the prolongation of clotting time and 
haemorrhage (Light et al. , 1944 ; Walker et al. , 1947).
It has been proposed that both hypervi taminos is A and 
vitamin A deficiency depress prothrombin levels (Elliott 
et al., 1940; Light et al., 1944; Walker et al., 1947; 
Mellette and Leone, 1960); Wostman and Knight (1965) 
reported that the intake of vitamin A had to be at least 
ten times the optimum of 1 0 , 0 0 0  iu/kg diet before any
signs of hypervitaminosis could be detected. In
contrast, the level of dietary vitamin A is an important 
factor when considering the degree of vitamin K
supplementation (Hacking and Lane-Petter, 1968) with 
depressed prothrombin- values reported in rats fed as low 
as 500 - 5 ,000 iu/kg vitamin A in the diet (Matschiner
and Doisy, 1962), thus antagonism between citral and 
vitamin A is possible.
Genetic defects have been reported in the clotting 
mechanism. For example, a platelet storage defect has 
been reported in Fawn hooded rats (Tschopp and Zucher, 
1972). Such a defect would not however be detected by 
the thrombotest since the assay relies on the clotting
factors alone for clot formation. The lack of
significant prolongation of thrombotest clotting time 
precludes any factor deficiency although such a
congenital factor VII deficiency has been reported for 
the beagle dog (Capel - Edwards, 1968; Hall, 1970). In 
addition stress has been implicated as a factor that 
contributes to haemorrhage and altered prothrombin time 
in rats (Jaques et al., 1956).
The results with the thrombotest assay are dependent 
upon the accuracy and reproducibility of the assay. 
Although a standard was employed throughtout, the assay, 
as carried out by hand, is very subjective and the 
significance of a 2 0 % increase in clotting time must be 
questioned (cf. Colucci et al., 1983) although it was 
statistically significant. The possible interaction of 
citral with vitamin A and/or vitamin K indicates that 
further work should be carried out specifically to 
examine any such interactions.
In summary, gastric intubation is a preferable route
of administration of citral when practical to do so. The
albino rats were more tolerant to citral than the hooded
rats. The maximum dose of citral used that did not cause
mortality was 2.4 g/kg. There was a strain difference
with regard to the degree of hepatomegaly and
prolongation of thrombotest clotting times with hooded
rats showing a 2 0 % increase in clotting time following
citral administration compared to controls and albino
rats showing no significant change. The degree of
hepatomegaly was greater following gastric intubation 
than dietary
^administration of citral with the albino rats showing
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greater hepatomegaly than the hooded rats. The mechanism 
of the strain difference appears to be genetically based 
and involves the metabolism of citral and/or the 
requirements of vitamin K and the interaction with 
vitamin A.
Chapter 4
The Interaction of Citral with Warfarin 
In Vivo and In Vitro.
Introduction
The aim of this work was to investigate the effect 
of preadministration and postadministration of citral 
upon the anticoagulant properties of warfarin in the rat 
in order to help to elucidate the mechanism of action of 
citral upon blood coagulation and the basis of the 
interstrain differences observed between hooded and 
albino rats (see Chapter 3). In addition to an in vivo 
approach, in vitro methodology was employed to 
investigate the protein binding of warfarin and it^s 
interaction with citral.
The synthesis of vitamin K dependent clotting 
factors is decreased following administration of oral 
anticoagulants. The mechanism of action of such
anticoagulants has been shown to be inhibition of vitamin 
K reductase and vitamin K epoxide reductase (Fasco and 
Princepe, 1982; Fasco et al., 1982) with consequent 
depletion of vitamin K and abnormal post-ribosomal 
carboxylation of glutamic acid residues in different 
proteins including the four clotting factors of the 
prothrombin complex, (II, VII, IX and X) (Sadowski et 
al. , 1976; Larson and Suttie, 1978; Blanchard et al. ,
1981; Shah and Suttie, 1983; Shah et al., 1983). The 
products are immunologically similar to the clotting 
factor proteins, but they are functionally abnormal as 
they prevent recirculation of vitamin K epoxide by 
blocking the action of the epoxide reductase enzyme 
(Mackie and Douglas, 1984). Warfarin is one such oral
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anticoagulant.
The anticoagulant activity can be modified by a 
number of parameters, some of which directly relate to 
effects upon warfarin itself, but others are more general 
effects upon the coagulation mechanism. These
modifications include altered vitamin K bioavailability, 
altered metabolic fate of warfarin (absorption, protein 
binding, biotransformation and excretion), changed 
prothrombin complex concentration by a direct effect upon 
synthesis or catabolism, altered receptor affinity for 
coumarins and an altered non-prothrombin complex 
dependent haemostatic mechanism (Koch-Weser and Sellers, 
1971; Mackie and Douglas, 1984). There are many reports 
in the literature of such interactions between drugs and 
warfarin by a variety of mechanisms. These include 
displacement from albumin binding by drugs (Meyer and 
Guttman, 1968; Sellers and Koch-Weser, 1971), 
displacement by fasting and competition with free fatty 
acids (Spector and Santos, 1973; Wosilait, 1973; 
Laliberte et al., 1977; Pepper and Wosilait, 1977; 
Wosilait and Ryan, 1980), altered coagulation (Kramer e^ 
al. , 1984 ) and increased metabolism of warfarin (Ikeda qt 
al. , 1968; Covell et al. , 1984; Qureshi et al. , 1984 ;
Kling et al., 1985).
No previous terpenoid - warfarin interactions have 
been reported, although citral has been reported to cause 
dehelicization of albumin and alter peptide maps
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(Bagdasar'yan and Troitskii, 1971) and this may affect 
the warfarin - albumin binding, which has been reported 
to be 97% under normal conditions in humans and rats 
(Koch-Weser and Sellers, 1971; Gungler et al. , 1974). In 
addition, citral induces cytochrome P-450 and the mixed 
function oxidases (Parke and Rahman, 1969); such 
compounds that induce this enzyme system decrease the 
anticoagulant effect of warfarin (Kling et al. , 1985).
Thus, citral may interact with warfarin to affect the 
plasma concentration and the anticoagulant properties of 
warfarin. The role of vitamin K in the toxicity of 
citral may thus be established by examining the effect of 
citral with a known vitamin K antagonist.
Materials and Methods
4.2.1 Chemicals
The following chemicals and test kits were obtained 
from the suppliers indicated:
Albumin Test Kit for Cobas Bio - kit no 0714119 -
Roche Products Limited, Welwyn Garden City, Herts., U.K.
Coomassie Blue G-250-Sigma Chemical Co. Ltd., Poole, 
Dorset, U.K.
Human serum albumin. Bovine serum albumin and rat 
serum albumin - Sigma Chemical Co. Ltd., Poole, Dorset, 
U.K.
Lipids Test Kit, Kit no. 124303 - Boehringer
Corporation London Ltd., Lewes, Sussex, U.K.
"Sagatal" - May and Baker Ltd., Dagenham, Essex,
U.K.
Warfarin - a gift from Sorex Ltd., Widnes, Cheshire,
U.K.
All other chemicals were obtained from supplies as
outlined in Chapter 3 (section 3.2.1).
4.2.2 Animals and Husbandry
Male Wistar albino (University of Surrey) and male 
Long Evans hooded (Charles River Ltd., Mansion, Kent, 
U.K.) rats weighing 200 i 20g were used and housed as 
described in Chapter 3 except that there were either 6 or 
9 animals per cage. All animals were fed an expanded 
pelleted diet, LAD-1 (Scientific Feeds, Croydon, Surrey, 
U.K.).
4.2.3 Administration of Citral and Warfarin
All animals were dosed by daily gastric intubation.
Two protocols were adopted. Each protocol employed a
total of 6 groups; 3 with hooded rats and 3 with albino 
rats. The two dosing regimes are summarised in table 
4.1. Citral was administered as a 50% (v/v) solution in 
cornoil at a dose level of 2.4g/kg and the warfarin was 
administered in distilled water as a 0.05% (v/v) solution 
at a dose level of 1 mg/kg for 3 days. At this dose 
level of warfarin, Greaves and Ayres (1973) reported no 
deaths in rats treated for 3 days.
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Table 4.1
Dosing Regimes for the Warfarin Studies
In the tables below, LEH refers to Long Evans hooded rats 
and WA refers to Wistar albino rats.
Protocol 1
Groups Number
per
group
Dosing on each Day Days of 
termination 
of 3/groupLEH WA 0 - 6 7-9 1 0 - 1 2
1 4 9 Citral Citral + Warfarin Citral 7, 10 & 13
2 5 6 Citral Citral Citral 10 & 13
3 6 9 Cornoil Cornoil Cornoil 7, 10 & 13
Protocol 2
Groups Number
per
group
Dosing on each day Days of 
termination 
of 3/groupLEH WA 0 - 2 3-5
7 1 0 6 Warfarin Citral 3 & 6
8 11 6 Citral Citral 3 & 6
9 1 2 6 Cornoil Cornoil 3 Sc 6
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4.2.4 Thrombotest Clotting Time Determinations
These were performed by hand as described in Chapter 
3, section 3.2.9.
4.2.5 The Autopsy and Histology
Following determination of the thrombotest clotting 
time using whole blood from a superficial venesection, 
the animals were anaesthetised with pentobarbitone 
("Sagatal") by an intraperitoneal injection of 0.1 ml per 
lOOg body weight. The abdominal viscera were examined 
for abnormalities and the animals exsanguinated from the 
posterior vena cava; the blood was added to 3.8% tri­
sodium citrate in a ratio of 9:1. The blood/citrate was 
mixed and then centrifuged at 1,200g for 5 minutes in a 
Beckman J6 B centrifuge (Beckman Ltd., High Wycombe, 
Bucks, U.K.); the supernatant plasma was stored at -20°C 
for subsequent assays. The livers were removed and 
weighed. Tissues were prepared for histological
examination as described in Chapter 3 with staining as 
previously described (section 3.2.11).
4.2.6 The Fluorometric Determination of Total Plasma 
Warfarin
The assay of plasma warfarin was adapted from the 
method of Corn and Berberich (1967).
Plasma (200 pi) was added to 4.0ml of analytical 
grade acetone in 15.0 ml Sovrill tubes and vortex mixed 
for 45s. The mixture was separated by centrifugation for
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5 minutes at 500g in a Beckman J 6 B centrifuge. The 
fluorescence of the supernatant (3.0 ml) was recorded on 
a Perkin-Elmer MPF-3 Fluorescence Spectrophotometer with 
a Perkin-Elmer 150 Xenon Power Supply (Perkin - Elmer 
Ltd., Beaconsfield, Bucks, U.K.) and a Hitachi QPR 
recorder. The excitation wavelength was set at 340nm 
with the emission wavelength set at 409nm. This initial 
fluorescence was designated F%. O.lN hydrochloric acid 
(50 ul) was then added to the above supernatant in order 
to acidify the warfarin and the resulting decreased 
fluorescence (F2 ) was recorded. A standard of 5 pg 
warfarin/ml plasma was assayed as above. The method was 
verified using excitation and emission wavelength scans.
The concentration of warfarin in each sample of 
plasma was then calculated according to the relationship: 
pg warfarin/ml plasma = (F% - F2 ) U X 5
(Fi - F2 ) St
where U = unknown and St = standard. All the samples 
were determined in duplicate.
4.2.7 Determination of Total Plasma Albumin
Plasma albumin was determined on a Cobas Bio 
Centrifugal analyser (Roche Products Ltd., Welwyn Garden 
City, Herts, U.K.) with a single reagent consisting of 
bromocresol green, sodium hydroxide, acetic acid and brij 
35. This method is based on that of Dow and Pinto 
(1969).
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40 pi of plasma was diluted with distilled water and 
mixed with 350 pi of the reagent to form a coloured 
product. The extinction was recorded at 620nm and was 
compared to a standard of 35 mg/ml HSA.
4.2.8 Determination of Protein
A single reagent was used according to the method of 
Read and Northcote (1981). Coomassie blue G250 (100 mg) 
was dissolved in 100 ml of 85% orthophosphoric acid and 
then 50 ml of 96% ethanol was added. Distilled water was 
added to make the volume up to 1 litre. The solution was 
stable for up to 3 months at room temperature with no 
loss of binding capacity.
A 100 pi aliquot of suitably diluted sample was 
added to 2.5 ml of reagent and mixed. The extinction was 
read after 10 minutes at 595 nm on a dual beam Unicam 
SP1800 Ultraviolet Spectrophotometer (Pye Unicam, 
Cambridge, U.K.) with water in the reference cuvette and 
compared to a standard curve of BSA in the range of 0-300 
pg/ml BSA.
4.2.9 Total Plasma Lipids
A total lipids test combination kit was used. The 
assay was based on the sulphophosphovanillin reaction 
(Zollner and Kirsch, 1962). 50 pi of plasma was mixed
with 2 . 0 ml of sulphuric acid and placed in a boiling 
water bath for 10 minutes. An aliquot (100 pi) of this 
solution was then mixed with 2.5 ml of colour reagent
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(14 M phosphoric acid/13mM vanillin). The colour was 
allowed to develop for 30 minutes and the extinction was 
then recorded at 530 nm on a dual beam Unicam SP1800 
Ultraviolet Spectrophotometer (Pye Unicam, Cambridge, 
U.K.) with water in the reference cuvette.
A blank and standard were assayed in parallel to 
test samples. Following subtraction of the blank from 
the standard and test samples, the concentration of total 
lipid in plasma was calculated according to the 
relationship :
total lipid (mg/lOOml) = 1,000 x E^-
Eg
where E^ = extinction of test sample
Eg = extinction of standard.
4.2.10 The Displacement of Warfarin from Protein Binding 
In Vitro
The method used was based on that of Henry and 
Wosilait (1975). The assay contained 7.24 pM HSA, 75mM 
TRIS-HCl, pH 7.4, warfarin ranging from 0 to 80 pM and 25 
pM citral. The concentrations given are the final
concentrations in the assay.
The warfarin solutions were made up in buffer, 
ranging from 2 - 100 pM. The fluorescence of the 
warfarin-buffer solution (2 . 0 ml) was recorded and 
designated Fi.0.5 ml of a 36.2 pM solution of HSA was 
added to give a final volume of 2.5 ml with final assay
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concentrations of 7.24 pM HSA and 80 pM warfarin (top 
concentration). The fluorescence of the HSA/warfarin 
complex was measured (F2 ) and the difference in 
fluorescence (F2-F1 ) represented the bound warfarin. A 
similar procedure was followed with BSA and RSA.
The displacing effect of citral was determined in 
the above assay system as follows. The citral was 
initially dissolved in glycerol due to itsj insolubility 
in aqueous media and the displacing properties of many 
organic solvents. The citral/glycerol was then diluted 
in buffer to give a final concentration of 25 pM in the 
warfarin/buffer solution. The fluorescence was recorded 
(Fi). The HSA was added to give a final concentration of 
7.24 pM HSA and 20 pM citral. The fluorescence (F2 ) was 
measured and the difference (F2 - F^) taken as the degree 
of warfarin binding. The control contained glycerol 
alone, with no citral.
All fluorometric measurements were performed on a 
Perkin - Elmer MPF-3 fluorescence spectrophotometer 
fitted with a Perkin - Elmer 150 Xenon Power Supply 
(Perkin - Elmer Ltd., Beaconsfield, Bucks, U.K.) and a 
Hitachi QPR recorder. The excitation wavelength was set 
at 320 nm with a corresponding emission wavelength of 385 
nm. The assay was verified by scanning the emission 
wavelength using a fixed excitation wavelength of 320 nm.
95
Results
4.3.1 Macroscopic and Microscopic Pathology Following 
Administration of Warfarin and Citral to Rats
During the course of the study, three hooded rats
died of gastric haemorrhage (figure 4.1). These rats had 
received citral for seven days, followed by a combination 
of warfarin and citral. In addition, both hooded and 
albino rats showed adhesion of the stomach, liver and 
diaphragm following citral administration. Gastric
irritation alone was evident in one albino rat following 
three days of citral administration.
Both strains of rat showed hepatomegaly. In the 
albino rats, the degree increased with time. This was 
not so apparent with the hooded rats (figure 4.2). The 
hooded rats showed a greater degree of hepatomegaly than 
the albino rats after 13 days, a result which is in
agreement with that found in Chapter 3 at the 2.4g/kg
dose level. Warfarin alone produced no hepatomegaly, but 
in combination with citral, liver enlargement was evident 
in both strains of rat (table 4.2).
4.3.2 The Effect of Citral and Warfarin Administration 
Upon the Thrombotest Clotting Time
A comparison of the thrombotest clotting times for 
the citral treated rats indicates that only the hooded 
rats showed any prolongation compared to controls. This 
prolongation was maximally 25% after 10 days
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Figure 4.1
Photograph of Formalin - Fixed, Paraffin Wax - Embedded 
Stomach Sections stained with Haematoxylin and Eosin.
'■ 1 I
B
(A) Longitudinal section taken from the forestomach of a 
control Long Evans hooded rat (x 400).
(B) Longitudinal section taken from the forestomach of a 
Long Evans hooded rat treated with 2.4 g/kg citral for 7 
days and 1 mg/kg warfarin/2.4g/kg citral for 3 days by 
gastric intubation (x 400). The section illustrates 
gastric heamorrhage with acute focal gastritis.
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Table 4.2
The Effect of Warfarin upon Clotting Time, Liver Weight and Plasma Biochemistry.
Measurement Controls 3 days 
Warfarin
3 days Warfarin 
followed by 
3 days Citral
7 days Citral 
followed by 
3 days Citral/ 
Warfarin
7 days Citral 
followed by 
3 days Citral/ 
Warfarin and 
3 days Citral
Total Plasma 
Warfarin 
(pg/ml) 1
LEH 0.0 2.111.2 1.710.6Î 1.010.5 0 .3 1 0 . 1
WA 0.0 i.oio.i 0 .3 1 0 . 0 4 1 1 0 .3 1 0 . 1 1 1 0 .2 1 0 . 0 3 1 1
Thrombotest 
Clotting 
Time (S) 2
LEH 50.613.0 300C (1/6
dilution)
240C 300C (1/6 
dilution)
5 3 .9 1 1 . 2
WA 51.4=3.8 300C (1/6
dilution).
6 8 .7 1 4 . 2 6 8 .0 1 7 .0 a (1/6 
dilution)
47.011.4
Liver wt.
(% body wt.)
3
LEH 4.310.1 3.910.la 4 .7IO .4 6.610.1C 7 .2IO.2 C
WA 4.510.1 4.710.1 6 .1 1 0 .2b 7 .7 1 0 .1c 6 .7IO.2 C
Total Plasma 
Protein 
(mg/ml) 4
LEH 49.011.8 41.311.3 b 37.612.8a 42.712.7 49.213.8
WA 42.811.3 45.4 1 0 .1 4 4 .5 1 1 . 6 41.413.3 42.311.1
Total Plasma 
Albumin 
(mg/ml) 5
LEH 29.910.5 27.1 1 0 .2 c 23.7 1 1 ,lb 25.3 1 0 .4 b 31.110.5
WA 28.110.4 28.410.4 27.210.4 24.210.9 a 29.210.4
Total Plasma 
Lipids 
(mg/100ml)6
LEH 314.6122.1 - 432.21127.0 - 305.11152.6 ■
WA 330.7123.3 - 186.4 1 1 0 .0 b 2 0 3 .4 1 1 0 .lb 370.61110.0
VO
00
All figures are the mean ± SEM with 3 animals per group.
LEH refers to Long Evans hooded rats and WA refers to Wistar albino rats.
1. i. P < 0.05 Comparison between strains.
ii. P < 0.01 Samples compared against administration of warfarin alone
2-6. a P<0.05
^ P< 0.01 Samples compared against control values, 
c p < 0.001
Figure 4.2a
The effect of Daily Gastric Intubation Administration of
Citral upon Absolute Liver Weight.
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The figures presented are the mean ± SEM with 3 animals 
per group for control (0,0 } and test (®,B ) Wistar albino 
and Long Evans hooded rats respectively. Citral was 
administered at a level of 2.4 g/kg in cornoil.
* P < 0.05, ** P <  0.01 and *** P < 0.001 compared to
controls.
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Figure 4.2b
The Effect of Daily Gastric Intubation Administration of
Citral upon Relative Liver Weight.
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The figures are the mean ±SEM for Wistar albino (# ) and 
Long Evans hooded ( ■ ) rats treated with 2.4 g/kg citral 
in cornoil. Ail relative liver weights of citral-treated 
rats are significantly greater (P < 0.001) than control 
animals.
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administration of citral (figure 4.3). Administration of 
warfarin, either alone, or concurrently with citral, 
resulted in a great prolongation of clotting time, to the 
extent where no clot formation could be recorded, even at 
a decreased dilution (1/6 dilution of blood : thrombotest 
reagent compared to the usual 1/51 dilution). 
Pretreatment of albino rats with citral decreased the
prolongation of thrombotest clotting time due to the
warfarin; this was not evident in hooded rats (table
4.2). Three days following the administration of 
warfarin, either alone, or concurrently with citral to 
albino rats, the thrombotest clotting time had returned 
to the control value; in the hooded rats, the return to 
control values only occurred following coadministration 
of warfarin and citral. This represents a strain
difference in the response to citral and warfarin
administration.
4.3.3 The Effect of Citral upon Plasma Warfarin Levels
The assay of plasma warfarin was verified by
excitation and emission wavelength scans carried out to 
establish the wavelengths that gave peak fluorescence of 
warfarin (figure 4.4). It was also shown that citral did 
not interfere with the fluorescence assay of warfarin
(f igure 4.5).
Pretreatment with citral greatly reduced the total 
plasma warfarin concentration in both albino and hooded 
rats. The plasma warfarin concentration immediately
1 0 1
Figure 4.3
The Effect of Daily Gastric Intubation Administration of
Citral Upon the Thrombotest Clotting Time.
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The figures presented are the mean ± SEM for Wistar 
albino ( ® ) and Long Evans hooded ( B ) rats, with 3 
determinations per time point. Citral was administered 
at a level of 2.4 g/kg in cornoil. * * P<0.01 compared 
to controls.
1 0 2
û)
u
c
<D
O
en
CD
Vj
c
3
f— I
lu
tü
CDCh
U
oU-J
en
c
O
-r4
aJ
•H
Xj
C
o
u
CD
J=
4-)
CD
C
£
u
0)Jj
CD
C
O
jJ
en
c
fO
u
œ
03
X: E
x J enen 03c 1—4
CD Çh
rH
CD c
> -r-t
03
[5 C
C Vj
0 03
XJ
en Vj
en 03
3:
E
CD XJ
0
03
c >1
03 03
en
C en
• 0 <
-rJ
jJ CD
CD 03X:
Vj jJ jj
3
03 U Vj
•H X 0
Cu Cx3 XJ
rSOO
4 5 0
- 4 0 0
3 5 0
r 4 0 0
3 5 0
1-300
E
c
en
c
o
a>
>
(0
fO
(D
a
E
C
en
o
(T3
4J
CD
en
ai
c
(D
pH
CD
>
fÜ
C
o
•f-H
en • 
en E
-r4 C
E o
(D TT 
m
l o
x: 
x: j-> 4J en
•H c
> CD
C
X: o
XJ -r4 
CJ1 4J
c 03 
CD X)
I—I -r-t
CD O 
> X 
03 CD
c
03
X) 
03
en
03 
(D
u 
c
CD 
U 
en 
CD 
Vj 
O 
3
03
CD
Cb
CD
x:
H
E
c
0
ro
X»
03
xJ
CD
en
x:jj
01
c
CDr4
CD
>
03
C
O
"'-4 ,
™ i
en
-r4 Q
CD u-j 
O
CD
x: x:j_i jj
en 
cX:jj
X3 y) 
-v-) en 
cn.rH
- B
CD <D
%
CD
5  XJ
03
C 
O
en 
en
•r4
E
CD
C 
<
< XJ CD XJ
103
QJ
x:
H
400
«
0 03
e
0)
Ü
c
03
CO
03
1-4
cu
u
03 c•i4XI
U
03 c-HXI
c Li03M XI
U
03 03
X: 3:jj
X
03 0
cn >13
03 03
0 COCO
0 <c
XI u•rH
CO Li
C XI
03 03
Ü e
C/3 0u
X: 03XI iHcn
C Cx
03 03i-H X:03 XI>
Ifl
03
3: X:XI
-H
C
0
)
Q) •I-l r—1
U c/3 03
3 CO U
cn-f-i XI•H Ê •HCi3 P
400
L3 5 O
400
400
350
e
c
ec
o
m
+J
jj
0)
(f)
x:4J
CDc
o
r-4
<D
>
03
>
C
o•r-i
03X
-r4
U
X
0)
03 .
J= x: z
4-" XI X
O)
c X tn
(D X (N-f—4
0 3 CO
>
(0 X
05
3
5
3
0 c•H
T3 3-1
03 03
•r-l X
Li 3-1
3-4 03
03 3
Ü T3
03
U
C
03
Q)
> 1—105
3-1
CO Xc •H
03 U
U
CO X
0X
X ccn 0
c ■H
03 X«—< 05
03 34
> X
05 C
3 0)
Ü
1— 1 C
rH 0
< Ü
T3
•I-l
U
05
U
•I-l
3-4
0 •
rH c
X •iH
u 3-1
0 03
3-1X
13 3-1
>1 03
X 3
. 13 T51—1 C C
03 03 03
3-1
X 1—1 rH
-r-l 03 05Ü 3-13-4
X X
03 •H •I-l
C Ü u
03
03 03 03 0)
C C C c
0 0 0 0X X X X
03 03 03 03
U U 0 Ü
05 03 03 03
X X X X
X X X X
•r4•H •I-l •H
3 3 3 3
C C c C
03 03 03 03
Ü Ü 0 0
CO CO CO CO
X X X X
X X X X
cn cn 03cn
c c c C
03 Q) 03 031—4rH 1—1rH
03 0) 03 03
> > > >
03 03 03 05
3 3 3 3
C C C C
0 0 0 0•H •I-l •f-i*fH
CO CO CO CO
CO CO CO CO
•I-l •H •H • iH
e Ê BGO CO CO
.
< 00 u Q
104
following the cessation of warfarin administration alone 
was greater in the hooded rats than the albino rats. 
Three days after the cessation of warfarin administration 
to albino rats, both alone and following citral
pretreatment, the plasma warfarin concentrations were
reduced to almost control levels. However, the hooded
rats only showed such a reduction following citral
pretreatment and warfarin administration. Three days 
following warfarin administration alone, the plasma 
warfarin levels were still 80% of the concentration 
immediately following cessation of warfarin
administration. This high level correlates with the 
greatly prolonged thrombotest clotting time (table 4.2) 
recorded at the same time.
4.3.4 The Effect of Citral and Warfarin Administration 
upon Plasma Protein, Albumin and Lipid
Following citral administration, there was a general 
decrease in total plasma protein concentration with time 
with both strains of rat (figure 4.6). Conversely, the 
albumin concentration showed only a transient fall 
(figure 4.7) suggesting that there was a fall in plasma 
proteins other than albumin following citral 
administration. Warfarin administration decreased both 
the total plasma protein and the albumin concentrations 
in hooded rats compared to control values (table 4.2). 
In the albino rats, albumin was only decreased following 
citral and warfarin administration.
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Figure 4.6
The Effect of Daily Gastric Intubation Administration of
Citral Upon Total Plasma Protein Concentration.
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The figures presented are the mean ± SEM with 3 animals 
per group for Wistar albino ( e ) and Long Evans hooded 
( ■ ) rats administered 2.4 g/kg citral in cornoil. The 
mean control values are given at time 0 of citral 
administration. * P < 0.05 and ** * P < 0.001 compared to 
controls.
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Figure 4.7
The Effect of Daily Gastric Intubation Administration of
Citral Upon Plasma Albumin Concentration.
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The figures presented are the mean ± SEM with 3 animals
per group for Wistar albino ( 9 ) and Long Evans hooded
( ■ ) rats administered 2.4 g/kg citral in cornoil. The
mean control values are given at time 0 of citral
administration. * P<0.05, * * P <0.01 and ** * P< 0.001 
compared to controls.
107
Figure 4.8
The Effect of Daily Gastric Intubation Administration of
Citral Upon Total Plasma Lipids.
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The figures presented are the mean ± SEM with 3 animals, 
per group for Wistar albino ( 9 ) and Long Evans hooded 
( ■ ) rats. Citral was administered at a level of 2.4 
g/kg in cornoil. The mean control values are given at 
time 0 of citral administration. * P < 0.05 compared to 
controls.
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Total plasma lipid concentrations showed transient 
increases in both strains, but the peak occurred at 
different times; at termination the concentrations were 
not significantly different from the initial values. 
Administration of warfarin in combination with citral 
reduced the total plasma lipids in albino rats compared 
to controls. The high standard errors make
interpretation of the results difficult with the hooded 
rats; however, warfarin administration appeared not to 
affect the total plasma lipids(figure 4.8 and table 4.2)
4.3.5 Diplacement of Warfarin from Albumin Binding by 
Citral In Vitro
In view of the important effects which reduced 
binding to albumin might have on the anticoagulant 
properties of warfarin, an in vitro method to determine 
the binding of warfarin was employed to investigate the 
displacement from the binding by citral. The method was 
again verified by scanning the emission wavelength on a 
preset excitation wavelength (figure 4.9) to indicate the 
emission wavelength that gave the peak fluorescence. The 
peak fluorescence was at an emission wavelength of 385
nm. A comparison between albumin species indicated that
warfarin was most highly bound to RSA (figure 4.10). The 
species difference showed differential binding, the 
binding varied as follows: RSA > HSA > ESA. During this 
work, HSA was employed due to its availability and
nearness of fit to RSA binding characteristics. In
vitro, citral did not significantly displace warfarin
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Figure 4.9
An Emission Scan to Verify the Conditions for the Assay 
of Warfarin to Protein Binding In Vitro.
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The excitation wavelength was set at 320 nm and this gave 
a peak fluorescence at an emission wavelength of 385 nm.
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Figure 4.10
The Binding Capacities of BSA (A), HSA (O) and RSA (□) 
with Warfarin.
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The binding of: the albumin species was measured
fluorometrically in vitro in an assay mixture 7.24 pM 
albumin with between 1 - 1 0  pM warfarin with an
excitation wavelength of 320 nm and an emission
wavelength of 385 nm.
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from albumin binding (figure 4.11). This suggests that 
citral alters the anticoagulant properties by another 
strain - related mechanism.
Discussion
The haemorrhage in the stomachs of hooded rats 
treated with citral and warfarin concurrently was 
associated with acute focal gastritis, which was also 
apparent in albino rats. Some work in collaboration with 
another student (see Carmichael, 1985) suggested that the 
gastritis was related to the concentration of citral 
administered, with hooded rats being more susceptible 
than albino rats. However, it is not known whether the 
strain difference was due to different metabolism of 
citral or due to a different gastric mucosal barrier in 
the two strains of rat. Selective histological
examination of the stomach sections suggested that there 
was an increased secretion of mucus*- in hooded rats, 
following citral administration, that acted to protect 
the gastric mucosa. Rainsford (1975) and Mackie and 
Douglas (1984) suggested that the ulcerogenic compound, 
aspirin, caused gastric and duodenal ulcers by impairment 
of mucjiis' synthesis and loss of integrity of the gastric 
mucous barrier resulting in mucosal damage by physical 
disruption and hydrogen ion irritation. The haemorrhage 
associated with aspirin was attributed to an active 
metabolite (Takahashi and Hiraga, 1985). The results 
presented here suggest that citral caused irritation with
1 1 2
Figure 4.11
The Displacement of Warfarin from Albumin Binding by 
Citral.
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The figures presented are the mean ± SEM with 4 
determinations per point. The in vitro fluorometric
assay with citral ( • ) consisted of 7.24 pM HSA, 25 pM
citral in glycerol and between 1 - 80 pM warfarin. In
the control assay ( O ), glycerol was used in place of
citral. The excitation wavelength was fixed at 320 nm 
with a corresponding emission wavelength of 385 nm.
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altered vessel permeability, but in combination with 
warfarin, which also increases vessel permeability 
(Chazov and Lakin, 1980), haemorrhage resulted. The 
adhesion between the organs due to ulceration and tissue 
repair suggests that the ulcerogenic effect of citral was 
an acute reaction.
Hepatomegaly only occurred following citral 
administration alone and in combination with warfarin, 
suggesting that the liver enlargement was a response to 
citral and not warfarin (see Chapter 3, section 3.3.2). 
In addition, to support this, no hepatomegaly was noted 
following warfarin administration alone.
Administration of citral to hooded rats resulted in 
a transient prolongation of the thrombotest clotting 
time, however, the time of onset was after 10 days of 
citral administration, which is later than the time of 
onset reported in Chapter 3. Citral administration to 
albino rats did not affect the thrombotest clotting 
time. Warfarin administration greatly prolonged the 
clotting time in both strains of rat and citral 
pretreatment decreased the plasma concentration of 
warfarin in both strains but only reduced the thrombotest 
clotting time in the albino rats.
The in vitro assay for displacement of warfarin from 
albumin binding by citral showed that there was no effect 
and so the decreased anticoagulant effect of warfarin
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must be due to altered absorption, metabolism or 
excretion. Absorption of warfarin is a passive process 
in the upper gastro-intestinal tract (Koch-Weser and 
Sellers, 1971) being complete within nine hours (Chazov 
and Lakin, 1980). The gastritis and associated
disturbances in mucous secretion and also possibly the 
gastro-intestinal microflora may alter the absorption of 
warfarin. Several other physiological states and foreign 
compounds have been shown to alter warfarin uptake. 
These include the contents of the stomach and intestine 
and cholestyramine, for example, which has been shown to 
reduce the anticoagulant action of warfarin by reducing 
the uptake (Benjamin and McCormak, 1971; Janchen and 
Meinertz, 1977).
Citral has been demonstrated to be a selective
antimicrobial compound (Stevens et al., 1970 ; Cole ejt
al. , 1975); such effects on the gut microflora would
result in more warfarin being excreted in the faeces with
less in the urine due to reduced absorption (Remmel e_t
al. , 1981). Any reduction in the microflora of the gut
in rats reduces the half-life of warfarin due to
decreased re-absorption and associated disrupted
enterohepatic recirculation (Remmel et al., 1981). If
the two strains of rat have different microbial
populations in the gastro-intestinal tract, citral may be
selective to the population in one strain only.
ta
Alternatively there may be adaption by the microflora in 
the gut of only one strain to the effects of citral.
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This may account for the greater relative reduction in 
the plasma warfarin in the albino rats compared to the 
hooded rats since the warfarin clearance will be greater 
with a reduced gut microflora (a 70% reduction in total 
plasma warfarin three days after cessation of 
administration in albino rats, but only by 20% in the 
hooded rats). This effect cannot be excluded, but seems 
unlikely between strains of the same species.
The fact that the albino rats were affected by
citral administration with regard to plasma warfarin 
levels, is supported by the results of Takeda and Levy 
(1980) and Covell et al., (1983). These groups reported
levels of plasma warfarin in rats 24 hours and 72 hours 
after the administration of Img/kg warfarin as being very 
similar to those reported here for the hooded rats at the 
same time points. The albino rats had plasma levels
below the previously reported levels.
Effects upon warfarin metabolism have been reported 
both by the gastro-intestinal microflora and by the mixed 
function oxidase system of the rat. Scheline (1968)
demonstrated metabolism of coumarin to dihydroxycoumarin 
by the rat caecal microflora. Since the parent compound 
has been identified as being responsible for the 
anticoagulant activity (Barker et al. , 1970), this
metabolite would not contribute to the anticoagulant 
activity. If such a metabolic change occurred in the 
upper gastro-intestinal tract, and the metabolite was
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absorbed, the assay, which is specific for warfarin, 
would not detect the metabolite, so giving a lower plasma 
warfarin concentration.
Compounds that induce the mixed function oxidase 
system have been shown to alter warfarin metabolism 
(Ikeda et al., 1968; Covell et al., 1984; Qureshi et al., 
1984; Kling et al., 1985). The work of Parke and Rahman 
(1969) has demonstrated that citral induces enzymes of 
the mixed function oxidase system in rats and this is 
borne out by the reduction in plasma warfarin 
concentrations in both strains of rat following citral 
pre-treatment and warfarin administration. The
difference between the strains with regard to warfarin 
concentration following warfarin administration alone 
suggests that the two strains have different basal levels 
of the inducible elements of the mixed function oxidase 
system, with albino rats having a greater basal level 
than hooded rats. In addition, the inducibility of the 
mixed function oxidase system may be different between 
the strains, so that citral pre-treatment results in a 
differential fall in plasma warfarin in the two strains.
Effects on absorption and metabolism will affect the 
excretion of warfarin and its metabolites from the body 
in the bile, urine and faeces. Barker et al. , (1970)
showed that under normal conditions, only 6% of the 
excreted metabolites is unchanged warfarin. If the 
metabolism is disturbed, then the amount of unchanged
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warfarin excreted may vary. The excretion is a factor of
hepatic uptake and so is a secondary effect of the
metabolism and rate of distribution within the body.
Despite these alterations in absorption, metabolism and
excretion that may occur, the different genetic pools of
the two strains of rat may explain the differences in
toxicity of warfarin. Indeed, Pyorala and Nevanlinna
(1968) have demonstrated that genetic factors play an
important role in the activity of warfarin metabolism.
Other mechanisms are more indirect with an altered
u
response to anticoagulants. For example, hyperthyroidism 
increases the response to anticoagulants and 
hypothyroidism decreases the response (Loeliger et al. , 
1964; O'Reilly and Aggeler, 1970; Breckenridge, 1978). 
Other hormones have been shown to influence the 
sensitivity to anticoagulants, and this has been reviewed 
by Pyorala (1965).
The lack of a reduction in the plasma albumin 
concentration suggests that the warfarin-albumin binding 
is not affected. The in vitro analysis of the effect of 
citral on warfarin - albumin binding confirmed the lack 
of effect. The difference in degree of binding between 
species is in agreement with the results of Sellers et 
al., (1977). If Wistar albino rat - derived albumin is
very different from Long Evans hooded rat - derived 
albumin, than there may be less binding between warfarin 
and albumin in the albino rats with an increase in the 
amount of free warfarin and a consequential increase in
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the rate of metabolism. However, the binding
characteristics of the two albumin species would have to 
be very great to account for the strain difference in 
warfarin levels.
The fall in total plasma protein only occurred in 
the hooded rats following citral administration. 
Warfarin had a similar effect, both alone and in
combination with citral administration. Such a fall may 
be related to the gastritis with the associated 
proteinaceous exudate seen in the hooded rats, but not 
the albino rats.
In summary, citral pre-treatment decreased the 
concentration of plasma warfarin. In combination, citral 
and warfarin caused a haemorrhagic death in hooded rats 
as a result of severe gastritis. Citral administration 
alone, caused a small transient prolongation in the
thrombotest clotting times only of hooded rats; there was
no effect in albino rats. Albino rats showed a reduced
plasma concentration of warfarin compared to hooded rats 
due to an effect upon absorption, metabolism or excretion 
of warfarin. These results suggest that vitamin K is not 
involved in the mechanism of citral toxicity with regard 
to the prolongation of the thrombotest clotting time. 
The hooded rats, where the prolongation was evident, 
showed no effect with citral and warfarin administration 
other than could be accounted for by the action of 
warfarin alone.
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Chapter 5
The Effect of Coadministration of Citral and
Vitamin A to Wistar albino and Long Evans hooded Rats
Upon Blood Coagulation and some Hepatic Xenobiotic
Metabolising Enzyme Activities.
Introduction
Antagonism between citral and vitamin A has been 
well documented, especially with regard to cellular 
differentiation, ocular toxicity and teratogenicity (see 
section 1.3.8). There is little published data on the 
mechanism of the citral/vitamin A interaction although 
recently, the structural similarity between retinol 
(vitamin A) and citral has been suggested as a cause of 
the antagonism (Schauenstein et al. , 1977; Wood, 1981).
The role of vitamin A in blood clotting was first 
reported during the 1940s when several groups of workers 
showed that hypervitaminosis A in rats resulted in 
haemorrhage and hypoprothrombinaemia (Light et al., 1944; 
Moore and Wang, 1945; Walker et al., 1947), however, the 
mechanism of action was not defined. Subsequent work 
suggested that vitamin A prevented vitamin K synthesis by 
the intestinal microflora (Quick and Stefanini, 1948), 
although later, hypervitaminosis A was shown to cause 
haemorrhage in germfree rats (Wostman and Knight, 1965).
Work with citral and vitamin A has shown that citral 
may act as a competitive inhibitor of vitamin A (Leach 
and Lloyd, 1956; Aydelotte, 1963; Crocker and Sanders, 
1970) , although most of this work was carried out in 
vitro. It has also been suggested that citral binds to 
RBP, displacing vitamin A, and it is the unbound vitamin 
A that causes the symptoms of hypervitaminosis A in vivo 
(Smith and Goodman, 1976). Thus the interaction may 
occur during the transport of vitamin A to the liver
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where it is stored.
The aim of this work was to study, in more detail, 
the interaction of citral with vitamin A. By employing 
dietary administration of different levels of vitamin A 
with simultaneous dietary administration of citral to 
both albino and hooded rats, the effect of both vitamin A 
and citral upon the thrombotest clotting time and upon
the vitamin A status itself was studied. In the study 
enzymes of the mixed function oxygenase system were also 
measured since they may indirectly affect the vitamin A 
status.
The aim of the work was to examine the interaction
between vitamin A and citral and to elucidate the
mechanism of the interaction.
Materials and Methods
5.2.1 Chemicals
The following reagents/chemicals were obtained from 
suppliers as indicated.
Benzphetamine Hydrochloride - Upjohn Co. Ltd. , 
Kalamazoo, Ml, USA
Casein (technical grade) - BDH Ltd., Poole, Dorset,
U.K.
Cornoil - SDS Ltd., Witham, Essex, U.K.
7-Ethoxyresorufin and resorufin - Molecular Probes 
Inc., Junction City, Or., USA.
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Glucose - 6 - Phosphate - Sigma Chemical Co. Ltd., 
Poole, Dorset, U.K.
Minerai Mix - SDS Ltd., Witham, Essex, U.K.
NADP+ - Sigma Chemical Co. Ltd., Poole, Dorset, U.K. 
Starch (Maize) - BDH Ltd., Poole, Dorset, U.K. 
Vitamin A Free Vitamin mix - SDS Ltd. , Witham, 
Essex, U.K.
Vitamin A Palmitate - BDH Ltd., Poole Dorset, U.K. 
Ail other chemicals and reagents were obtained from 
sources as outlined in earlier experimental chapters. 
All histological materials were obtained as outlined in 
Chapter 3. In addition, some specialist stains were 
obtained from BDH Ltd., Poole, Dorset, U.K.
5.2.2 Materials
Brand Microhaematocrit Sealant - Brand Ltd. , 
Wertheim, West Germany.
Heparinized capillary tubes - Lancer Ltd. , St. 
Louis, Mi., USA.
5.2.3 Animals and Husbandry
Male Wistar albino (University of Surrey) and male 
Long Evans hooded rats (Charles River Ltd., Manston, 
Kent, U.K.) weighing 55 l 5 g were obtained and housed in 
polypropylene cages with sawdust as litter.
For each strain, the animals were housed ten to a 
cage in eight cages. With the four vitamin A levels 
used, each strain had two cages per vitamin A level (one
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control and one test group). Body weight and water 
consumption were monitored daily. Food consumption was 
measured every other day. All animals were given the 
semi-synthetic diet (see section 5.2.4) ad libitum for a 
period of 7 days prior to the addition of citral in order 
to acclimatise to the diet. Free access to the diet was 
continued during the test period.
5.2.4 Diets
Semi-synthetic diets were used to enable adjustment 
of the vitamin A levels. The basic diet consisted of:
71% Starch All percentages are w/w
16% Casein 
5% Mineral Mix
2% Vitamin A - free vitamin mix 
6% Cornoil
Vitamin A was added in the form of retinyl 
palmitate. This was supplied as a concentrate containing
1,700,000 i.u. which was added to the diet to give four 
levels of vitamin A; 1,000, 10,000, 20,000 and 100,000
i.u./kg diet, the normal level being 10,000 i.u./kg diet 
(as reported in the manual on Laboratory Diets issued by 
Spratts Ltd.). The vitamin A levels used here were thus 
O.lx, Ix, 2x and lOx the normal dietary level. Citral 
was added to the test diets at a level of 2% (w/w).
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The relative contributions of the mineral and 
vitamin A - free vitamin mix are summarised in table 5.1.
The diet was changed completely every other day from 
stocks made up weekly. These stocks were stored in brown 
glass jars at 4°C to minimise reported losses of both 
citral and vitamin A (Jones et al., 1962; Allwood and 
Plane, 1984). The administration of the vitamin A is 
summarised in table 5.2.
5.2.5 Thrombotest Clotting Times
The thrombotest clotting times for whole blood were 
carried out as described in Chapter 3 (section 3.2.9).
5-2.6 The Autopsy
The study was terminated on day 14 and the autopsy 
was carried out as previously described (Chapter 3 and 4) 
with "Sagatal" anaesthesia. Enough blood was withdrawn 
to provide two samples to be used as follows: 1 ml of
whole blood was added to EDTA containing tubes 
(séquestrant) for blood films and packed cell volume 
determinations whilst thrombotest determinations were 
carried out on citrated samples prior to the separation 
of plasma as described in Chapter 4, (section 4.2.5).
Portions of liver, spleen, kidney and testis were 
taken and processed for routine histology (Chapter 3, 
section 3.2.11). From the liver, one slice was fixed in 
Rossman's Fluid for 24 hours, two slices were fixed in
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Table 5.1a
Mineral Mix Composition.
Salt g/kg mix g/kg diet (5% w/w 
concentration)
Sodium Chloride 50 2.50
Calcium Phosphate 400 20.00
Iron Citrate 35 1.75
Potassium Iodide 1 0.05
Magnesium Sulphate 80 4.00
Acid Sodium Phosphate 105 5.25
Potassium Chloride 250 12.50
Sodium Fluoride 0.04 0.002
Manganese Sulphate 0.2 0.01
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Table 5.1b
Vitamin A - Free Vitamin Mix
Vitamin Unit/kg diet
D3 2 ,000 in
E 1 0 0 in
B2 10 mg
K 10 mg
Nicotinic Acid 20 mg
Calcium Pantothenate 20 mg
Folic Acid 1 . 0 mg
Bl 10 mg
B6 10 mg
Biotin 40 meg
B12 10 meg
C 5 0 mg
Inositol 500 mg
Choline 400 mg
pAminobenzoic Acid 1 0 0 mg
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Table 5.2
Vitamin A Feeding Protocol.
The following table summarises the feeding study for 
citral and vitamin A. Both strains of rat received the 
same feeding regime:
Diet ' 
(Vitamin A as iu/kg diet)
Number of Animals Duration
(days)
1,000 iu vitamin A 10 14
1,000 iu + 2% citral 10 14
10,000 iu vitamin A 10 14
10,000 iu + 2% citral 10 14
20,000 iu vitamin A 10 14
20,000 iu + 2% citral 10 14
100,000 iu vitamin A 10 14
100,000 iu + 2% citral 10 14
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10% (w/w) saline - phosphate buffered formalin, pH 7.4
for 7 days and the remainder was cooled in ice-cold 
homogenising medium (0.25M sucrose/5mM TRIS, pH 7.4) 
prior to the preparation of an 89 fraction and hepatic 
microsomes (see section 5.2.7).
5.2.7 Preparation of the 89 Fraction and Microsomes 
From Liver Homogenates
Following removal of sections for light microscopy, 
the residue of the liver was reweighed, cooled in 
ice-cold homogenising medium (0.25 M sucrose/5 mM TRI8- 
HCl, pH 7.4) and homogenised by three complete strokes of 
a Potter Elvehjem homogeniser with a pestle rotating at
2,000 revs/min. The volume of the homogenate was 
adjusted so that 5m 1 of homogenate contained Ig tissue. 
An aliquot of 20ml was diluted with 20ml of
homogenising medium and centrifuged at 10,000g for 15 
minutes at 4°C in a Beckman J2-21 centrifuge using a
JA-17 14 X 50 titanium rotor (Beckman Ltd., High Wycombe, 
Bucks, U.K.). The resulting supernatants (the 89 
fractions) were decanted and an aliquot kept for later 
assays. The remainder of the 89 fraction was centrifuged 
for 1 hour at 100,000g at 4°C in a Beckman L5-65
Ultracentrifuge using an 8 X 30 60Ti titanium rotor. The 
resulting supernatants (cytosol) were discarded and the 
microsomal pellets frozen overnight at -20°C. These were 
then resuspended in 26ml of homogenising medium using a 
Potter Elvehjem homogeniser as described above. The 
suspensions were centrifuged again at 100,000g as
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described above. The pellets were finally resuspended in 
5m 1 of the homogenising medium containing 20% (v/v)
glycerol and stored at -70“C in 1.0ml aliquots for 
subsequent assays. The final volume of the microsomal 
suspensions were noted.
5.2.8 Histology
Samples of the formalin - fixed tissues were wax -
embedded and sectioned as described in Chapter 3 (section
3.2.11). These were then stained by the routine
haematoxylin and eosin procedure as outlined previously.
After 24 hours of fixation in the Rossman's Fluid, the
liver sections were washed in absolute alcohol for 5 days
prior to wax - embedding and sectioning. These sections
were stained by the routine Periodic Acid Schiffs (PAS)
method (Culling, 1974). The remaining formalin - fixed
liver sections were sectioned on a sledge microtome
(Reichet, Austria) with a freezing stage (Mectron
Instrumentation Division, Hanovia Ltd., Slough, Berks,
U.K.). Free floating sections were then stained by
Lillie and Ashburn's Oil Red "0" method for lipids
lè.
(Culling, 1974). These stained sections were subsquently
A
mounted in glycerin jelly.
5.2.9 Preparation of Blood Films and Packed Cell Volume 
Determinations
Blood smears were made with the EDTA blood samples. 
The glass microscope slides used were washed in absolute 
alcohol and dried before the smears were made. Each
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smear was then rapidly air-dried and fixed in methanol 
for 20 minutes. Fixed blood films were placed in freshly 
prepared May-Grunwalds stain for 5 minutes. These were 
then stained in freshly prepared Giemsa stain for 10 
minutes followed by differentiation for 2 minutes in 
distilled water. Finally, the smears were dried in air
and a differential RBC count was made using light
microscopy.
The packed cell volume (PVC) was determined by the 
haematocrit micro - method with 75mm heparinized 
capillary tubes. Blood was drawn up the tubes by
capillarity leaving approximately 20mm unfilled. Each 
tube was then sealed with vinyl plastic putty (Brand 
Microhaematocrit Sealant) and centrifuged in a 
micro-haematocrit centrifuge (MSE Ltd., Crawley, Sussex, 
U.K.) for 5 minutes at 12,000 g . The PCV was then read 
using an MSE micro-haematocrit reader with the results 
expressed as percent PCV.
5,2.10 Determination of Plasma Vitamin A
The assay was carried out in 15 ml screw top Sovrill 
tubes according to the method of Hansen and Warwick 
(1978). Plasma samples (200 pi) were added to 1.0 ml of 
distilled water and 2.0 ml of absolute alcohol. The 
mixture was then vortex mixed for 15 seconds. A 5.0 ml 
aliquot of 60 - 80 ether (petroleum spirit ether) was
added and the mixture was further vortex mixed for 30 
seconds. The layers were allowed to separate and the
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fluorescence of the vitamin A containing ether extract 
was measured in a Perkin - Elmer MPF-3 fluorescence 
spectrophotometer with a Perkin - Elmer 150 Xenon Power 
Supply (Perkin - Elmer Ltd., Beaconsfield, Bucks, U.K.) 
and a Hitachi QPR Chart Recorder. The excitation 
wavelength was set at 340nm with a corresponding emission 
wavelength of 480nm. These wavelengths were verified by 
scanning the excitation and emission wavelengths to 
obtain the peak fluorescence.
Retinyl acetate was employed as standard in the 
range of 0 - 1 . 0  pg/ml. The vitamin A levels were 
calculated according to the relationship:
Concentration from Standard Curve X 0.3 X 10 0
0.344
This gave the "corrected" concentration of vitamin A 
in plasma in pg/lOOml. The "corrected" value takes into 
account the fact that retinyl acetate was used as 
standard for the measurement of retinal palmitate in the 
plasma.
5.2.11 Determination of Hepatic Vitamin A
Hepatic vitamin A levels were determined according 
to the method of Thompson et al., (1971). Liver
homogenate (0.6ml) was saponified by heating in a boiling 
water bath for 15 minutes with 60% (w/v) potassium
hydroxide (0.5ml) in the presence of 1% (w/v) ethanolic
pyrogallol (1.0ml). The tubes were then cooled and 1.0ml 
of distilled water was added. The unsaponified material
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was extracted by two 5.0ml aliquots of hexane. The 
fluorescence of the pooled extracts was measured as 
described for the plasma vitamin A. Results were 
expressed as mg vitamin A/whole liver.
5.2.12 Benzphetamine N-Déméthylation (specific for
cytochrome P-450)
The assay was based on the method of Lu et al. , 
(1972) except that benzphetamine hydrochloride was used 
in place of ethylmorphine.
A 0.5ml aliquot of S9 (see section 5.2.7) was 
incubated for 10 minutes at 37°C with an incubation
cocktail consisting of 0.3M TRIS-HCl, pH 7.6 (0.5ml),
O.lM magnesium chloride (0.1ml), lOmM benzphetamine 
hydrochloride (0.25ml), 2% (w/v) semicarbazide
hydrochloride, pH 7.0 (0.2ml), 0.03 M glucose - 6 -
phosphate (0.5ml) and 2.5mM NADP+ (0.5ml). The reaction
was terminated by the addition of 1.0ml of 15% (w/v) zinc
sulphate followed by 1.0ml of a 2:1 mixture of a 
saturated solution of barium hydroxide and sodium 
tetraborate. A standard of 20 pi of a .40 pmol/ml
aqueous formaldehyde solution was employed. This was 
added in place of the benzphetamine hydrochloride. With 
the blank, the benzphetamine hydrochloride was added to 
the incubation mixture after the reaction had been 
terminated.
Protein was sedimented by centrifugation to leave a
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clear supernatant. Aliquots (2.0ml) of the supernatant 
were then added to 2.0ml of fresh Nash reagent (Nash, 
1953) (4M ammonium acetate containing 4ml/L of
acetylacetone). The mixture was incubated for 40 minutes 
at 37°C in a shaking water bath to allow colour 
development. The extinction was then recorded at 412nm 
on a Cecil 292 Digital Ultraviolet Spectrophotometer with 
a CE 235 Micro - Sipette control attachment (Cecil 
Instruments, Cambridge, U.K.).
The results were then calculated as follows:
Standard - blank = A 
Unknown - blank = B
X = Concentration of Standard x B
A
pmol/g liver/h = X x 2 x 5 x 6 = 6 0 X ,  where pmol refers 
to the reduction of NADP^.
5.2,13 7 - Ethoxyresorufin 0-Deethylation (a specific
substrate for cytochrome P-448)
The method of Burke et al. , (1977) was used with a
reaction mixture of O.lM TRIS-HCl, pH 7.8 (2.0ml), 20%
microsomal suspension (50 p i )  and 50 p M  ethoxyresorufin 
(10 p i ) .  The reaction was carried out in fluorescence 
cuvettes equilibrated at 37°C. A baseline fluorescence 
was recorded in a Perkin - Elmer LS-5 Luminescence 
Spectrophotometer with a 561 Recorder (Perkin - Elmer 
Ltd., Beaconsfield, Bucks, U.K.). The excitation
wavelength was set at 510nm with the emission wavelength 
fixed at 586nm. Finally, 10 p i  of 50mM NADPH was added
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to the reaction mixture and the change in fluorescence 
was followed for at least 2 minutes to obtain a steady 
rate of reaction. The fluorescence of 10 and 20 pi of 
O.OlmM resorufin was recorded as the standard. This was 
then used in the calculation of the rate of reaction as 
follows:
Standard - 10 pi of O.OlmM (= O.OlmM/L) = O.lnM. 
Thus, the factor to give InM is 10.
% change = Number of units change (standard) x 10
fixed scale (standard)
For the sample, calculate the gradient: 
a = Number of units change (sample) 
fixed scale (sample)
Finally, a = nmols/min x 20 = nmols/min/ml microsomes 
% change
where the nmols refers to the oxidation of NADPH.
5.2.14 Cytochrome P-450 Difference Spectra
The spectra were carried out by the procedure of 
Omura and Sato (1964). The 20% microsomal suspensions 
were diluted 1 in 10 with O.lM phosphate buffer, pH 7.4 
and were then aliquoted into two cuvettes, one for the 
reference and the other for the sample position of the 
dual beam Varian 2,200 Spectrophotometer (Palo Alto, Ca. , 
USA). A corrected baseline was first obtained by 
scanning the extinction between 500nm and 400nm.
Approximately 25mg of sodium dithionite was then 
added to both cuvettes; carbon monoxide (British Oxygen
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Special Gases, London, U.K.) was then bubbled through the 
sample cuvette at a rate of one bubble per second for 30 
seconds. A differen[ce spectrum was then obtained by 
scanning between 500 and 4iÔ0nm. The cytochrome P-450 was 
expressed as a difference in extinction between 490 and 
4 5 0 nm.
5.2.15 Determination of Protein
Protein was determined by the coomassie blue method 
as described in Chapter 4 (section 4.2.8).
Results
5.3.1 The Effect of Citral Administration and Dietary 
Vitamin A upon Food and Water Consumption
With citral in the diet, the food consumption was 
lower than with the control diets; this was also found 
with previous work (see Chapter 3). The level of dietary 
vitamin A had no effect upon food consumption in either 
strain of rat. The change in body weight was related to 
the food consumption (figures 5.1 and 5.2). The hooded 
rats showed a greater body weight gain than the albino 
rats, with a correspondingly greater food consumption 
(figure 5.1). The difference in food consumption between 
the test and control groups also resulted in a lower 
vitamin A intake in the test groups compared to the 
corresponding control groups (figure 5.3), although the 
hooded rats had a higher vitamin A intake than the albino 
rats due to the food consumption.
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Figure 5.1
The Effect of Dietary Administration of Citral and 
Vitamin A Upon Food Consumption in Long Evans hooded (A) 
and Wistar albino (B) rats.
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Figure 5.2
The Effect of Dietary Administration of Citral and
Vitamin A upon Body Weight Gain.
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The figures presented are the mean ± SEM with 10 animals 
per group for Wistar albino ( O ) and Long Evans hooded 
rats { □ ). Citral was added to the diet at a level of 2% 
(w/w) for both Wistar albino ( • ) and Long Evans hooded 
( ■ ) rats. All animals fed a ci t ra 1-con ta i n i ng diet had 
a significantly lower (P< 0.001) body weight gain than 
controls.
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Figure 5.3
The Relationship Between Food Consumption and Vitamin A 
Intake.
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The figures are derived from the mean food consumption 
for the dietary levels of vitamin A for control Wistar 
albino ( O ) and Long Evans hooded ( □ ) rats. Line 1 
represents 1,000 iu/kg, line 2 - 10,000 iu/kg, line 3 -
20,000 iu/kg and line 4 - 100,000 iu/kg vitamin A.
Citral was added to the diet at a level of 2% (w/w) for
both Wistar albino ( • ) and Long Evans hooded ( ■ ) rats 
respect ively.
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During the study, the water intake was measured to 
gauge the effect of citral in the diet. Figure 5.4 
illustrates the results expressed as water intake per 
gram of food consumed. Citral in the diet increased the 
water intake for both strains of rat. The absolute water 
intake (ml water/animal/day) did not increase with citral 
in the diets (results not shown). Vitamin A in the diet 
did not affect the water intake.
5.3.2 Histopathology and Organ Weight Data
The relative organ weights show that dietary 
administration of citral caused hepatomegaly, testis and 
kidney enlargement in both strains of rat but no effect 
was observed with the spleen. However, the degree of 
organ enlargement was greater for the hooded than the 
albino rats with regard to the kidneys, liver and testes 
(figures 5.5 and 5.6). Organ enlargement was independent 
of dietary vitamin A intake in both strains of rat.
Histological examination of the organs by routine 
haemotoxylin and eosin staining did not reveal any 
pathological changes. Special stains for glycogen and 
lipid showed that following administration of citral, 
there was almost a complete loss of glycogen with 
periportal accumulation of lipid droplets in both strains 
of rat (figures 5.7 and 5.8, table 5.3).
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Figure 5.4
The Effect of Dietary Administration of Citral and
Vitamin A Upon Water Intake.
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The figures are the mean i SEM with 10 animals per group 
for control and citral treated Wistar albino (O,®) and 
Long Evans hooded rats (□,■) respectively. Where no SEM 
is shown, it is within the symbol for that point. All 
animals receiving a citra1-containing diet (2% w/w) had a 
significantly greater ( P <C 0.001) intake of water than 
controls.
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Figure 5.5
The EEÊect of Dietary Administration of Citral and 
Vitamin A Upon the Relative Kidney (A), Liver (B), Spleen 
(C) and Testis (D) Weights in Wistar albino rats.
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The figures are the mean ± SEM with 10 animals per 
group. Where no SEM is shown, it is within the symbol 
for that point. The figures compare control ( O ) with 
citral - treated ( # ) animals. Citral was added to the 
diet at a level of 2% (w/w). * P < 0.05, ** P < 0.01 and
* * * P < 0.001 compared to controls.
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Figure 5.6
The Effect of Dietary Administration of Citral and 
Vitamin A Upon the Relative Kidney ( A ) ,  Liver (B), Spleen 
(C) and Testis (D) Weights in Long Evans hooded Rats.
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The figures are the mean ± SEM with 10 animals per group. 
Where no SEM is shown, it is within the symbol for that 
time point. The figures compare controls { □ ) with 
citra1-treated ( ■ ) animals. Citral was added to the
diets at a level of 2% (w/w). * p < 0.05, ** P < 0.01 and
* * * P< 0.001 compared to controls.
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Figure 5.7
Photographs of Rossman's Fluid—fixed. Paraffin Wax 
Embedded Liver Sections Stained for Glycogen by the 
Periodic Acid Schiffs Reaction.
B
*
ti'
A) Section taken from the liver of a control Long Evans 
hooded rat (X 400),
B) Section taken from the liver of a Long Evans hooded 
rat fed 2% (w/w) citral in the diet for 15 days (x 400). 
Note the loss of glycogen from the centr ilobular (C.L.) 
region. Vitamin A had no effect upon this loss. Wistar 
albino rats showed similar centrilobular glycogen 
depletion.
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Figure 5.8
Photographs of formalin-fixed, frozen sections of Liver 
stained for Neutral Lipid by the Oil Red "0" method.
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A) . Section from the liver of a control Long Evans 
hooded rat (x 200).
B) Section from the liver of a Long Evans hooded rat 
fed a diet containing 2% (w/w) citral for fifteen days
(X 400). Note the periportal/midzonal (pp/mz)
accumulation of lipid. Wistar albino rats showed a 
similar pattern and dietary vitamin A had no effect upon 
the distribution of neutral lipid.
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Table 5.3
Change in' Glycogen levels in the Livers of Long Evans 
hooded and Wistar albino rats following dietary 
administration of citral (2%).
Hepatic Glycogen
Group Long Evans hooded Wistar albino
1,000 iu/kg vitamin A Minimal c.l. loss Minimal c.l. loss
+ 2% citral Complete loss Complete loss
10,000 iu/kg vitamin A No loss Minimal c.l. loss
+ 2% citral Complete loss Massive loss
20,000 iu/kg vitamin A No loss Minimal c.l. loss
+ 2% citral Complete loss Complete loss
100,000 iu/kg vitamin A Minimal c.l. loss Minimal c.l. loss
+ 2% citral Complete loss Complete loss
c.l. denotes centrilobular regions of liver.
All samples stained by the P.A.S. method for glycogen with 
a corresponding diastase blank.
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5.3.3 The Effect of Citral and Vitamin A upon the 
Thrombotest Clotting Time
During the study, the thrombotest clotting times 
were determined in all groups. In the albino rats, 
administration of citral had no effect upon the clotting 
time. With the hooded rats, there was a transient 
prolongation of the thrombotest clotting time after 10 
days of citral administration; this corresponds with the 
time of onset reported in Chapter 4 but only occurred at 
the top level of dietary vitamin A administration, and 
was only a 5 second prolongation. There was no 
dose-related effect of the dietary vitamin A upon the 
thrombotest clotting time (figure 5.9).
5.3.4 Blood Parameters
Since changes had only previously been reported in 
the hooded rat, the packed cell volume was only
determined for the hooded rats. Following 14 days of 
citral administration with four levels of vitamin A to 
hooded rats, there was no change in the packed cell 
volume. Neither the citral nor the dietary vitamin A
level significantly altered the values (table 5.4). The
blood films also showed no change in the erythrocytes 
following citral administration and dietary vitamin A
had no effect (table 5.5).
5.3.5 The Effect of Citral Administration upon Plasma 
and Hepatic Vitamin A levels
In order to determine the effect of citral upon
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Figure 5.9
The Effect of Dietary Administration of Citral and 
Vitamin A Upon the Thrombotest Clotting Time in Long 
Evans hooded (A) and Wistar albino (B) rats.
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The figures presented are the mean ± SEM with 5 
determinations per time point. The mean clotting times 
are given at time 0 of citral administration. A 
comparison between the dietary vitamin A levels of 1,000 
( A ), 10,000 ( A ), 20,000 ( □ ) and 100,000 ( ■ ) iu/kg
showed no related effect.
* P<0.05, ** P < 0 .01 and *** P< 0.001.
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Table 5.4
The Haematocrit of Long Evans hooded rats following 
administration of both citral and vitamin A.
PCV determined with sequesterine blood samples.
Dose Group PCV (%)
1.000 iu/kg vitamin A 41.1 ± 1.7
+ 2% citral 41.0 ± 1.7
10.000 iu/kg vitamin A 40.4 ± 1.8
+ 2% citral 41.9 ± 1.6
20.000 iu/kg vitamin A 40.8 ± 1.7
4- 2% citral 41.4 ± 0.5
100.000 iu/kg vitamin A 40.7 ± 2.2
+ 2% citral 40.4 ± 1.8
Figures presented are the mean ± SEM of 10 determinations
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vitamin A status both the plasma and the hepatic vitamin 
A levels were measured. The assay was verified by 
scanning the excitation and emission wavelength (figure 
5.10). The plasma vitamin A (figure 5.11) levels were 
not influenced by the level of dietary vitamin A. 
However, the hooded rats had higher plasma vitamin A 
levels than the albino rats. Administration of citral 
slightly, but not significantly, decreased the plasma 
vitamin A in both strains. In contrast, the total
hepatic vitamin A levels were significantly increased 
with the increase in dietary vitamin A. This was true 
for both strains, although the hooded rats had greater 
levels than the albino rats. The administration of
citral slightly decreased the total hepatic vitamin A, 
although this decrease was not significant (figure
5.12). The increases in total hepatic vitamin A were 
approximately proportional to the increases in dietary
vitamin A.
5-3.6 Induction of the Mixed Function Oxidase System by 
Citral
The effect of citral upon the mixed function oxidase 
system was studied by determination of the levels of 
two cytochrome P-450 isoenzymes. 7-ethoxyresorufin 
0-deethylation, a measure of the level of cytochrome
P-448, was not induced by citral administration in either 
strain, although in the hooded rats, activity increased 
with vitamin A concentration in the diet. Benzphetamine 
N-demethylation activity, a measure of cytochrome P-450,
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Figure 5.11
The Effect of Dietary Administration of Citral and
Vitamin A Upon the Concentration of Plasma Vitamin A.
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The figures presented are the mean ± SEM with 10 animals 
per group. Control Wistar albino ( O ) and Long Evans 
hooded ( □ ) rats are compared to c i t ral-t rea ted rats 
(corresponding solid symbols). Citral was added to the 
diet at a level of 2% (w/w).
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Figure 5.12
The Effect of Dietary Administration of Citral and
Vitamin A Upon Total Hepatic Vitamin A.
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The figures presented are the mean ± SEM with 10 animals 
per group. Where no SEM is shown, it is within the 
symbol for that time point. Control Wistar albino ( O ) 
and Long Evans hooded (□ ) rats are compared with citral- 
treated rats (corresponding solid symbols). Citral was 
added to the diet at a level of 2% (w/w).
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was increased following citral administration in both 
strains, although the increase in activity was only 
significant with the albino rats. As the level of
dietary vitamin A increased, so did the 
benzphetamine-N-demethylase activity; this occurred in 
both strains of rat; both strains had a similar control 
activity (figure 5.13). The cytochrome P-450 activity as 
measured spectrally, was induced in both strains
following the administration of citral, however, the 
increase was only significant with the hooded rats. This 
contrasts with the increase to benzphetamine N-
demethylase activity. Both strains had similar control 
levels of cytochrome P-450. Dietary vitamin A did not 
affect the level of cytochrome P-450.
Discussion
The food consumption and corresponding body weight 
gain figures are similar to those reported earlier (see 
Chapter 3). The dietary level of vitamin A had no effect 
upon body weight gain in the control groups of both 
strains and this supports the findings of Spit (1983) and 
Hicks et al., (1984). However, other published data 
suggests that both vitamin A supplementation and 
deficiency results in reduced body weight gain (Tuchweber 
et al., 1976; Donoghue et al., 1983, Garcin and Higueret, 
1983; Ott and Lachance, 1983; Kurtz et al., 1984; Tom e_t 
al. , 1984). Such a difference in body weight gain can
often be attributed to an altered food consumption
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Figure 5.13
The ÜllecL of 
Vitamin A Upon
B) Cytochrome 
0-Dee thyla t ion.
Dietary Administration of Citral and 
A). Benzphetamine N-Demethylation
P-450 and C) 7-Ethoxyresorufin
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The figures presented are the mean ± SEM with 10 animals 
per group. Citral was added to the diet at a level of 2% 
(w/w). The figures compare Wistar albino ( # ) with Long 
Evans hooded ( ■ ) rats. * P < 0.0 5, * * P < 0.0 1 and 
* * * P < 0.001 compared to controls.
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pattern and the results presented here support this, in 
so much as the food consumption was constant between 
groups irrespective of the dietary vitamin A level.
Citral administration in the diet again reduced the 
food intake and body weight gain. In addition, the water 
consumption was increased in the groups receiving 
citral. This was possibly due to the strong aroma of the 
citral that resulted in increased thirst and saliva 
secretion. Carmichael (1985) reported a similar effect 
following administration of citral by gastric intubation 
for 3 days.
Vitamin A administration at levels of up to 100,000 
iu/kg of diet had no effect upon the relative organ 
weights; this agrees with previous reports (Tuchweber e_t 
al. , 1976 ; Ott and Lachance, 1983; Tom et al., 1984).
However, chronic vitamin A toxicity has been reported to 
cause hepatomegaly and splenomegaly (Olson, 1983). 
Citral administration caused hepatomegaly and enlargement 
of the kidneys and testes in both strains; there were no 
macroscopic changes with no gastric ulceration as shown 
in Chapter 4 following administration of citral. This may 
be due to the protection afforded by vitamin A (Javor 
et al., 1983). The mechanism for the enlargement is 
unknown, however, histological examination showed no 
pathological changes in the kidney or testes suggesting 
enzyme induction and/or hormonal changes. In the livers 
of citral-treated rats of both strains, there was a
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massive, if not complete, loss of glycogen and periportal 
accummulation of lipid. Such a decrease in hepatic 
glycogen may be related to the reduced food intake, 
although centrilobular loss of glycogen has been reported 
in the livers of rats treated with compounds that cause 
proliferation of peroxisomes (Lake et al. , 1975; Reddy
and Lalwani, 1984; Mann et al., 1985). The accumulation 
of lipid has also been reported in the livers of animals 
treated with compounds and diets that cause proliferation 
of peroxisomes (Gaunt et al, 1971; Barnard et al. , 1980; 
Neat et al. , 1981; Price et al., 1982; Price et al.,
1984, Mann et a1., 1985). However, lipid accumulation
itself does not cause proliferation of peroxisomes (Price 
et al. , 1985). Although excess vitamin A has been
reported to cause fatty livers (Mallia et al., 1975; Kent 
et al., 1976 ; Forouhar et al. , 1984) , dietary vitamin A
at ten times the optimum level resulted in no significant 
accumulation of lipid. This may be due to the short 
period of administration of the high vitamin A level diet 
and suggests that the administration of citral caused the 
lipid accumulation; thus, it is possible that citral also 
causes proliferation of peroxisomes, although this has 
not been reported in the literature to date.
The thrombotest clotting times were measured and 
recorded during the study to examine the effect of citral 
and simultaneous vitamin A administration. Only the 
hooded rats showed any prolongation, and this was at the 
top level of dietary vitamin A. This prolongation was
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only about a 10% increase compared to the control value.
It has been reported that hypervitaminosis A causes 
haemorrhage and hypoprothrombinaemia (Light et al., 1944; 
Moore and Wang, 1945; Walker et al., 1947 Wostman and 
Knight, 1965), although the mechanism of action of 
vitamin A was not defined. The results presented here 
suggest that the top level of dietary vitamin was not 
high enough to cause such haematological changes, 
although it was used because it has been reported that 
the intake of vitamin A in germfree rats has to be at 
least ten times the optimum before any 
hypoprothrombinaemia is observed (Wostman and Knight, 
1965). Other workers used a much higher daily vitamin A 
intake than used here. The dietary administration 
resulted in a daily intake of 1,300 to 1,600 iu vitamin A 
compared to the range of 25,000 to 400,000 iu vitamin A 
reported in the literature. In addition, the lowest
vitamin A level was used because it has been shown that
feeding rats levels as low as 500 - 5,000 iu/kg vitamin A
caused a depression in prothrombin values (Matschiner and 
Doisy, 1962), In this study, the lowest vitamin A level 
used was 1,000 iu/kg diet. Again the results
presented here suggest that within the range of dietary 
concentrations used, the vitamin A intake had no effect 
upon the thrombotest clotting time in either strain of 
rat.
Studies in both rats and man (Mallia et al., 1975;
158
Smith and Goodman, 1976) have shown that vitamin A 
toxicity is associated with increased plasma levels of 
retinol and retinyl esters circulating in association 
with plasma lipoprotein and not bound to RBP. The assay 
procedure employed here measured the total plasma vitamin 
A (as retinol); the dietary level of vitamin A did not 
affect the total plasma vitamin A levels in the control 
groups. This supports the findings of Donoghue et al. ,
(1983) and suggests that the unbound retinol did not 
increase significantly since most RBP circulates as the 
retinol - RBP complex and the circulating concentration 
of RBP has been reported as being 50 pg/ml plasma 
(Goodman, 1984) compared to the measured retinol of 40 
ug/100 ml plasma. Thus, it would necessitate a massive 
increase ( > 100 fold) in the plasma vitamin A 
concentration to saturate the RBP binding capacity and so 
increase the concentration of free circulating vitamin 
A. The addition of citral to the diets reduced the 
plasma and hepatic vitamin A concentrations in both 
strains of rat, although in general, the decrease was not 
significant. It is possible that citral, which has a 
high affinity for RBP (Opdyke, 1979, cites Hase et al. , 
1976), displaces vitamin A from it's binding site, so 
increasing the proportion of free vitamin A. However, 
since no change was found in the clotting times or the 
plasma vitamin A concentration with citral 
administration, such displacement is of little 
s ignif icance.
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The increase in hepatic vitamin A levels with 
' 'dietary! " '
increasing^ levels confirmed that the rats did, in fact 
receive the different dietary vitamin A levels and these 
results support the findings of Tuchweber et al., (1976); 
Donoghue et al., (1981); Ott and Lachance, (1983); Hicks 
et al. , (1984) and Tom et al., (1984). The plasma
vitamin A thus stayed in a "steady state" with the 
different dietary vitamin A levels. This has also been 
reported in man (Goodman, 1984) although several groups 
of workers have shown that the plasma vitamin A level 
varies with daily intake (Ott and Lachance, 1983; Hicks 
et al., 1984; Tom et al., 1984).
The slight decrease in the hepatic concentration of 
vitamin A following administration of citral suggests a 
metabolic interaction. Indeed, Tuchweber et al. , (1976 )
and Leo et al (1984) have shown that hepatic vitamin A 
was depressed following administration of compounds that 
induced the microsomal enzymes and cytochrome P-450. 
Previous work with citral has shown that the cytochrome 
P-450 level was increased in vivo following short term 
administration to rats (Parke and Rahman, 1969). The 
results presented also show induction of cytochrome P-450 
following the administration of citral with 
consequentially increased metabolism of vitamin A and 
citral itself. It has been reported that vitamin A 
deficiency reduces the level of cytochrome P-450 
(Becking, 1973; Colby et al., 1975; Tomani and Olson,
1983; Tom et al., 1984); the lowest vitamin A level used
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in this study also showed reduced cytochrome P-450 levels 
compared to the other three dietary vitamin A levels and 
so the results support the previous reports. Thus, 
citral administration protects against vitamin A toxicity 
due to the increased rate of metabolism suggesting that 
there is no antagonism of citral with vitamin A resulting 
in haemorrhage and hypoprothrombinaemia. Administration 
of citral to rats fed the optimum level of vitamin A did 
not result in a significantly altered plasma or hepatic 
vitamin A level, so ruling out both hypo and 
hypervitaminosis A as a mechanism of action of citral 
with regard to prolongation of thrombotest clotting time.
In addition to the lack of significant changes in 
thrombotest clotting times, other haematological 
parameters were measured but showed no change with 
vitamin A level or with citral administration in the 
hooded rats. The packed cell volume showed no change 
although it has been shown to be reduced as the 
concentration of vitamin A increased (Kurtz et al. ,
1984). Mark et al., (1983) showed that there was a 
transient decrease with duration of administration of 
retinoic acid to Lewis rats. Assessment of blood films 
for red blood cell abnormalities showed that neither 
vitamin A nor citral caused any changes in hooded rats.
Overall, the citral reduced the hepatic vitamin A in 
both strains of rat possibly by increasing the rate of 
metabolism by induction of cytochrome P-450. There was a
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slight prolongation of thrombotest clotting time in the 
hooded rats, but this was transient, and suggests that 
citral has little effect, if any, upon the clotting 
mechanism. There may be an indirect effect of citral 
administration upon the protein clotting factor synthesis 
in the liver as a result of the changes in lipid, 
glycogen and mixed function oxidase enzyme system, but 
there is no direct effect. The haemorrhage in hooded 
rats reported by Flude (1977) must have been under 
circumstances of vitamin K deficiency and not vitamin A 
excess. The change in the lipid distribution in the 
livers of citral treated albino and hooded rats suggests 
that the metabolism of lipids may be disrupted and the 
circulating cholesterol and triglycerides may also be 
altered as a result. This implies that citral may cause 
proliferation of peroxisomes similar to the 
hypolipidaemic compound clofibrate, although it is not 
structurally related. However, the effects upon the 
clotting mechanism are secondary to hepatic changes 
following citral administration.
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Section III
Aspects of the Hepatic Toxicity of Citral 
and Related Biochemistry.
Chapter 6
Introduction
Mammalian Peroxisomes and Associated Changes
Following Administration of Hypolipidaemic Compounds.
6.1 Introduction
In 1954, Rhodin described a morphologically distinct 
class of cytoplasmic organelles consisting of a single 
membrane enclosing a fine granular matrix in the 
convoluted tubule cells of mouse kidney. Two years 
later, structures resembling the kidney microbodies were 
described in rat liver parenchymal cells (Rouiller and 
Bernhard, 1956). However, these liver microbodies also 
contained a crystalline core. Subsequent studies
identified the core as being mainly urate oxidase 
(Novikoff et al., 1953).
During the 1960s, extensive cellular fractionation 
and biochemical studies by de Duve and his co-workers 
demonstrated that urate oxidase, D-amino acid oxidase and 
catalase were present in a novel cellular particle in rat 
liver and kidney cells (de Duve et al., 1960; Baudhuin 
al., 1964). On the basis of the association of the H2 O2 
- producing oxidases and H2 O2 - destroying catalase with 
microbodies, the organelle was called a "peroxisome" (de 
Duve, 1965).
The identification of peroxisomes was facilitated by 
the 3,3' - diaminobenzidine (DAB) method of Novikoff and
Goldfischer (1969). This cytochemical method relies on 
catalase which results in peroxidat i'veoxidat ion of the 
DAB in the presence of H2 O2 to yield a dark-brown product 
(see review by Litwin, 1979).
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Subsequent studies have shown that structures 
resembling microbodies (although they vary in size, shape 
and matrix density) occur in numerous tissues (for 
example, heart, adrenal cortex, neural, ectodermal, 
epididymal, prostate, intestinal, embryonic, hepatoma and 
mucosal tissues) (Hruban and Rechcigl, 1969). In 
addition, microbodies have also been found in plants 
("glyoxysomes") and unicellular organisms (yeast and 
Tetrahymena puriformis for example). In spite of 
differences in enzyme constituents between these 
microbodies, they are all characterized by their ability 
to produce and destroy H2 O2 .
6.2 Terminology
The term microbody refers to the morphology and 
figure 6.1 summarises the different types of microbody in 
the form of a Venn diagram illustrating the connection 
between the different classes of microbody. Glyoxysomes 
are a class of peroxisome that contain the enzymes for 
glyoxylate metabolism and are found in germinating seeds 
for example. Hydrogenosomes refer to microbodies which 
contain a system for anaerobic transfer of electrons 
between pyruvate and protons. Glycosomes contain the 
early enzymes of the glycolytic sequence and the last two 
enzymes of the pyrimidine biosynthetic pathway. They do 
not usually contain H2 O2 - producing oxidases or catalase 
(Opperdoes, 1982).
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Figure 6.1
Microbody Terminology. The Interrelationship Between the 
Different Classes of Microbody.
G lycosomes Lysosomes
Peroxisomes
Storage
GranulesiGlyoxysomes
Microbodies
Secretion
Granules
Hydrogenosomes
Adapted from de Duve (19 69) and Alexson (1985)
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6.3 Morphology and Spatial Relationship to other
Organelles
Rat liver peroxisomes are usually spherical or oval 
in shape with a diameter of approximately 0.5 pm. They 
are delimited by a single membrane, 60 - 80 Â thick,
which encloses a finely granular matrix with a 
characteristic electron dense central core or 
crystalloid, associated with insoluble urate oxidase 
(Baudhuin et al., 1965). In rat liver peroxisomes or 
castor bean glyoxysomes the nucleoid consists of straight 
tubules arranged in parallel that give a regular 
crystalloid structure, whereas in mouse liver peroxisomes 
the tubules appear as twisted strands. However, in some 
organs (human and rat kidney for example), peroxisomes 
lack urate oxidase but contain some nucleoid structures 
(Hruban and Rechcigl, 1969); human - liver peroxisomes 
are devoid of both urate oxidase and nucleoids (Afzelius, 
1965; Hruban and Rechcigl, 1969). The peroxisomal 
membrane is highly permeable to small molecules such as 
sucrose, substrates and inorganic ions; this is in 
contrast to lysosomes which exhibit low permeability to 
these substrates (de Duve and Baudhuin, 1966; Masters and 
Holmes, 1977).
The topographic relationship of peroxisomes and 
other cellular organelles may be indicative of the 
cellular origin of peroxisomes. The close spatial 
relationship between peroxisomes and sections of the 
endoplasmic reticulum (ER) prompted Novikoff and Shin
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(1964) to suggest that some peroxisomes or microbodies 
may maintain a long-term functionally important 
connection with the ER. However, autoradiographic 
studies by Staubli et al. , (1977) concluded that the ER
and peroxisomes constituted two distinct intracellular 
compartments. This latter conclusion was supported by 
Fahimi and Yokota (1981), although it has been shown that 
microperoxisomes are connected to the ER (Novikoff et 
, 1973) .
Plant peroxisomes and glyoxysomes show a close
association with other cellular organelles that can be 
readily correlated with their functional metabolic roles 
(Lord, 1980). For example, photosynthesizing plant cells 
produce glycolic acid within chloroplasts, a major
photorespiratory pathway substrate (Tolbert, 1971). 
Since most of the enzymes of the photorespiratory pathway 
are located in peroxisomes, the first requirement of this 
pathway is to transfer the glycolic acid from 
chloroplasts to peroxisomes. This is facilitated by the 
close spatial relationship of the two organelles 
(Tolbert, 1981).
6.4 Physiological Functions of Peroxisomes
de Duve and Baudhuin (1966) suggested that
peroxisomes had three main functions, namely
(i) they play a protective role in the disposal of
H2 O2 which otherwise would achieve toxic concentrations 
(ii) they participate in specific metabolic pathways
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such as gluconeogenesis for example, and
(Hi) they play a role in energy production and
oxidative metabolism.
It is now clear that there are four major functions 
with a number of minor roles. The functions initially 
proposed were all related to catalase which was thought 
to be the major enzyme in peroxisomes. However, 
subsequently a variety of enzymes have been found to be 
associated with peroxisomes (table 6.1). The roles of 
these enzymes are discussed below.
6.4.1 Respiration
Peroxisomes contain a simple respiratory pathway of 
oxidases which reduce oxygen to H2 O with concomitant 
oxidation of a substrate RH2 to R , together with catalase 
which breaks down the H2 O2 by the action of both catalase 
and peroxidase. The H2 O2 reacts preferentially with 
peroxisomal catalase, although the mode of removal of 
H2 Q2 by extraperoxisomal systems is unclear (Masters and 
Holmes, 1977). The catalase has been reported to account 
for 16% (Goldfischer et al. , 1971) or 40% (de Duve and
Baudhuin, 1966) of peroxisomal protein. The peroxisomal 
respiration is cyanide - insensitive and thermogenic and 
has been estimated to account for 20% of the oxygen 
consumption of the liver (de Duve and Baudhuin 1966).
6.4.2 Thermogenesis
The role of the liver in nonshivering thermogenesis
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Table 6.1
Enzymes Demonstrated in Liver Peroxisomes of Various 
Species.
Class Enzyme
Hydroperoxidases Catalase
Oxidases D-Amino acid oxidase
Fatty acyl-CoA oxidase
L - o f -  hydroxyacid oxidases A and B
Polyamine oxidase
Uric acid oxidase
Dehydrogenases 1-acyl/alkyl, glycero1-3-phosphate 
NADP oxidoreductase 
Aldehyde dehydrogenase (NAD, NADP) 
Glycerol-3-phosphate dehydrogenase
(NAD)
Glyoxylate reductase (NADH) 
L-p-hydroxy fatty acid CoA
dehydrogenase 
Isocitrate dehydrogenase (NADP) 
Xanthine dehydrogenase
Amino Transferases Alanine ;glyoxylate
aminotransferase 
Glutamate tglyoxylate
aminotransferase 
Serinecglyoxylate aminotransferase 
Serine:pyruvate aminotransferase
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other Transferases Carnitine :acetyl-CoA
acetyltransferase 
Carnitine :acyl-CoA acyltransferase 
Carnitine :palmitoyl CoA
palmitoyltransferase 
Dihydroxyacetone phosphate:
acyl-CoA, acyltransferase
Other Acyl-CoA hydrolase, long chain
Alkyl-dihydroxy acetone-phosphate
synthase
Allantoicase
Allantoinase
Cytochrome c reductase (NADH)
2 - 4 ,  dienoyl-CoA reductase 
Enoyl-CoA hydratase 
Enoyl-CoA isomerase
Fatty acyl-CoA synthetase
3-hydroxy-3-methylglutaryl-CoA
reductase
Palmitoyl-CoA oxidising system
("p-oxidation")
Thiolase
Data adapted from Bock et al. , (1980), Bieber e_t
al., (1981), Cohen and Grasso (1981), Leighton and Lazo
(1982), Farrell and Bieber (1983), Bronfman et al.,
(1984) and Keller et al., (1985).
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is not fully understood. Morphological changes in the 
livers of rats, golden hamsters and bats in response to 
cold have been studied by Horwitz (1976). He reported 
increases in the "size" of both peroxisomes and 
mitochondria. Two biochemical studies produced
conflicting changes in peroxisomal enzymes. Antonenkov 
et al., (1983) reported no changes in either mitochondria 
or peroxisomes, while Pollera et al., (1983) found 
increases in some peroxisomal enzymes and an increase in 
peroxisomal . numbers. Recently however, Alexson and 
Hashimoto (1981) reported changes in the p-oxidation 
enzymes of rat liver peroxisomes and mitochondria. These 
enzymatic changes correlate well with the morphological 
changes reported by Horwitz (1976), although it was 
suggested that the changes could be attributed to a 
higher calorific intake rather than a response to the 
cold.
Adaptation to the cold results in an increase in 
brown fat and catalase - positive particles have been 
reported in histochemically stained brown fat (Ahlabo and 
Barnard, 1971). They noted an increase in the number of 
the particles compared to mitochondria after cold 
adaptation in rats. The catalase - positive particles 
were initially called microperoxisomes since they did not 
have a crystalline nucleus (Novikoff and Novikoff, 1972) 
although Pavelka et al., (1976) demonstrated that they 
were "true" peroxisomes as defined by de Duve in that 
they "possess at least one hydrogen peroxide - producing
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oxidase together with catalase" (de Duve, 1969).
Nedergaard et al., ( 1980) reported that cold 
adaptation in the rat resulted in an increase in the 
p-oxidation system in brown adipose tissue peroxisomes. 
More recently, induction of catalase and acyl - CoA 
oxidase has been reported in the brown adipose tissue of 
rats after cold acclimatisation (Alexson et al., 1985).
6.4.3 Gluconeogenesis
The glyoxysome is important in gluconeogenesis in 
germinating fatty seedlings since it contains all the 
glyoxylate cycle enzymes (Beevers, 1969). In
Tetrahymena, the peroxisomes also contribute to 
gluconeogenesis (Müller et al., 1968). However, the 
peroxisomes of Tetrahymena only contain two enzymes of 
the glyoxylate cycle, isocitrate lyase and malate 
synthetase; the other enzymes of the cycle are in the 
mitochondria, thus there is co-operation between these 
organelles in carrying out the glyoxylate cycle.
In animal tissues, the glyoxylate cycle has only 
been reported for toad bladder and foetal tissue (Goodman 
et al., 1980; Khan and McFadden, 1980). In addition to 
the glyoxylate cycle, in plant and animal peroxisomes, 
many other reactions are related to glyoxylic acid.
In animal cells, the generation of glyoxylate is 
peroxisomal. It occurs by oxidative deamination of
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glycine catalyzed by D-amino acid oxidase (Niems and 
Hellerman, 1962) and by the oxidation of glycolic acid 
mediated by the isoenzyme A or L-c<-hydroxyacid oxidase 
(Masters and Holmes, 1977).
6.4.4 Lipid Metabolism
The involvement of liver peroxisomes in fat 
metabolism was firmly established following the 
demonstration of a peroxisomal fatty acid oxidation 
pathway (Lazarow and de Duve, 1976). The p-oxidation 
system was first found in glyoxysomes by Cooper and 
Beevers (1969). This peroxisomal p-oxidation has been 
observed in protozoa, yeast germinating seedlings and 
various mammalian tissues, although the peroxisomes have 
different sets of enzymes, some of which overlap with the 
enzymes from other types of peroxisome.
Hess et al., (1965) and Svoboda and Azarnoff (1966)
found proliferation of peroxisomes in the livers of rats 
fed clofibrate. Peroxisomal number was increased several 
fold, however, the catalase was only slightly increased. 
The demonstration of the mammalian peroxisomal 
p-oxidation followed. The system contains all the 
enzymes necessary to carry out a true p-oxidation of 
fatty acids (Lazarow, 1978; Osumi and Hashimoto, 1979b). 
The initial step in fatty acid oxidation (acyl 
activation) has been shown in peroxisomes (Shindo and 
Hashimoto, 1978; Krisans et al. , 1980; Mannaerts et al. , 
1982) and all enzymes of the p-oxidation pathway of
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peroxisomes have been purified and characterized: 
acyl-CoA synthetase (Shindo and Hashimoto, 1978; Krisans 
et al., 1980; Mannaerts et al., 1982), acyl-CoA oxidase 
(Osumi and Hashimoto, 1978), enoyl-CoA hydratase/3- 
hydroxyacyl-CoA dehydrogenase ("bifunctional protein") 
(Osumi and Hashimoto, 1979a; Osumi and Hashimoto, 1980) 
and 3-ketoacyl-CoA thiolase (Miyazawa et al., 1980b). 
The reaction is summarized in figure 6.2. The pathway 
resembles that of mitochondria except that the first 
dehydrogenase transfers it's electrons to oxygen 
producing H2 O2 . The system is highly inducible by a 
number of compounds and dietary states; this is discussed 
in more detail in section 6.6.2.
The relative contribution of peroxisomes and other 
organelles is not clear when considering in vitro data 
alone (Lazarow, 1978; Mannaerts et al., 1979). Some 
studies in vitro suggest that peroxisomal oxidation of 
lipid is relatively small and may be subservient to 
mitochondrial processes under steady state conditions 
(Mannaerts et al., 1979; Foerster et al., 1981); other
data suggests a substantial contribution by the 
peroxisomes (Cannon et al., 1982; Osmundsen, 1982). In 
vivo experiments provide support for an important 
contributory and regulatory role of peroxisomes in the 
overall balance of lipid metabolism. Indeed, data 
suggests that peroxisomal p-oxidation is a mechanism for 
eliminating fatty acids that are poorly oxidized by 
mitochondria; for example, rare long chain and trans
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Figure 6.2
Peroxisomal p-Oxidation.
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Adapted from Lazarow and de Duve (1976), Lewis (1976), 
Hashimoto (1982) and Reddy and Lalwani (1983).
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fatty acids (Osmundsen, 1982).
Long chain fatty acids control lipid metabolism and 
their role as characteristic end products provides feed­
back or feed-forward regulation in relation to lipid 
synthesis and degradation (Block and Vance, 1977). In a 
similar way, fatty acids of medium chain length may be 
regarded as characteristic products of peroxisomal 
metabolism, acting in the translation of peroxisomal 
influences on lipid metabolism (Masters and Crane,
1984). Thus, communication between tissues would
possibly be via peroxisomal messengers; namely, the end 
products of metabolism, the medium chain fatty acids and 
ketone bodies.
6.4.5 Other Functions
Peroxisomes participate in a variety of other 
metabolic processes. Urate oxidase catalyses the
oxidation of urate. The conversion of urate to 
allantoin represents the final step in the metabolic 
degradation of the purine ring in many mammalian species 
(except primates, birds and man) resulting in the 
formation of allantoin (Masters and Holmes, 1977). 
Allantoicase, allantoinase and urate oxidase are all 
peroxisomal enzymes (Scott et al., 1969; Noguchi et al.,
1979) but "have undergone progressive deletion during 
evolution, apparently because they do not confer a 
biochemical selection factor (Leighton and Lazo, 1982). 
In addition, peroxisomes participate in the oxidation of
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ethanol in liver (Thurman and McKenna, 1975; Lord, 1980), 
and of methanol in yeast (van Dijken et al., 1982). In 
green leaves, peroxisomes participate in photorespiration 
(Tolbert and Yamazaki, 1969; McGroarty and Tolbert, 1973; 
Tolbert, 1982).
6.5 Hepatic Changes to Peroxisome Proliferating
Compounds
6.5.1 Hepatomegaly
The liver is the primary site of toxic action of 
hypolipidaemic and peroxisome proliferating compounds. 
These compounds cause hepatomegaly (Duncan et al. , 1964) 
accompanied by proliferation of hepatic peroxisomes (Hess 
et al., 1965; Svoboda et al., 1967). The liver
enlargement occurs within a few days of the start of the 
administration of the compound and reaches a steady state 
between 10 to 14 days (Reddy and Lalwani, 1983). It is 
then sustained throughout the period of compound 
administration; Reddy and Rao (1977) reported sustained 
hepatomegaly during a 25 month treatment period with 
nafenopin. Removal of the compound resulted in a return 
to the normal liver size within 2 weeks (Hess et al., 
1965; Svoboda et al. , 1967); however, peroxisome
proliferation persisted (see section 6.6.1).
The hepatomegaly caused by peroxisome proliferators 
is generally dose-dependent (Reddy and Lalwani, 1983) as 
it is with most other hepatic enzyme inducers. Liver
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enlargement is not confined to rats and has also been 
reported in mice, hamsters, cats, chickens, pigeons and 
monkeys (Platt and Thorp, 1966; Blane and Pinaroli, 1980; 
Reddy et al., 1982; Reddy et al., 1984 and others). 
Studies in man have generally not shown any hepatic 
changes with peroxisome proliferators of rodents 
(Hanefeld et al., 1980; Blane and Pinaroli, 1980; Bliimcke 
et al., 1983) and suggests limitations of work in rodents 
with regard to extrapolation to man.
The mechanism of liver enlargement has been reported 
to be a combination of hyperplasia and hypertrophy (Reddy 
and Lalwani, 1983) although clofibrate has been reported 
to cause hepatomegaly by hypertrophy alone (Hess et al. , 
1965; Beckett et al., 1972). The increase in hepatic DNA 
and associated mitotic burst caused by some peroxisome 
proliferators is suggestive of a hyperplastic response, 
but some workers have suggested that neoplastic changes 
may also be a feature of peroxisome proliferators 
(Beckett et al., 1972; Moody et al., 1977; Reddy et al., 
1978; Reddy and Qureshi, 1979; Svoboda and Azarnoff,
1979). Such stimulation of DNA does not occur with 
classical chemical carcinogens; these compounds inhibit 
normal DNA synthesis by covalent binding (Holbrook,
1980). However, Goel et al., (1985) reported that the 
peroxisome proliferators nafenopin and Wy-14,643 did not
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bind to DNA either in vivo or in vitro. This supports 
the idea of Reddy et al., (1980) who suggested that the
peroxisome proliferators formed a "novel class of 
carcinogens". However, Cohen and Grasso (1981), grouped 
the peroxisome proliferators together with microsomal 
enzyme inducers in their classification of 
hepatocarcinogens due to their similarity with regard to 
liver enlargement, proliferation of smooth endoplasmic 
reticulum and microsomal enzyme induction.
6.5.2 Histological and Enzymatic Changes
Few histological changes have been reported with 
administration of peroxisome proliferators. Periportal 
accumulation of lipid has been reported by Barnard e^ 
al., (1980),Neat et al., (1981), Price et al., (1982) and 
Mann et al., (1985) following administration of 
peroxisome proliferators. In addition, Mann et al. ,
(1985) demonstrated a centrilobular decrease in hepatic 
glycogen in rats following administration of di(2-ethyl- 
hexyl) phthalate.
Liver enlargement and peroxisome proliferation is 
often associated with induction of microsomal enzymes 
(Goljbergi , 1966). Clofibrate has been shown to induce
cytochrome P-450 and in particular, cytochrome P-452 
(Gibson et al., 1982: Tamburini et al., 1984; Gibson and 
Bains, 1985) as have clofibric acid and di(2-ethylhexyl) 
phthalate (Lake et al. , 1984; Mann et al. , 1985). Many 
studies give variable results and so generalisations are
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difficult to make. The strain of experimental animal 
appears to be important, as does the biphasic response
reported by Mann et al., (1985). This latter observation 
may explain the variation in induction of the mixed 
function oxidase system due to the different dosing
regimes employed by different workers.
6.6 Peroxisomal Changes Following the Administration
of Xenobiotics to Rats
6.6.1 Factors Affecting Proliferation of Peroxisomes
As mentioned in section 6.4.4., clofibrate was the 
first hypolipidaemic drug found to increase the number of
liver peroxisomes in rats (Hess et al., 1965; Svoboda and
Azarnoff, 1966; Svoboda et al. , 1967). Proliferation of
peroxisomes is generally associated with hypotriglyceri- 
daemic compounds but not with hypocholesterolaemic 
compounds (table 6.2) and has been shown to persist while 
administration of the compound is maintained (Hess e^ 
al. , 1965; Reddy et al., 1969). The number of
peroxisomes is increased within 24 hours of the first 
dose of a peroxisome proliferator if the dose is high 
enough (Hess et al. , 1965; Reddy and Lalwani, 1983).
Following cessation of treatment, the number of 
peroxisomes falls to the control level within 3 weeks 
(Hess, 1965; Svoboda et al., 1967), the time being
dose-dependent.
Following administration of peroxisome proliferating
compounds, the peroxisomes generally lack the nucleoid
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Table 6.2
Correlation between hepatic peroxisome proliferation, 
hypolipidaemic activity and hepatomegaly in Rats and 
Mice.
Group of Hepatic Hepatomegaly Hypolipidaemic
Compounds Peroxisome Activity
Proliferation
Triglyceride-
lowering
agents
+ + +
Cholesterol-
lowering
agents
+ +
Non-
hypolipidaemic 
agents (a)
(b)
+ = Effect - = No effect
Summarized from Cohen and Grasso, 1981.
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core (Hess et a1>, 1965; Hruban et al., 1966; Svoboda et 
al., 1967; Mann et al., 1985). Clofibrate - induced
proliferation of peroxisomes has been demonstrated in the 
rat, mouse, dog and hamster but not in the guinea pig, 
chicken, rabbit or monkey (Svoboda et al., 1967). Reddy 
ejb aJL. , ( 1982) demonstrated that oral administration to
hamsters of fenofibrate, pyrinixil, clofenapate and 
clofibrate caused proliferation of peroxisomes and
induced p-oxidation, although the induction by clofibrate 
was less pronounced than with the other compounds. Reddy 
et al., (1984) demonstrated proliferation of peroxisomes 
in cats, chickens, pigeons, rhesus and cynomolgus monkeys 
following administration of ciprofibrate. The species 
differences are due to different doses, metabolism and
disposition between studies (Lake and Gray, 1985). No 
evidence of peroxisome proliferation has been reported in 
man following administration of fenofibrate (Blane and 
Pinaroli, 1980; Bliimcke et al., 1983), although Hanefeld 
et al., (1983) did report increased numerical density of 
peroxisomes following administration of clofibrate to
man.
The data on sex differences are complicated by the 
use by different workers of different strains of rat or 
mouse. However, the general conclusion is that there are 
no sex differences with regard to proliferation of 
peroxisomes.
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6.6.2 Changes in Peroxisomal Enzymes
The compounds that induce liver enlargement and 
proliferation of peroxisomes, also induce peroxisomal 
enzymes. Neither catalase nor the group of oxygenases is 
influenced as markedly as carnitine acetyltransferase or 
the enzymes of the p-oxidation system (Cohen and Grasso, 
1981; Osumi and Hashimoto, 1984). Peroxisomal
p-oxidation is markedly enhanced by administration of 
peroxisome proliferators: various compounds including the 
hypolipidaemic agents clofibrate (Lazarow and de Duve, 
1976; Lazarow, 1977; Reddy et al., 1982), tibric acid
(Lazarow, 1977) and Wy-14,643 (Lazarow, 1977; Watanabe et 
al., 1985) the plasticizer di (2-ethylhexyl) phthalate,
(Hashimoto, 1982; Mann et al., 1985; Watanabe et al.,
1985) and aspirin (Ishii and Suga, 1979; Sakurai et al.,
1981), all enhance peroxisomal p-oxidation. In addition, 
feeding very long chain fatty acids (Christiansen et al. , 
1979; Neat et al., 1980), a high fat diet (Ishii et al., 
1980a; Thomassen et al., 1982), starvation (Ishii et al., 
1980b; Thomassen et al., 1982; Van den Branden and Roels,
1985), diabetes (Horie et al., 1981) or feeding a vitamin 
E deficient diet (Dabholkar, 1981; Reddy et al., 1981) 
also result in enhanced peroxisomal p-oxidation.
Peroxisomal p-oxidation is inducible whereas the 
mitochondrial system is constitutive. There is no 
accurate method for determining the participation of the 
peroxisomal system in whole cells, although Lazarow 
(1978) reported that in clofibrate-treated rats, most of
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the hepatic palmitoyl-CoA oxidation occurred in 
peroxisomes. This was confirmed by Krahling et al., 
(1978) who also used gradient centrifugation. The 
inducibility of the system suggests that the peroxisomal 
system plays a role in the "fuel" supply to the 
mitochondria.
Peroxisomal p-oxidation activity is lower than 
mitochondrial p-oxidation in the resting state, however 
the activity of the former system becomes higher after 
induction by peroxisome proliferators. The peroxisomal 
system has been reported to be induced by up to 30-fold 
in the liver following administration of di(2-ethylhexyl) 
phthalate to rats; in comparison, mitochondrial induction 
was only 2-fold (Furuta et al., 1981; Hashimoto, 1982), 
with the results expressed per gram of liver.
A good indicator for enhanced peroxisomal
p-oxidation is the induction of a polypeptide with a 
molecular weight of approximately 80,000 daltons (Reddy 
and Kumar, 1977; Reddy, 1981; Reddy and Warren, 1982). 
This has been identified as the bifunctional enzyme 
complex of enoyl-CoA hydratase and 3-hydroxyacyl-CoA 
dehydrogenase (Osumi and Hashimoto, 1979b). The
polypeptide has been called PPA-80 (peroxisome
proliferation associated) (Reddy et al. , 1981) and has
been localized in peroxisomes by immunocytochemistry 
(Bendayan and Reddy, 1982). Induction has been shown 
with aspirin, clofibrate, simfibrate, fenofibrate,
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ciprofibrate, methyl clofenapate, Wy-14,643, di(2-ethyl- 
hexyl) phthalate, pyrinixil and high fat diets (Ishii and 
Suga, 1979; Ishii et al., 1980; Watanabe and Suga, 1980; 
Reddy et al., 1982; Watanabe et al., 1985), and in rats, 
hamsters, cats, chickens, rhesus and cynomolgus monkeys 
(Reddy and Kumar, 1977; Reddy et al., 1982; Reddy et al., 
1984; Watanabe et al., 1985).
In addition to changes in peroxisomal p-oxidation,
catalase has been shown to be induced approximately
2-fold by peroxisome proliferators (Hess et al., 1965; 
Svoboda and Azarnoff, 1966; Svoboda et al., 1967; Crane 
et al., 1980; Mann et al., 1985 and others). Induction 
of catalase is proportional to the increase in hepatic 
protein (Lazarow and de Duve, 1976) following 
administration of peroxisome proliferators and 
consequently, the specific activity shows little change 
(Cohen and Grasso, 1981). Hepatic carnitine
acetyltransferase has also been reported to be induced by 
peroxisome proliferators; for example, induction has been 
shown following administration of clofibrate, nafenopin, 
Wy-14,643, tibric acid, aspirin and di(2-ethylhexyl) 
phthalate (Moody and Reddy, 1974; Goldenberg et al., 
1976; Markwell et al., 1977; Moody and Reddy, 1978a and
1978b; Ishii and Suga, 1979). In contrast, the oxidase
group of enzymes show little, if any change following
administration of peroxisome proliferators (Cohen and 
Grasso, 1981 ) .
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6.7 Biogenesis of Peroxisomes
Although the exact mechanism of peroxisome 
biogenesis is unknown, many models have been proposed. 
Recent results have suggested that peroxisomal and 
glyoxysomal protein share common features. The models
generally fall into two groups. The first set of models
is based around the endoplasmic reticulum. It has been 
suggested that the peroxisomal proteins are 
co-translationally sequestered within the endoplasmic 
reticulum. They then move through the canal and enter 
into the expanding buds or the organelle. This model
assumes that the proteins are not exposed to the cytosol 
and that the sorting out of the precursors destined for a 
certain organelle is carried out on the endoplasmic 
reticulum membrane or on the luminal site of the
endoplasmic reticulum (Kindi, 1982). In addition, this 
mechanism presupposes that the peroxisomal membrane is 
the same as the endoplasmic reticulum membrane. However, 
it has been shown that the protein composition of the two 
membranes is very different (see Osumi and Hashimoto, 
1984).
The second model suggests that most protein 
components of peroxisomes or glyoxysomes are synthesized 
at free ribosomes and are imported post-translationally 
in the growing organelle. Assembly then takes place 
within the organelle by acquiring prosthetic groups, 
processing or oligomerization, respectively (Lazarow and 
de Duve, 1973b; Kindi, 1982). This latter model has
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been shown to apply to catalase (Lazarow and de Duve, 
1973a). In addition, Kindi et al., (1980) demonstrated 
that in germinating cucumber cotyledons, isocitrate 
lyase, malate synthetase and catalase were all
synthesized via cytosolic pools. Selective uptake and
selective retention may be employed for selective 
post-translational concentration of enzymes in an
organelle (Lazarow, 1981).
Nothing is known about the molecular mechanisms
controlling entry of proteins into peroxisomes, nor is 
the site of synthesis or manner of assembly of the 
membrane protein understood, although Lord (1980) 
reviewed this and proposed that the membrane proteins are 
synthesized and given their asymmetric membrane 
orientation in the endoplasmic reticulum. Thus, the two 
models are not mutually exclusive and may eventually be 
combined to give a single model involving the endoplasmic 
reticulum and free ribosomes to explain peroxisomal 
biogenesis.
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Chapter 7
The Effect of Short-Term Administration of Citral
to Wistar albino and Long Evans hooded Rats
Upon Hepatic Peroxisomes, Hepatic
and Plasma Biochemistry.
Introduction
The observation that treatment of rats with citral 
resulted in periportal lipid accumulation as reported in 
Chapter 5 and the structural similarity to fatty acids 
suggested a possible involvement of peroxisomal 
p-oxidation in the metabolism of citral. There have been 
a number of reports of lipid accummulation following 
administration of compounds known to cause proliferation 
of peroxisomes in rodents (Svoboda et al., 1967; Gaunt e_t 
al. , 1971; Lake et al., 1975; Moody and Reddy, 1978;
Barnard et al., 1980; Price et al., 1982; Reddy and 
Lalwani, 1983; Mann et al., 1985). Recently, it has been 
shown that the lipid accumulation itself does not cause 
the proliferation of peroxisomes, but is a result of 
altered lipid metabolism (Price et al., 1985).
In addition, such peroxisomal proliferators have 
been shown to induce peroxisomal p-oxidation activity and 
cytochrome P-450 isoenzymes. The latter effect was 
reported in Chapter 5 and again suggests a link between 
citral and proliferation of peroxisomes. This data taken 
together suggested that citral might cause a change in 
hepatic peroxisomes and circulating lipids. Accordingly, 
the aim of this work was to examine the effect of citral 
administration to rats upon hepatic peroxisomes, 
peroxisomal enzymes including p-oxidation and lipid 
metabolism. The two strains of rat were compared since 
it has been suggested that the degree of enzyme induction 
and the effect upon the serum lipids is strain dependent
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(Anthony et al., 1978; Parker and Orton, 1980; Harrison, 
1984; Mann et al., 1985).
Materials and Methods
7.2.1 Chemicals
DNA and RNA Standards - BDH Ltd., Poole, Dorset,
U.K.
Electron Microscopy - all chemicals were obtained 
from EMscope Laboratories Ltd., Ashford, Kent, U.K.
Ferric Perchlorate - Hopkin and Williams Ltd., 
Chadwell Heath, Essex, U.K.
D-Glucose-6-Phosphate (di- sodium salt) - Sigma 
Chemical Co., Poole, Dorset, U.K.
Palmitoyl CoA and Reaction cocktail - all chemicals 
were obtained from Sigma Chemical Co., Poole Dorset, U.K.
SDS - PAGE Gel Electrophoresis - all chemicals were 
either analytical or electrophoretic grade from BDH Ltd., 
Poole, Dorset, U.K.
Triglycerides Test Kit No. 405 - Sigma Chemical Co., 
Poole, Dorset, U.K.
All other chemicals were obtained from suppliers as 
listed in previous chapters, or were analytical grade 
from BDH Ltd., Poole, Dorset, U.K.
7.2.2 Materials
The tanks, plates and combs for the SDS PAGE gel 
electrophoresis were made in the University of Surrey
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Biochemistry Department workshop.
Power supply for electrophoresis - Power Supply EPS 
500/400, Pharmacia Fine Chemicals, Uppsala, Sweden.
7.2.3 Animal Caging and Husbandry
This work was carried out on two occasions due to 
the large number of animals employed. On each occasion, 
20 male rats weighing 200 ± 20g from each strain (Long 
Evans hooded rats - Charles River Ltd., Margate, Kent, 
U.K., and Wistar albino rats - University of Surrey) were 
randomised into four cages; all animals were allowed free 
access to standard expanded pelleted diet (LAD-1, 
Scientific Feeds, Croydon, Surrey, U.K.) and water. All 
animals were kept at a temperature of 21 ± 2“C and at a 
humidity of 50 ± 3% with an artificially controlled 12 
hour light/dark cycle.
7.2.4 Administration of Citral
Citral was administered to the treatment groups at a 
level of 2.4 g/kg body weight in a 50% (v/v) solution in 
cornoil by daily gastric intubation; this dose level was 
found to be the maximum tolerated, non-lethal dose as 
reported in Chapter 3 (section 3.3.2). Control groups 
received an equal volume of cornoil alone. The body 
weight change and food consumption were monitored daily.
7.2.5 The Autopsy and Sample Collection
Groups of animals (5 treatment and 5 controls of
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each strain) were killed by exsanguination under 
pentobarbitone anaesthesia ("Sagatal") 3 and 10 days 
after commencement of treatment in both experiments. 
Blood was taken from the posterior vena cava and the 
plasma separated and stored as previously described 
(Chapter 4, section 4.2.5).
The livers were excised and weighed. Portions were 
prepared for electron microscopy and histology. The 
remainder of each liver was reweighed and cooled in ice- 
cold sucrose buffer (0.25M sucrose/5mM TRIS-HCl, pH
7.4). These were then homogenised; S9 and microsomal 
fractions were prepared as previously described (Chapter 
5, section 5.2.7).
7.2.6 Histology
Liver samples for histology were fixed, sectioned 
and stained by the haematoxylin and eosin, P.A.S. and Oil 
Red "O" methods as previously described (Chapters 3 and 
5, sections 3.2.11 and 5.2.8).
7.2.7 Preparation of Specimens for Electron Microscopy
The method of Mann et al., (1985) was followed using 
double fixation with glutaraldehyde and osmic acid. 
Immediately after removal of the liver from the animal, a 
thin slice was cut from the centre of the median lobe. 
This was then sliced into 1mm cubes and these 1mm blocks 
were fixed for 4 - 6  hours at room temperature in freshly 
prepared 4% glutaraldehyde (supplied as an 8% solution
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and kept frozen at -20°C prior to use) buffered with 
O.IM sodium cacodylate, pH 7.4 (pH adjusted with nitric 
acid). After fixation, the glutaraldehyde was decanted 
and the tissue blocks were washed overnight in O.IM 
sodium cacodylate, pH 7.4. The following day, the 
tissues were counterfixed in 2% (w/v) osmic acid buffered 
with O.IM sodium cacodylate, pH 7.4, dehydrated through 
graded alcohols and embedded in Epon 812 with resin 
polymerisation at 60°C for 48 hours.
Silver-gray sections were cut on a Reichardt 
Ultramicrotome ( Reichardt-Jung, Austria), counterstained 
with uranyl acetate and lead citrate (Lewis and Knight, 
1977) and examined on a JEOL lOOB electron microscope 
(JEOL, Japanese Optical Company, Japan).
7.2.8 Assays of Reconstituted Monooxygenase Activities 
Dependent on Cytochrome P-450 and the assay of Cytochrome 
P-450
Benzphetamine N-demethylation, 7-ethoxyresorufin 
0-deethylation and cytochrome P-450 were measured as 
previously described in Chapter 5 (sections 5.2.12, 13
and 14).
7.2.9 Determination of Glucose-6-Phosphatase Activity 
in Rat Liver Homogenate
The method of Prospero and Hinton (1973) was 
followed. To 0.5ml of sample (1/40 dilution of fresh 
whole liver homogenate in 0.25M sucrose/5mM TRIS-HCl, pH
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7.4) 0.4ml of 0.3M dimethylglutarate containing 25mM EDTA 
and 25mM sodium ( + ) tartrate, pH 6.5, and 0.1ml of 5mM 
glucose-6-phosphate solution was added. The solution was 
mixed and incubated for 25 minutes at 37°C (linear 
reaction over this period).
The reaction was stopped by the addition of 1.5ml of 
6% (w/v) trichloroacetic acid. The samples were then
frozen at -20°C prior to the assay of the released
inorganic phosphate (refer to section 7.2.10).
Tissue blanks, substrate blanks and reagent blanks 
were prepared according to the scheme set out in table 
7.1.
7.2.10 Determination of Inorganic Phosphate
The method of Lindberg and Ernster (1956) was 
employed. The samples obtained from the assay of 
glucose-6-phosphatase were defrosted and centrifuged at 
l,200g for 5 minutes in a Beckman J6-B centrifuge
(Beckman Ltd., High Wycombe, Bucks, U.K.) in order to 
sediment the protein. 2.0ml of each sample was then
added to 1.0ml of a 0.5% (w/v) ammonium molybdate in 5%
PCA solution (made by diluting 10% (v/v) PCA with 1%
(w/v) ammonium molybdate in a ratio of 1:1) and mixed 
well. 0.3ml of freshly made 0.2% (w/v) ascorbic acid was 
added and mixed well. The extinction was recorded 20
minutes later at 700nm on a Cecil 292 Digital Ultraviolet 
Spectrophotometer with a CE 235 micro-sipette control
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Table 7.1
Blanks Required when Estimating Inorganic Phosphate
Released During an Enzyme Reaction.
Blank Water Buffer Substrate Tissue
(ml) (ml) (ml) (ml)
Substrate 0.5 0.4 0.1 0
Reagent 0.6 0.4 0 0
Tissue 0.1 0.4 0 0.5
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(Cecil Instruments Ltd., Cambridge, U.K.).
A standard curve and blank were prepared each time 
the assay was performed. 0.5 pmol potassium hydrogen 
phosphate was prepared in 5% PCA and diluted to give a 
standard curve of 0-0.5 pmol phosphate.
7.2.11 Estimation of Cyanide-Insensitive Palmitoyl CoA 
p-Oxidation
The method of Bronfman et al., (1979) was adopted. 
A reaction cocktail consisting of 75 pM CoA, 180 jjM FAD, 
555 uM NAD+, 141mM niacinamide, 4.2mM dithiothreitol, 3mM 
potassium cyanide and 0.225 mg/ml BSA in 60mM TRIS-HCl, 
pH 8.3 was freshly prepared and kept on ice. In 
addition, 1% (w/v) triton X-100 in 60mM TRIS - HCl, pH
8.3 and 7.65 mM palmitoyl CoA in 60mM TRIS - HCl, pH 8.3 
were freshly prepared and kept on ice prior to use.
The assay was carried out at 340nm in a Cary 219 
Spectrophotometer (Varian Ltd., Palo Alto, Ca., USA) with 
a heating block preheated to 37°C.
A 2.0ml aliquot of the reaction cocktail and 0.96ml 
of the 60mM TRIS-HCl, pH 6.3 buffer were equilibrated 
together at 37°C for 5 - 1 0  minutes in a plastic LP4 tube 
(Luckhams Ltd., Burgess Hill, Sussex, U.K.). Meanwhile, 
50 pi of sample (liver homogenate diluted 1:1 with the 
60mM TRIS-HCl, pH 8.3 buffer) was mixed with 50 pi of the 
1% triton X-100 and kept at 37°C for 1 minute. A 40 pi
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aliquot of the sample mix was added to the cocktail/ 
buffer mix and centrifuge mixed at 400g for 3 minutes in 
an lEC Centra-4X centrifuge (International Equipment 
Company, Dunstable, Beds., U.K.). Each sample was 
transferred to a cuvette and placed in the rotating 
turret of the Cary 219. Palmitoyl CoA (20 pi) was added 
to each cuvette and the change in extinction was recorded 
for at least 10 minutes with an air blank.
The activity was then calculated as follows;
Activity = E3 4 Q/min x 24.1 pMol/min/ml of test solution 
assuming a molar absorbance of NADH at 340 nm of 6.22 x 
103.
7.2.12 Determination of Total Hepatic DNA
Hepatic DNA was estimated using the Schneider 
procedure as reported by Munro and Fleck (1966). The 
preliminary treatment was to obtain a nuclease free acid 
- insoluble fraction. To 1ml of whole liver homogenate, 
7.0ml of 5% (v/v) PCA was added and mixed. This was
allowed to stand for 2-3 minutes at 0°C and was then 
centrifuged at l,200g for 5 minutes in a Beckman J6-B 
centrifuge (Beckman Ltd., High Wycombe, Bucks., U.K.) set 
at 0°C. The supernatant was rejected and the pellet was 
then washed twice in 7.0ml of ice-cold 2% (v/v) PCA with 
centrifugation between each washing.
The washed pellet was then finely suspended in 3ml 
of 5% (v/v) PCA and the DNA was extracted for 20 minutes
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at 80°C with occasional mixing. Following cooling and 
centrifugation, the supernatant was kept and the pellet 
re-extracted as before. The resulting supernatants were 
pooled and 0.6ml was used for the determination of DNA.
Blanks consisted of the appropriate amounts of 5% 
PCA (0.6ml). A standard curve of DNA was carried through 
the procedure in the range of 10 - 100 pg DNA. In 
addition, 100 pg RNA was assayed to check the specificity 
of the assay.
Colour development for DNA was by the diphenylamine 
method. To 0.6ml of blank, standards and tests, 2.4ml of 
1.5% (w/v) diphenylamine in glacial acetic acid
containing 1.5% (v/v) concentrated sulphuric acid was
added and mixed (this reagent was freshly prepared and 
stored in the dark. Just prior to use, 10 pi acetalde- 
hyde/50ml reagent was added). The samples were kept 
in the dark at room temperature overnight and the 
extinction was read at 600nm on a Cecil 292 Digital 
Ultraviolet Spectrophotometer with a CE 235 micro-sipette 
control (Cecil Instruments Ltd., Cambridge, U.K.).
7.2.13 Protein Determination
All protein was measured using coomassie blue as 
previously described in Chapter 4 (section 4.2.8).
7.2.14 Plasma Albumin Determination
This was estimated on the Cobas Bio centrifugal
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analyser as previously described in Chapter 4, section 
4.2.7.
7-2.15 Plasma Cholesterol Determinations
The method employed was slightly adapted from that 
of Wybenga et al., ( 1970) as reported by Henry et al., 
(1974). The cholesterol reagent was made by dissolving 
520mg of ferric perchlorate in 600ml of ethyl acetate. 
Concentrated sulphuric acid (400ml) was then gradually 
added with mixing after each addition. During the 
mixing, the temperature of the reagent was kept below 
45°C by keeping it on ice. This was stable for 1 year at 
room temperature.
The assay consisted of adding 50 pi of cholesterol 
standard (200 mg cholesterol/100 ml glacial acetic acid) 
or blank or plasma to 5.0ml of cholesterol reagent and 
mixing. The tubes were then incubated in a boiling water 
bath for 1.5 minutes and then cooled. The extinction for 
each sample was read at 610nm in quartz cuvettes. The 
cholesterol concentrations was calculated as follows:
Cholesterol (mg/lOOml plasma) = E test ^ 200
^ standard
7.2.16 The Determination of Plasma Triglycerides
The procedure was outlined in the Sigma technical 
bulletin number 405, that accompanied the test kit. The 
triglycerides were initially extracted from 200 pi of 
plasma by mixing with 5.0ml of isopropanol and 0. 8g
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purifier. A 2.0ml aliquot of the clear supernatant was 
then mixed with 0.5ml of IN potassium hydroxide and 
incubated at 60°C for 5 minutes.
The tubes were then cooled to approximately 20°C and 
0.5ml of sodium m-periodate solution was added. Exactly 
10 minutes after the additon of the periodate, 3.0ml of a 
colour reagent was added (200ml 2M ammonium acetate + 
40ml of isopropanol and 0.15ml acetylacetone). The 
colour was developed at 60“C for 30 minutes. Finally, 
the extinction was read at 410nm using a Cecil 292 
Ultraviolet Spectrophotometer with a CE 235 micro-sipette 
control (Cecil Instruments Ltd., Cambridge, U.K.).
A water blank and a triolein standard (300 mg/100ml) 
were taken through the assay on each occasion. The 
concentration of triglycerides was calculated as follows:
Triglycerides (mg/100ml plasma) = E test x 300
 ^ standard
This calculation assumes that the blank had already 
been subtracted from the test and standard extinction 
values.
7.2.17 Gel Electrophoresis of Microsomal Proteins. 
Sodium Dodecyl Sulphate Polyacrylamide Slab Gel 
Electrophoresis
The method of Laemmli (19 70) was employed for 
analysis of microsomal proteins. The following stock 
reagents were used:
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Gel stock - 30% (w/v) acrylamide containing 0.8% (w/v) 
N,N' - methylenebis - acrylamide.
Buffer 1 - 1.5M TRIS-HCl (pH 8.8) containing 0.4% (w/v)
SDS.
Buffer 2 - SOOmM TRIS-HCl (pH 6.8) containing 0.4% (w/v) 
SDS.
Buffer 3 - 25mM TRIS-HCl (pH 8.3) containing 192mM 
glycine and 0.1% (w/v) SDS.
Buffer 4 - 62.5mM TRIS-HCl (pH 6.8) containing 2.3%
(w/v) SDS, 15% (v/v) glycerol, 5% (v/v)
2-mercaptoethanol and 0.001% (w/v)
bromophenol blue.
The vertical slab gel was contained within a glass 
and perspex cuvette with internal dimensions of 120 x 100 
X 1.5mm. Electrophoresis was carried out .at room 
temperature.
The glass plates of the cuvette were washed in 
distilled water and cleaned with acetone prior to use. 
The cuvette was assembled and sealed with molten agar 
(2.0%, w/v) and was then clamped in a vertical position. 
The seal was checked by filling the cuvette with water 
before the lower running gel was added. The lower gel 
was prepared by mixing 10ml of buffer 1, 13.3ml of gel
stock and 16.6ml of water. Polymerisation was initiated 
by the addition of 20pl of N.N' - tetramethylethylened- 
iamine (TEMED) and 240 yil of a 10% (w/v) solution of 
ammonium persulphate (freshly prepared). The solution
2 0 0
was poured into the cuvette to a height of 80mm. A layer 
of distilled water was introduced above the lower gel to 
ensure a smooth interface with the upper stacking gel 
after polymerization. When polymerization was complete, 
the water layer was poured off and the stacking gel was 
added. This consisted of 2.5ml of buffer 2, 1.0ml of gel 
stock, 6.5ml of water, 20ul of TEMED and 60 ul of a 10% 
(w/v) solution of ammonium persulphate. A ten track 
perspex comb was introduced into the stacking gel before 
polymerization to form the sample wells. The comb was
removed when polymerization was complete and a small 
amount of electrode buffer was introduced to keep the
wells separate. The lower spacer was removed from the
cuvette which was then clamped in the electrophoresis 
tank. Electrode buffer was added to the upper and lower 
reservoirs and air bubbles were removed from the lower 
gel surface with a syringe.
Microsomal suspensions were diluted with buffer 4 to 
give a final concentration of Img protein/ml. Samples 
were then incubated in a boiling water bath for 3
minutes. The samples were cooled and between 10 - 25 pi 
was applied to the stacking gel. After an electro­
phoretic power supply had been connected to the tank with 
the negative terminal connected to the upper reservoir, a 
constant current of 20mA was applied to the gel until the 
bromophenol blue entered the running gel. At this point, 
the current was increased to 40mA until the front was 
within 5mm of the end of the gel.
2 0 1
The cuvette was removed from the tank and the glass 
plates were separated. The stacking gel was discarded 
and the running gel (lower gel) was stained by immersion 
overnight in propan-2-ol/acetic acid/water (5:2:13 by 
volume) containing 0.05% (w/v) coomassie blue G-250. The 
background was destained by immersing the gel in 
progressive changes of propan-2-ol/acetic acid/water 
(1:1:8 by volume) over a period of 6 hours. The gels 
were stored in 3% (v/v) glycerol at room temperature once 
the background was cleared.
Results
7.3.1 The Effect of Citral Upon Body Weight Gain, Food 
Consumption and Macroscopic Pathology
Both the citral - treated albino and hooded rats 
showed a transient fall in food consumption and body 
weight gain, (figures 7.1 and 7.2), being most marked in 
the hooded rats over the first 5 days of citral admin­
istration. The food consumption in both strains had 
returned to normal within 3 - 6  days, however the rate of 
body weight gain remained lower than the control groups 
in both strains of rat. Thus, the final body weights of 
the citral- treated rats were significantly lower than 
the equivalent controls (table 7.2).
The test animals of both strains showed a time 
dependent hepatomegaly (table 7.2). This is shown by an 
increase in the absolute and relative liver weights of
2 0 2
Figure 7.1
The Effect of Oral (Gastric Intubation) Administration of 
Citral to A) Wistar albino and B) Long Evans hooded Rats 
upon Food Consumption.
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The figures presented are the mean figures with 10 
animals per cage per time point. Citral was administered 
in cornoil at a dose level of 2.4 g/kg (0,0 ) to Wistar 
albino and Long Evans hooded rats respectively; the 
controls received cornoil alone (•,■).
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Figure 7.2
The Ffcfect of; Oral (Gastric Intubation) Administration of 
Citral to A) Wistar albino and B) Long Evans hooded rats 
upon Body Weight Gain.
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The figures presented are the mean ± SEM with 10 animals 
per time point. Citral was administered in cornoil at a 
dose level of 2.4 g/kg (0,0) to Wistar albino and Long 
Evans hooded rats respectively; control animals received 
cornoil alone (•,■). * P < 0.05, * * P < 0.01 and
*** P< 0.001.
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citral - treated animals and supports the previous 
findings of citral - induced hepatomegaly (see Chapters 
3, 4 and 5). No gross macroscopic changes were seen in
the treatment groups from either strain, including the 
s tomach.
7.3.2 Light and Electron Microscopy
The number of mitotic figures was slightly, but not 
significantly increased in the livers of hooded rats 
treated with citral for 3 days (table 7.3). In addition, 
there was evidence for glycogen and fat changes in the 
haematoxylin and eosin stained sections of both strains 
of rat treated with citral(see Chapter 3, section 3.3.4),
In liver sections stained with PAS, there was 
perivascular loss of glycogen after 3 and 10 days from 
citral - treated rats of both strains. This was 
previously seen following dietary citral administration 
for 14 days (Chapter 5, section 5.3.2). The
distribution of neutral fat was altered in the livers of 
citral-treated rats of both strains with periportal and 
midzonal accumulation of lipid droplets and a 
corresponding centrilobular loss (see Chapter 5, section 
5.3.2).
The electron microscopy showed that in the livers of 
citral-treated rats of both strains there was an increase 
in the number of peroxisomes together with proliferation 
of smooth endoplasmic reticulum. Many, but not all
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Table 7.3
Mitotic Counts in the Livers of Control and Citral 
Treated (2.4 g/kg) Wistar albino and Long Evans hooded 
rats.
Duration of Long Evans hooded Wistar albino
Treatment
(days) Control Test Control Test
5.560.6 11.063.7 3.461.2 2.460.5
10 2.360.8 1.160.7 1.460.7 0.560.2
The figures presented are the mean 6 sEM with 10 
animals per group.
The number of mitotic figures (at metaphase) was 
counted in 20 fields of view at a magnification of x 200.
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peroxisomes possessed the uricase-rich "core" also seen 
in the control sections (figures 7.3 and 7.4). In 
addition, the mitochondria appeared to be increased in 
size and number in the livers of rats treated with citral 
for 10 days. These sections also showed accumulation of 
lipid droplets within the hepatocytes; this was 
especially evident with the hooded rats (figure 7.5). 
The bile canaliculi of citral-treated rats appeared 
larger and, compared to those of control rats, contained 
debris.
7.3.3 Hepatic Biochemistry
Glucose-6-phosphatase activity in the livers of 
citral treated animals showed a reduction to about 70% of 
the control value in hooded and albino rats after 10 days 
(table 7.4); however, these differences, which were less 
after 3 days, were not statistically significant.
The activity of the peroxisomal marker, cyanide - 
insensitive palmitoyl CoA p-oxidation, was increased in 
the livers of animals treated with citral (table 7.5). 
The increase was maximally 4-fold in the albino rats 
compared to the controls and 3-fold in the hooded rats.
The mixed function oxidase enzymes showed induction 
of cytochrome P-450 as indicated by the significant 
increase in the activity of benzphetamine N-demethylase 
and by the increase in cytochrome P-450 by spectral 
assay. The 7-ethoxyresorufin 0-deethylase activity, a
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Figure 7.3
Electronmicrograph of a Section taken from the Liver of a 
Control Wistar albino Rat.
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The section was prepared for electron microscopy as 
described in section 7.2.7. There are very few
peroxisomes (P) (x 16,500). M-Mitochondria, rER - Rough 
Reticulum, sER - SmoothEndoplasmic
Reticulum.
Endoplasmic
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Figure 7.4
Electronmicrograph of a Section Taken From the Liver of a 
Male Wistar albino Rat Treated with 2.4 g/kg Citral for 3 
Days by Gastric Intubation.
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The section was prepared for electron microscopy as 
described in section 7.2.7. Note the increase in 
peroxisomes (P) compared to mitochondria (M) (x 10,000). 
A similar change was seen in the livers of Long Evans 
hooded rats.
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Figure 7.5
Electronmicrograph of a Section Taken From the Liver of a 
male Long Evans hooded Rat treated with 2.4 g/kg citral 
for 10 days by Gastric Intubation.
#
The section was prepared for electron microscopy as 
described in section 7.2.2. Note the accumulation of 
lipid droplets (L.D.) within the hepatocyte (x 12,700). 
The accumulation of lipid was more marked in Long Evans 
hooded rats than Wistar albino rats.
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Table 7.4
Glucose-6-phosphatase activity in the livers of Long 
Evans hooded and Wistar albino rats following oral 
administration of 2.4 g/kg citral.
Duration of Long Evans hooded Wistar albino
Treatment
(days) Control Test Control Test
11.262.0 10.062.2 9.761.7 7.361.0
10 17.064.0 11.663.4 14.762.9 9.961.
Figures presented are the mean 6 sEM with 10 animals 
per group.
Units - nmol/min/mg protein.
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specific substrate for cytochrome P-448, did not show any 
significant change following citral administration in 
either strain of rat (table 7.6).
The polypeptide composition of the hepatic 
microsomes was defined by SDS gel electrophoresis. The 
electropherogram indicated induction of cytochrome P-450, 
(molecular weight, 53,000 daltons) with a band at 
approximately 80,000 daltons molecular weight also being 
induced, especially in albino rats (figure 7.6).
The nature of the hepatomegaly was further 
investigated by a measurement of the hepatic DNA and 
protein (table 7.7). Hepatic DNA was significantly 
increased after 3 days of citral administration in the 
livers of hooded, but not albino rats. This correlates 
with the increase in mitotic figures observed in the 
livers of citral-treated hooded rats after 3 days (table 
7.3). There were no statistically significant
differences after 10 days of citral administration in 
either strain. Although the protein was increased in the 
livers of all citral-treated animals, the only 
statistically significant increase was after 10 days of 
citral administration to hooded rats.
7.3.4 Plasma Biochemistry
The total plasma protein was only reduced following 
citral administration in the albino rats which also had 
higher control values than the hooded rats. However, the
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Figure 7.6
SDS-Polyacrylamide Slab Gel Electrophoresis.
925
^  68 
60
^  53 
43
36
8
SDS - PAGE profiles of the protein from microsomal
fractions obtained from the livers of control Wistar 
albino (lanes 4 and 5) and Long Evans hooded rats (lanes
8 and 9) . The profiles from microsomes of citral -
treated rats (2.4 g/kg for 3 days) are shown from Wistar n
albino (lanes 2 and 3) and Long Evans hooded (lanes 5 and 
6) rats. The protein concentration , was 20 ug in lanes 
3, 5, 7 and 9 and 25 ^g in lanes 2, A, 6 and 8. Lane 
1 .represents standard proteins with molecular weights in 
K daltons. The upper arrow (a) indicates the position of 
polypeptide PPA-80 with the lower arrow (b) indicating 
the position of cytochrome P-450.
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decrease was only significant after 3 days of citral 
administration. Citral had no effect upon the plasma 
protein concentration in hooded rats. In contrast, the 
plasma albumin was decreased in all animals following 
administration of citral (table 7.8). The control levels 
were similar in both strains.
There were no significant effects upon total plasma 
cholesterol in either strain. Citral administration did, 
however, slightly increase the plasma triglycerides in 
both strains, but due to the large variation between 
individual values, the differences were not statistically 
s ignifleant.
Discussion
As reported in the previous chapters, citral 
administration caused a reduction in food consumption and 
body weight gain compared to the controls (see Chapters 3 
and 5). Both reductions were transient and food 
consumption had returned to the control level by 10 days 
although the body weight gain was still lower than the 
controls in both strains suggesting a fall in food 
conversion efficiency (also see Chapter 3, section
3.3.2).
A treatment - related hepatomegaly was observed in 
the citral-treated rats and this is a common feature of 
compounds which induce microsomal cytochrome P-450,
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including some which also cause peroxisomal proliferation 
(Reddy et al., 1978; Reddy, 1980; Fahimi and Reimicke, 
1982; Fort et al., 1983; Reddy and Lalwani, 1983; Mann et 
al., 1985). Recently, it was reported that clofibrate
caused peroxisomal proliferation in the absence of 
hepatomegaly (Hietanen et al., 1985). However, the 
relative liver size expressed as a percentage of body 
weight did not agree with the figures presented for 
absolute liver weight and body weight, suggesting that 
the authors' quoted figures are incorrect.
The mechanism of such hepatomegaly has been 
attributed to hyperplasia followed by hypertrophy since 
the hyperplastic response could be seen within the first 
few days of compound administration (Reddy and Lalwani, 
1983). However, with clofibrate, hypertrophy alone has 
been reported as being responsible for the liver 
enlargement (Hess et al., 1965; Beckett et al., 1972). 
It has been suggested though, that peroxisome 
proliferation is very closely but not invariably 
associated with hepatomegaly induced by hypolipidaemic 
agents and that peroxisome proliferation is a 
contributory factor in increased liver weight (Cohen and 
Grasso, 1981). The initial increase in mitotic figures 
reported here, following the administration of citral 
suggests that hyperplasia was the immediate response of 
the liver and this was then followed by hypertrophy since 
the liver enlargement was time related. The increase in 
total hepatic DNA supports this, especially in the
2 2 0
hooded rats. However the stimulation of DNA synthesis by 
citral might not have been expected since most other 
2-alkenals inhibit DNA synthesis (Scliau^nstein jst al. ,|l977)
The histological observations of a fall in 
centrilobular glycogen and an increase in periportal 
lipid support the previous findings (Chapter 5, section
5.3.2). It is uncertain whether this fall in hepatic 
glycogen was due to reduced food intake or due to an 
increased demand for cell respiration. Indeed, the 
number of mitochondria was increased after 10 days of 
citral administration to both strains. Electron
microscopy also showed that citral caused proliferation 
of peroxisomes, endoplasmic reticulum and an increase in 
intracellular lipid droplets in both albino and hooded 
rats. Various hypolipidaemic drugs/agents, for example, 
cetaben, clofibrate, fenofibrate, nafenopin, Wy-14,643 
and tibric acid have also been reported to cause an 
increase in the number of peroxisomes (Hess et al., 1965; 
Svoboda et al., 1966; Reddy and Krishnakantha, 1975;
Moody and Reddy, 1978a; Barnard et al. , 1980; Blane and 
Piharoli, 1980; Fort et al., 1983). However, prolif­
eration of peroxisomes is not confined to hypolipidaemic 
drugs; plasticizers for example, di (2-ethylhexyl) 
phthalate, phenoxyacetic acid herbicides, 2,4-dichloro- 
phenoxy-acetic acid and other chemicals for example 
acetylsalicylic acid, have all been shown to produce 
proliferation of peroxisomes and liver enlargement (Lake 
et al., 1975; Moody and Reddy, 1978b; Ishii and Suga,
2 2 1
1979; Reddy et al », 1979), although most of these
compounds do possess hypolipidaemic properties. This has 
been reviewed by Cohen and Grasso (1981) who correlated 
hepatic peroxisome proliferation with hypolipidaemic 
activity in rats and mice.
Concomitant with the increase in the number of 
peroxisomes, there was also induction of peroxisomal 
cyanide - insensitive palmitoyl CoA p-oxidation following 
administration of citral to both strains of rat. The 
degree of induction was different in the two strains of 
rat being maximally four-fold in the albino rats and 
three-fold in the hooded rats. However, it is not clear 
to what extent this was influenced by the reduced food 
intake. Several authors have reported an increase in 
peroxisomal p-oxidation following starvation, but the 
degree of induction was generally below two-fold (Ishii 
et al., 1980; Thomassen et al., 1982; Van den Branden e^ 
al. , 1984; Van den Branden and Roels, 1985); it has also 
been reported that starvation does not affect peroxisomal 
p-oxidation (Slauter and Yamazaki, 1984). Other workers 
have shown that starvation does not decrease the levels 
of fatty acid oxidative activity in rat liver (Mannaerts 
et al., 1979; Cubeddu et al., 1985). However, the fact 
that the palmitoyl CoA p-oxidation activity remained 
elevated while food consumption was essentially normal 
from 3 to 10 days in the albino rats suggests that the 
increased p-oxidation was a direct consequence of citral 
administration.
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Compared to other hepatic peroxisomal proliterators, 
citral is a weak inducer since induction of up to 
sixteen-fold has been reported for hypolipidaemic 
compounds (Svoboda et al., 1969; Lazarow, 1977; Moody and 
Reddy, 1978a,; Holloway and Orton, 1980; Hietanen et al., 
1985). Similar induction has been reported for 
plasticizers (Reddy et al., 1976b; Moody and Reddy, 
1978b; Osumi and Hashimoto, 1979; Mann et al. , 1985).
Acetylsalicylic acid however has been reported to result 
in a maximal four-fold induction of peroxisomal 
p-oxidation (Ishii and Suga , 1979), and is thus similar 
to citral in this regard.
The fall in glucose - 6 - phosphatase activity in 
the livers of both albino and hooded rats following the 
administration of citral suggests liver damage. However, 
the losses in glycogen and in glucose - 6 - phosphatase 
activity were much less than is seen with the 
hepatotoxins carbon tetrachloride and dimethylnitrosamine 
and there was no evidence of cell necrosis.
Citral administration to both strains of rat caused 
induction in the cytochrome P-450 level, but at this 
stage -it is not known whether cytochrome P-452 is also 
induced. This isoenzyme has recently been shown to be 
induced by hypolipidaemic compounds (Gibson et al., 1982; 
Tamburini et al., 1984; Gibson and Bains, 1985) and thus 
it would be of interest to study the effect of citral 
administration upon this isoenzyme. SDS gel electro-
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phoresis of microsomes isolated from the livers of 
citral-treated rats of both strains indicated induction 
of a polypeptide with a molecular weight of approximately
80,000 daltons in the albino rats, but not the hooded 
rats. This polypeptide has been designated PPA - 80
(peroxisome proliferation associated) and corresponds to 
peroxisomal enoyl-CoA hydratase and fatty acyl-CoA 
oxidase (Osumi and Hashimoto, 1979b; Inestrosa et al. , 
1980; Reddy et al., 1981). This polypeptide has been 
shown to be induced by hypolipidaemic compounds (Reddy 
and Kumar, 1977; Reddy et al., 1979; Reddy et al., 1981).
Unlike the hypolipidaemic compounds, citral did not 
alter the concentration of plasma triglycerides or 
cholesterol. This supports the findings of Wood (1962) 
and Herzmann (1966) and suggests that citral is a 
peroxisome proliferator, but not a hypolipidaemic 
compound. In addition, citral administration caused a 
transient fall in plasma albumin levels in both strains 
and a fall in total plasma protein in the albino rats. 
However, the total plasma protein levels in the control 
albino rats was greater than that of the hooded rats and 
the administration of citral reduced the concentration to 
that of the hooded rats. The fall in plasma albumin was 
independent of the total plasma protein level and 
suggests that the concentration of some other components 
of the total plasma proteins were increased.
In summary, administration of citral to both albino
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and hooded rats resulted in a number of hepatic changes 
in parallel with changes reported for hypolipidaemic 
compounds. These were periportal accumulation of lipid 
and a fall in centrilobular glycogen. In addition, there 
was an increase in the amount of hepatic DNA and number 
of mitotic figures suggestive of early hyperplasia. The 
other parallels are proliferation of smooth endoplasmic 
reticulum and peroxisomes as indicated by electron 
microscopy and induction of cyanide-insensitive palmitoyl 
CoA p-oxidation. The induction of the PPA-80 polypeptide 
following administration of citral serves as a reliable 
indicator of enhanced peroxisomal p-oxidation (Reddy e_t 
, 1981).
There was little difference between the strains of 
rat except that the induction of cytochrome P-450 was 
greater in the hooded rats than the albino rats. 
Correspondingly, PPA-80 was only detected in albino rats 
and the peroxisome proliferation was greater in the 
albino rats compared to the hooded rats as indicated by 
the palmitoyl CoA levels. These results suggest that 
p-oxidation is a more important early route of metabolism 
for citral in albino rats than hooded rats where the 
mixed function oxidase system is more inducible than in 
the albino rats and so is a more important route of 
metabolism. Thus, the changes in peroxisomes will be 
more marked in the albino rats than the hooded rats, 
especially following short-term administration of citral.
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Chapter 8
Peroxisomal and Related Changes Associated with
the Administration of Citral to Wistar albino Rats
Introduction
The results presented in the previous chapter showed 
that administration of citral to both Long Evans hooded 
and Wistar albino rats resulted in hepatomegaly, 
proliferation of smooth endoplasmic reticulum and an 
increase in the number of peroxisomes. In these 
respects, citral parallels the effects of hypolipidaemic 
compounds (Cohen and Grasso, 1981), however it differs in 
having no effect on plasma triglycerides or cholesterol.
It has been shown that administration of the 
hypolipidaemic compound clofibrate, to rats, results in 
induction of a novel form of cytochrome P-450 (Gibson e^ 
al. , 1982; Tamburini et al., 1984, Gibson and Bains, 
1985) with a selective increase in the liver microsomal 
Gu and Caj - 1 -oxidation of fatty acids such as lauric
(dodecanoic) acid, with preferential formation of the 
12-hydroxylauric acid metabolite (Parker and Orton, 
1980). Metabolism of citral via (^-oxidation was first 
suggested by Kuhn and Livada ( 1933) and this route of 
metabolism subsequently has been demonstrated for
geraniol (Asano and Yamakawa, 1950). More recently, 
Licht and Coscia ( 1978) demonstrated Co)-hydroxylation of 
geraniol and nerol, the alcohol form of the two isomers 
of citral, in a rabbit liver microsomal system. This 
data suggests that citral may induce ^-oxidation in vivo.
Also of interest was the fact that the hypo­
lipidaemic and peroxisomal proliferating compounds are
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not chemically related to one another; it has been 
suggested that agents capable of eliciting a persistent 
hepatic peroxisome proliferation and hepatomegaly are 
also capable of inducing liver tumours and thus represent 
a novel class of chemical carcinogens (Reddy et al. , 
1980). Indeed, it has already been shown that many of 
these compounds do cause hepatic carcinomas in rodents 
(Reddy et al., 1976; Reddy and Rao, 1977a and b ; Reddy 
and Qureshi, 1979; Reddy et al., 1979; Reddy et al., 
1980; Reddy and Lalwani, 1983). However, studies in 
monkeys (Platt and Thorp, 1966; Svoboda et al., 1967, 
Blane and Pinaroli, 1980) and in man (Schwandt et al., 
1978; Blane and Pinaroli, 1980; Hanefeld et al., 1980 
Bliimcke et al., 1983 ) failed to show any early hepatic 
changes that are so prominent in rodents. More recently, 
however, Reddy et al., (1984) have shown dose-dependent, 
non species - specific proliferation of peroxisomes in 
the livers of cats, chickens, pigeons, rhesus monkeys and 
cynomolgus monkeys. These findings suggested that the 
association between rodent carcinogenicity with 
peroxisome proliferation may have more relevance to man 
than was first thought.
Thus, it was the aim of this work to further 
characterize the hepatic changes caused by citral 
administration to rodents, in an attempt to elucidate the 
mechanism of action with regard to proliferation of 
peroxisomes and hence to suggest the relevance to man.
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Materials and Methods
8.2.1 Chemicals
Agarose - Litex Agarose, Litex, Denmark (Type No.
HSA) .
Antisera - Rabbit to rat antiserum - Dako 
Immunoglobulins, Denmark.
Developer, Fixer and X-Ray Film - Kodak Ltd., U.K. 
Hydrogen Peroxide (30%) - Sigma Chemical Co., Poole, 
Dorset, U.K.
[l-l^C] Lauric Acid and [methyl - Thymidine
Amersham International pic, Amersham, Bucks, U.K.
LKB Optiphase Safe, Scintillation Fluid - Fisons 
pic, Loughborough, Leicestershire, U.K.
Tissue Tek II OCT compound (for histochemistry) 
R.A. Lamb Ltd., London, U.K.
All other chemicals were obtained from suppliers as 
indicated previously or were obtained from BDH Ltd., 
Poole, Dorset, U.K. or Sigma Chemical Co., Poole, Dorset, 
U.K.
8.2.2. Materials
TLC plates, Merck Silica gel GF plates (20 x 20) -
Anderman and Co. Ltd., East Molesey, Surrey, U.K.
8.2.3 Animal Husbandry
Male Wistar albino rats weighing 200 ± 20g were
obtained from the University of Surrey Breeding Unit.
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They were randomly distributed into twenty cages with 
five animals per group. Throughout the work, the animals 
were fed an expanded pelleted diet (LAD - 1, Scientific 
Feeds Ltd., Croydon, Surrey, U.K.). All animals were 
allowed free access to both food and water. The animals 
were maintained at a temperature of 21 ± 2°C and humidity 
of 50 ± 3%. There was an artificially controlled 12 hour 
light/dark cycle from 0700 to 1900 hours GMT.
8.2.4 Administration of Citral
Citral was administered to four groups of rats by 
daily gastric intubation at dose levels of 0 (controls), 
0.096, 0 .48 or 2. 4g citral/kg body weight. The citral
was administered as solutions in cornoil of 0, 2, 10 and
50% (v/v) respectively at a constant volume of
0.48ml/100g body weight.
8.2.5 The Autopsy
At intervals of 1, 3, 7, 10 and 28 days after
commencement of citral administration, five animals from 
each dose group (including controls) were killed by 
exsanguination under pentobarbital anaesthesia and 
autopsied as described in Chapter 5, section 5.2.6. 
Plasma was collected as previously described in Chapter 
4, section 4.2.5; serum was collected from clotted whole 
blood in conical glass tubes after centrifugation at
1,000 g for 5 minutes. The samples were stored at -70°C 
until required for biochemical assays.
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The livers were weighed and samples were processed 
for histology and electron microscopy as previously 
described (Chapters 3 and 5, sections 3.2.11 and 5.2.6). 
Liver samples were also taken for histochemistry; the 
small pieces of tissue were frozen in a hexane/cardice 
chilling bath (see section 8.2.6).
The remainder of the liver was reweighed; an S9 and 
a microsomal fraction was then prepared for each sample 
as previously described (Chapter 5, section 5.2.7).
8.2.6 Histochemistry - Glucose - 6 - Phosphatase
Staining
Small pieces of liver (0.5 cm^) were immersed in a 
hexane bath at -70°C, chilled in a mixture of cardice and 
96% ethanol. The tissues were kept in the hexane for 
between 1 and 2 minutes and then transferred to dry, 
precooled beta vials at -70°C using pre-cooled forceps. 
The samples were then stored at -70°C prior to 
sectioning.
8pm sections were cut for histochemical staining at 
-30°C in a cryostat (Bright Instrument Company Ltd., 
Huntingdon, Cambs., U.K.) using tissue-tek II OCT 
mounting compound. All sections were mounted onto glass 
microscope slides and stored in the cryostat prior to 
staining.
The method for staining glucose - 6 - phosphatase
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was adapted from that of Wachstein and Meisel ( 1956). 
The sections on the slides were incubated in 0. IM sodium 
acetate, pH 6.5 (40ml), O.lM lead nitrate (1.0ml) and
di-sodium glucose - 6 - phosphate (26mg) for 10 minutes 
at 37°C.
Following the incubation, the slides were washed 
twice in tap water and once in distilled water. Finally, 
the slides were immersed in 0.5% (v/v) ammonium sulphide 
for 1 minute, washed twice in distilled water and mounted 
in glycerine jelly. Blanks were taken through the same 
procedure, except that the incubation medium contained no 
glucose-6-phosphate.
8.2.7 Lauric Acid Hydroxylation
The radiometric assay of Parker and Orton (1980) was 
used. Duplicate samples were set up for each sample in 
screw-top sovrill tubes. A blank was also set up for 
each TLC plate to be used. Hepatic microsomes were added 
to give 0. 5mg protein/ml in an assay system of 0.2ml 
[l^c] lauric acid (200mM lauric acid in methanol; take 
50pl and add to 9.9 5ml of 500mM TRIS/HCl, pH 7.4), lOpl 
[1 - 14c] lauric acid (0.1 pCi/lOpl in methanol) and 
distilled water to give a total volume of 1.96ml. The 
tubes were covered and incubated at 37°C for 5 minutes in 
a shaking water bath. 40pl of 0.04M NADPH (in 1% (w/v) 
NaHCOg) was then added to each test sample; water was 
used for the blanks. All microsomes were then incubated 
for a further 5 minutes and the reaction was terminated
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by the addition of 0.2ml of 3M HCl.
Ether (8.0ml) was then added to each tube and shaken
for 10 minutes to extract the hydroxylauric acid. After 
leaving to stand for 5 minutes to allow the phases to 
separate, the upper ethereal layer was transferred to a 
test tube and evaporated to dryness under a stream of
nitrogen.
The dried ether extracts were redissolved in 60pl of 
methanol; 25pl of the extracts was spotted onto the
Silica gel GF TLC plates. The plates were developed in a 
hexane: diethylether: acetic acid system (140:56:3 by
volume).
The developed plates were labelled with a [1 - 
lauric acid bromophenol blue mixture and the
unmetabolized lauric acid and the 11- and 12-
hydroxylaur ic acids were localized by applying X-ray film 
(Kodak U.K. Ltd.,) to the plates. The film was taped in 
place and kept in contact with the plates for at least 3 
days. The X-ray film was then developed for
approximately 4 minutes, washed in . tap water (stop 
reagent) and fixed for approximately 3 minutes. Both the 
developer and fixer were obtained from Kodak Ltd., and 
they were made up according to the manufacturers 
instructions. The spots with the greater Rf value 
represented the unmetabolised lauric acid with the 
metabolites being the spots with the lower Rf value.
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These were marked into equal areas and scraped into 
scintillation vials. Scintillation fluid (Optiphase 
Safe) (4.5ml) was then added to each vial which were then 
counted for [^^C] on an LKB Rackbeta B scintillation 
counter.
The amount of lauric acid metabolised was then 
calculated as follows:
Metabolite Counts - Blank x 200 x 2/5 nmols/mg 
Total Counts (Unchanged and Metabolites) protein/min
8.2.8 Determination of Catalase Activity
Catalase activity (EC. 1.11.1.6) was measured in 
fresh liver homogenates using the method described by 
Bock et al., (1980).
With the test samples, the reaction mixture 
consisted of 1.9ml of 0.05M phosphate buffer, pH 7.0 with 
0.33% (w/v) BSA plus 0.1ml of diluted sample (dilute 1/40 
in 1% triton X-100 containing 0.33%, BSA and 2% sodium 
chloride) and 1.0ml of 30mM H2 O2 (start). 1.0ml of 
buffer was used in place of the H2 O2 in the blank 
samples. All assays were carried out at 25°C at 240nm in 
1cm quartz cuvettes in a Cary 219 Spectrophotometer 
(Varian Ltd., Palo Alto, Ca., U.S.A.). The reaction was 
followed for 1 minute and the change in extinction was 
measured over the first 30 seconds of reaction. From the
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rate, the catalase activity was calculated as follows:
Rate (k) = 2.3 x Log Ej 
30 E2
where E% = extinction of reactants with diluent in place 
of sample,
and E2 = E% plus decrease in extinction over the 30 
seconds of the reaction.
Now, k X sample dilution x homogenate dilution = 
units/g liver/s.
8,2.9 Estimation of Uric Oxidase Activity
The uric oxidase activity (EC. 1.7.3.3) was 
determined by the method of Beaufay et al., (1959).
The substrate (0.03M phosphate buffer, pH 7.4, 
containing 7.6 mg/lOOml of uric acid and 9.3% (v/v)
triton X-100) and blank diluent (0.03M phosphate buffer, 
pH 7.4, containing 0.3% (v/v) triton X-100) solution were 
equilibrated at 37°C. Then, into two test tubes labelled 
"test" and "blank", 1.0ml of the sample (1/40 diluted 
liver homogenate) was added. These were also
equilibrated at 37°C. To these, 1.0ml of 5mM phosphate 
buffer, pH 7.4, was added. The solutions were then 
transferred to two 1cm silica cuvettes. 1.0ml of the 
substrate solution was then added to the test cuvette and 
1.0ml of the blank diluent solution was added to the 
blank cuvette. The cuvettes were placed into the sample 
and reference positions of a Cary 219 Spectrophotometer
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(Varian, Palo Alto, Ca., U.S.A.) fitted with a constant 
temperature block at 37°C. The change in extinction was 
followed at 292.5nm for 4 minutes. The activity was 
calculated with a molar extinction coefficient of 12.2. 
That is:
Activity = Extinction 292.5/min x 3 pmoles/min (uric
12.2 acid destroyed).
8.2.10 Determination of |3-Galactosidase Activity
This assay was adapted from the method of Hinton and 
Norris (1972) for an autoanalyser. The reaction mixture 
consisted of 0.23ml of 5mM pNP - Galactoside plus 0.8ml 
of 0.3m acetate, pH 5.0 with 0.2% (v/v) triton X - 100
plus 0.23ml of water and 0.32ml of sample (1/20 dilution 
of liver homogenate). The mixture was incubated at 37°C 
for 30 minutes and was stopped by the addition of 1.6ml 
of IN sodium hydroxide. The amount of p-Nitrophenol 
released was estimated at 402nm in a Cecil 292 
Ultraviolet Spectrophotometer fitted with a CE 235 
sipette control (Cecil Instruments Ltd., Cambridge, 
U.K.).
The results were calculated using a standard curve 
in the range of 0-5pM/ml p-Nitrophenol.
8.2.11 Estimation of Mitochondrial OGGlycerophosphate 
Dehydrogenase Activity
The method of Lee and Lardy ( 1965) was followed. 
lOpl of a 1/10 dilution of whole liver homogenate was
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mixed with SOpl of 0.125M phosphate buffer, pH 7.5,
containing 5mM potassium cyanide and 0.15M sodium 
fT-glycerophosphate (test) or 30pl of 0.125M phosphate 
buffer, pH 7.5, containing 5mM potassium cyanide 
(blank). The tubes were then incubated at 37°C for 10 
minutes. To each tube, 90pl of distilled water and lOOpl 
of a freshly prepared solution of 2-p-iodophenyl-3-p- 
nitrophenyl tétrazolium chloride (INT) (4mg/ml) and 
phenazine methosulphate (2.5 mg/ml in 0.05M phosphate 
buffer, pH 7.5). The tubes were then incubated for 15
minutes at 37°C. Finally, 50pl of 10% (w/v) TCA and 
2.5ml of 96% ethanol were added to each tube. These were 
then centrifuged to remove any precipitate and the 
extinction was read at 500nm on a Cecil 292 Ultraviolet
Spectrophotometer with a CE 235 sipette control (Cecil
Instruments Ltd., Cambridge, U.K.).
The activity was calculated as follows:
Activity = Etest“^blank ^ 20 =*E/min/ml of tissue
15
8.2.12 Estimation of Mitochondrial Succinate
Dehydrogenase Activity
The method of Prospero (1974) was slightly adapted 
to measure succinate dehydrogenase (EC 1.3.9-9.1). Each 
sample had a corresponding blank, but no substrate blank 
was used. During the assay, prior to the incubation, all 
tubes were kept on ice. A 0.25ml aliquot of 0.2M 
phosphate buffer, pH 7.4, containing 1.25mg/ml INT and
236
0.5ml of a 1/10 dilution of whole liver homogenate were 
added to each tube. Finally, 0.25ml of 0.3M sodium 
succinate, pH 7.4 was added to each test sample and 
0.25ml of 0.3m sodium malonate, pH 7.4, was added to each 
blank sample. The tubes were mixed and incubated for 10 
minutes at 37*C. The reaction was stopped by the 
addition of 4ml of stopping reagent (a mixture of 96% 
ethanol, ethyl acetate and 15% TCA, 13:20:2 by volume). 
Following mixing, the tubes were centrifuged to remove 
the denatured protein and the extinction was read at 
490nm on a Cecil 292 Ultraviolet Spectrophotometer with a 
CE 235 sipette control (Cecil Instruments Ltd., 
Cambridge, U.K.). The activity was calculated assuming a 
molar absorbance coefficient of 20,000 for the coloured 
product.
Activity = Etest “ ^blank x 5 x 0.1 x 2 x 50
20
= a E X 2.5 umol INT reduced/min/g liver.
8.2.13 Crossed Immunoelectrophoresis (LaurelIs)
The principle of this technique was outlined by 
Weeke ( 1973). The barbitone buffer used had an ionic 
strength of O.lp and was prepared as set out in appendix 
1.
1% (w/v) agarose gel was used and was prepared by
dissolving Ig agarose in 100ml 0.05p barbitone buffer 
(see appendix 1).
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The method was in two parts. First, 10ml of heated 
1% agarose solution (approximately 50*C) was poured onto 
a clean glass plate (8cm x 8cm) which was placed on a
levelling table. Once the gel had set, two holes were 
cut 1.5cm from each edge as illustrated in figure 8.1. 
The plates were then placed on the platen in an 
electrophoresis tank (Chemlab Instruments Ltd., Ilford, 
Essex, U.K.). Bromophenol blue was placed in one hole to 
act as a marker; sample (Ipl) was added to the other 
hole. The gel was then connected to the barbitone buffer 
(see appendix 1) by means of Whatman No.l filter paper 
wicks of" a thickness of 3 filter papers. The connection 
between the gel and the wicks was checked to ensure good 
electrical contact. The plates were electrophoresed in 
the first dimension at 180v (MBI Electrophoresis Power 
Supply Type 264, Medical and Biological Instrumentation 
Ltd., Ashford, Kent, U.K.). until the bromophenol blue
had almost reached the top of the gel (approximately 1 
hour). The plates were placed on the levelling table and 
a line, 0.5cm from the sample hole, was scored. The gel 
to the right of the sample hole was cut away and 
discarded (see figure 8.1). This plate was then wiped
dry and 10ml of an antibody - containing (rabbit to rat 
antisera) agarose (5% w/v) was poured onto the remaining 
part of the plate. After the gel had set, the plates 
were returned to the tanks and run perpendicular to the 
first dimension. The gels were again connected to the 
buffer by means of filter paper wicks and run at 40v 
overnight.
238
Figure B .1
A I't ;ni|') 1 .3 F 1: f > r first and second dimension 
immunoelectrophores is.
I s t
dimension
1% AGAROSE GEL.
1 .5 cm lulsamp1e
1 . 5 cm 1 m 1 B romp hen 0,1 
blue
1st
d ime ns ion
c
03 4-1
in
o
1 . 5cm
+
2nd dimension
239
The plates were then removed from the tank, covered 
with 3 layers of Whatman No. 1 filter paper and paper 
towels and pressed under glass plates for 10 - 15 minutes 
to remove excess buffer. The immunoplates were then 
washed for 1 hour in 0.9% (w/v) saline, pressed again,
and then rewashed. The plates were further pressed, 
washed in distilled water for 90 minutes, pressed again 
briefly and dried in a stream of warm air. Once they 
were dry, the plates were stained in coomassie brilliant 
blue R for 15 minutes. The excess stain was removed with 
destainer (appendix 2).
8.2.14 [^H] Thymidine Incorporation in DNA
In a separate experiment, male Wistar albino rats 
weighing 200 ± lOg from the University of Surrey breeding 
unit, were dosed with 2.4g/kg citral for 1 or 3 days in 
a 50% (v/v) solution in cornoil. Controls received
cornoil alone. Exactly 60 minutes prior to anaesthesia, 
all the animals were injected intraperitoneally with 
[methyl thymidine (specific activity 51 Ci/mmol) at
a level of 500 pCi/kg of body weight.
The animals were killed by exsanguination from the 
posterior vena cava and the livers were excised, weighed 
and immersed in homogenising medium (0.25M sucrose/5mM 
TRIS-HCl pH 7.4). The livers were then homogenised as 
previously described (Chapter 5, section 5.2.7) and the 
total DNA was estimated as described in Chapter 7 
(section 7.2.12). The supernatant (0.5ml) from the first
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washing (acid-soluble fraction) was transferred to a 
scintillation vial, to which 4.0ml of scintillation fluid 
(Optiphase Safe) was added and counted for ^H. In 
addition, 0.5ml of the pooled supernatants from the 
extraction stage was added to scintillation vials with 
4.0ml of scintillation fluid and counted for [^h ] - DNA.
8.2.15 Other Determinations
All other determinations were carried out according 
to procedures outlined in previous chapters (Chapters 4, 
5 and 7).
Results
8.3.1 Animal Health
Body weight and food consumption were both monitored 
during the study (figures 8.2 and 8.3). The food
consumption figures show that rats in the top dose group
had a significantly reduced food intake over the first
three days of citral administration, after which the food 
consumption was greater than the controls when food 
intake was expressed as g food eaten/lOOg body
weight/day. Administration of citral for shorter periods 
of time showed a similar pattern of food consumption to 
that in figure 8.2 for 28 days.
Only the top dose groups of citral (2. 4g citral/kg 
body weight) had a significantly lower body weight gain 
than the control groups; after 28 days of citral
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Figure 8.2
The Effect of Oral Administration of Citral to Wistar
albino Rats Upon Food Consumption.
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The figures presented are the mean with 5 animals per 
cage per dose group. Citral was administered by daily 
oral gastric intubation at 0.096 ( e ), 0.48 ( A  ) or
2.4 ( ▲ ) g/kg body weight. Control animals received the
cornoil vehicle alone.
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Figure 8.3
The Effect of Oral Administration of Citral to Wistar
albino Rats Upon Body Weight Gain.
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The figures presented are the mean ± SEM with 5 animals 
per cage per dose group per time point. Citral was 
administered by daily oral gastric intubation at 
0.096 {•), 0.48(A) and 2.4 ( A )  g/kg body weight. The 
controls ( O ) received the cornoil vehicle alone. The 
figures with arrows refer to termination days of 5 
animals/group. * R < 0.05 and ** P < 0.01.
243
administration, the final body weight in the top dose 
group was 77% of that of the controls. Food conversion 
was only reduced in the top dose group of citral 
administration during the first three days of citral 
administration (data not shown).
8.3.2 Liver Morphology
At the autopsy, no macroscopic lesions were noted 
for any organs. However, the citral - treated animals 
in the mid and top dose groups did show a dose and 
time-related hepatomegaly (figure 8.4). The lowest dose 
group (0.096g citral/lOOg body weight) did not show any 
significant liver enlargement at any time during the 
study.
Selective histological staining for glycogen and 
lipid in liver sections indicated a transient loss of 
glycogen from centrilobular regions of the top dose group 
after three days of citral administration (see figure 5.7 
section 5.3.2). This corresponds with the reduced food 
intake, which may be the cause of the glycogen 
depletion. However, by 28 days, the loss was minimal 
(table 8.1). In addition, citral administration caused 
lipid accumulation in the liver, especially in periportal 
regions. Lipid accumulation was marked in the top dose 
group and was transient being maximal after 3 days of 
citral administration (table 8.2). The pattern of lipid 
droplet accumulation was similar to that shown in figure
5.8 (section 5.3.2).
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Figure 8.4
The Effect of Oral Administration of Citral to Wistar
albino Rats Upon Relative Liver Weight.
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The figures presented are the mean ± SEM with 5 animals 
per group. Citral was administered by daily oral gastric 
intubation at 0.096 (®), 0.4 8(A) and 2.4 ( A )  g/kg body
weight. Control animals (O) received cornoil alone. * P 
<0.05 and *** P < 0.001.
245
Table 8.1
Hepatic Glycogen in Control and Citral - Treated Male 
Wistar albino rats.
Day
Dose (g Citral/lOOg body weight/day)
0(controls) 0.096 0.48 2.4
1 0 0 0 + +
3 0 0 0 + + +
7 0 0 0 0
10 0 0 0 +
28 0 0 + +
The data are the overall hepatic glycogen as
assessed in PAS stained, 6pm thick liver sections with 
5 animals per group.
0 - no loss of hepatic glycogen 
+ - minimal loss of hepatic glycogen 
++ - marked loss of hepatic glycogen 
+++ - massive loss of hepatic glycogen.
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Table 8.2
Lipid Accumulation in the Livers of Control and Citral 
Treated Male Wistar albino rats.
Day
Dose (g Citral/lOOg body weight/day)
0(controls) 0.096 0.48 2.4
1 + + ++ +4“
3 + + ++ + + +
7 + + + ++ ++
10 + + + ++ ++
28 0 + + 0
The data presented is from assessment of Oil Red "O" 
stained 6pm thick liver sections with 5 animals per 
group. The crosses refer to accumulation of lipid 
droplets; they refer to the sections overall, although 
most accumulation noted was in periportal regions of the 
liver sections.
0 - no accumulation of lipid 
+ - minimal accumulation of lipid 
++ - marked accumulation of lipid 
+++ - massive accumulation of lipid.
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Routine haematoxylin and eosin staining of liver 
sections revealed no pathological changes in most dose 
groups. However, after 3 days of citral administration, 
there was an increase in the number of mitotic figures 
(metaphase) in both the mid and top dose groups (table 
8.3). Histocytochemical staining for localisation of 
glucose-6-phosphatase showed that citral administration 
had no effect upon the distribution within the liver 
(figure 8.5).
Electron microscopy revealed that citral 
administration resulted in proliferation of smooth
endoplasmic reticulum and peroxisomes, especially in the 
top dose group. However, the proliferation of
peroxisomes appeared to be transient, the effect being 
reduced after 10 days of citral administration. In 
different regions of the liver, the peroxisomes appeared 
morphologically different. In periportal areas, a
majority of the peroxisomes had a uricase rich dense 
core; this was generally absent in peroxisomes from other 
areas of the liver. In addition, the number of
mitochondria appeared to be increased in the livers of 
citral treated rats (figures 8.6a, b and c).
8.3.3 Microsomal Cytochrome P-450 Dependent Mixed
Function Oxidase Activities
The cytochrome P-450 spectral assay indicated that 
citral administration caused induction of cytochrome 
P-450 in a dose-related manner; this was only
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Table 8.3
Mitotic Figure Counts from the Livers of Citral-Treated 
Male Wistar albino rats.
Dose (g citral/lOOg body weight/day)
Day
0(controls) 0.096 0.48
2017
10
28
The number of mitotic figures (metaphase) was 
counted in 20 fields of vision at a magnification of x400 
in haematoxylin and eosin stained 6 um thick liver 
sections.
Figures presented are the mean of counts from 5 
sections per group (1 section per animal).
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Figure 8.5
Photograph of a Frozen, Chryostat - Cut Liver Section 
Histochemically Stained for Glucose-6-Phosphatase 
Activity.
'
V-'
v/
Photograph of a liver section from a Wistar albino rat 
treated with 2.4g/kg citral for 28 days (x 400). 
Sections from control rats showed a similar pattern of 
staining.
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Figure 8.6
Electronmicrographs of Liver sections from Wistar albino 
Rats.
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Samples were prepared for electron microscopy as
described in section 7.2.7.
a) A section from the liver of a control Wistar albino 
rat (X 6,500).
b) A section from the liver of a Wistar albino rat
treated with 2.4g/kg citral for 3 days (x 8,000).
c) A section from the liver of a Wistar albino rat
treated with 2.4g/kg citral for 10 days (x 11,000).
CP-cored peroxisome, LD-lipid droplet, M-mitochondria 
P-peroxisome, rER-rough endoplasmic reticulum, sER-smooth 
endoplasmic reticulum.
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statistically significant at the highest dose level 
(figure 8.7). Using a specific substrate for cytochrome 
P-450, benzphetamine hydrochloride, it was shown that 
citral administration caused a dose - and time - related 
induction of cytochrome P-450. There was a slight 
decrease in benzphetamine N-demethylase activity after 3 
days of citral administration (figure 8.8) and this 
corresponded to the peak in activity of lauric acid 
hydroxylation (figure 8.9), which is mediated by 
cytochrome P-452. The spectral assay included all 
isoenzymes of cytochrome P-450 and so represents a 
combination of the induction of cytochrome P-450 and 
P-452.
SDS gel electrophoresis of microsomes isolated from 
the livers of control and citral-treated rats showed that 
there was induction of cytochrome P-450 and P-452 after 3 
and 7 days of citral administration (figure 8.10). In 
addition, the profiles showed induction of a polypeptide 
with a molecular weight of approximately 80,000 daltons. 
This was evident after 3 and 7 days of citral 
administration.
8.3.4 Liver Biochemistry
Total hepatic DNA only showed a statistically 
significant increase relative to controls in the top dose 
group after 10 days of citral administration. In 
comparison, the specific DNA (mg DNA/g liver) showed no 
statistically significant increase relative to controls,
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Figure 8.7
The Effect of Oral Administration of Citral to Wistar 
albino Rats upon Microsomal Cytochrome P-450 as Measured 
by Spectral Assay.
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The figures presented are the mean ± SEM with 5 animals 
per group. Citral was administered by daily oral gastric 
intubation at 0.096 (•), 0.48(A) and 2.4 ( A )  g/kg body 
weight. Control animals ( O ) received cornoil alone. 
Figure 8. 7A is the data expressed as percentage of 
control for the results expressed as nmols cytochrome 
P-450/mg protein (figure B.7B). * P < 0.05, compared to
con t rols.
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Figure 8.8
The Eftect of Oral Administration of Citral to Wistar 
albino Rats Upon Benzphetamine N-Demethylase Activity 
(Specific for cytochrome P-450).
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The figures presented are the mean ± SEM with 5 animals
per group. Citral was administered by daily oral gastric
intubation at 0.096 (®), 0.48(A) and 2.4 ( A )  g/kg body 
weight. Control animals ( o ) received cornoil alone.
* P < 0.05, ** P < 0.01 and *** P < 0.001 compared to
controls.
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Figure 8.9
The Effect of Oral Administration of Citral to Wistar 
albino Rats Upon Microsomal Lauric Acid Hydroxylation 
(Specific for W -  and GO-l- oxidation mediated by 
cytochrome P-452).
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The figures presented are the mean ± SEM with 5 animals
per group. Citral was administered by daily oral gastric
intubation at 0.096 ( © ), 0.48( A ) and 2.4 ( A ) g/kg body
weight. Controls ( o ) recieved cornoil alone.
* P < 0.05, ** P < 0.01 and *** P< 0.001 compared to
controIs .
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Figure 8.10
SDS-Polyacrylamide Slab Gel Electrophoresis
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Profiles of proteins from microsomal fractions of control 
Wistar albino rats (lanes 2 and 5) and.Wistar albino rats 
treated with 2.4 g/kg.body weight citral for 3 (lanes 3 
and 6) and 7 (lanes 4 and. 7) days. - The protein
concentration was 10 yig for lanes 2, 3 and 4 ^ and 15 jag 
for lanes 5, 6 and 7.. Lanes 1 and 8 represent standard 
proteins with molecular weights in K d a l t o n s T h e  upper 
arrow (a) indicates the position of polypeptide P.PA-80 
and the lower arrow (b) indicates the position of the 
cytochrome P-452 protein band.
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although after both 1 and 10 days, there was an increase 
in the specific content of DNA in the top dose group 
(table 8.4).
In addition, total hepatic vitamin A was measured 
since it was previously shown to be reduced following 
citral administration (Chapter 5, section 5.3.6). A 
significant decrease was only observed following 28 days 
of citral administration in the top dose group, although 
the fall was dose related at 28 days (figure 8.11). This 
agrees with the results presented in Chapter 5.
Parallel with the histocytochemistry for
glucose-6-phosphatese, the enzyme activity was measured 
in total liver homogenates. Citral administration 
reduced the enzyme activity after 28 days of 
administration (figure 8.12a) although the fall was not 
significant. However, the enzyme activity fell with time 
in all groups, including controls. In addition, citral 
administration had no effect upon the lysosomal enzyme 
(3-galactosidase (figure 8.12b).
Three peroxisomal markers were measured to gauge the 
effect of citral administration upon peroxisomes. 
Palmitoyl CoA p-oxidation was initially induced in a 
dose-related manner, but by 10 days after commencement of 
treatment, the specific activity had returned to control 
values in the two lower dose groups. Only in the top 
dose group was an increase in specific activity sustained
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Table 8.4
Specific DNA Content in the Livers of Male Wistar albino 
rats Following Oral Administration of Citral
Day
Dose (g citral/lOOg body weight/day)
0(controls) 0.096 0.48 2.4
1 0.41 ± 0.02 0.40 ± 0.02 0.40 ± 0.02 0.43 ± 0.02
3 0.41 ± 0.01 0.40 ± 0.02 0.40 ± 0.02 0.41 ± 0.02
7 0.28 ± 0.03 0.27 ± 0.02 0.32 ± 0.01 0.25 ± 0.01
10 0.40 ± 0.03 0.44 ± 0.04 0.39 ± 0.01 0.44 ± 0.03
28 0.39 ± 0.03 0.38 ± 0.02 0.34 ± 0.03 0.36 ± 0.02
The figures presented are the mean ± SEM with five 
animals per group.
Specific hepatic DNA - mg DNA/g liver.
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Figure 8.11
The Effect of Oral Administration of Citral to Wistar
albino Rats Upon Total Hepatic Vitamin A levels.
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The figures presented are the mean ± SEM with 5 animals 
per group. Citral was administered by daily oral gastric 
intubation at 0.096 (•), 0.48(A) and 2.4 ( A )  g/kg body
weight. Controls (O ) received cornoil alone.
** R < 0.01 compared to controls.
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Figure 8-12
The Effect of Oral Administration of Citral to Wistar
albino Rats Upon A) Hepatic Glucose-6-Phosphatase and
B) Hepatic p-Galactosidase Activities.
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For both figures, the data presented are the mean ± SEM 
with 5 animals per group. Citral was administered by 
daily oral gastric intubation at 0.096 ( • ) , 0.4b ( A ) and
2.4 ( A ) g/kg body weight. Controls ( O ) received
corno i1 alone.
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throughout the experiment (figure 8.13a). The induction 
in specific activity was maximally 4 fold after 7 days of 
citral administration, however, the total hepatic 
palmitoyl CoA p-oxidation activity remained at a constant 
elevated level throughout (figure 8.13b).
Catalase specific activity was induced, but in a 
non-dose-related manner (figure 8.14a). The induction 
was at a maximum of 3 fold after 10 days of citral 
administration in the mid-dose group (0.48g citral/lOOg 
body weight), although the variation was great, resulting 
in few statistically significant changes compared to 
controls. Uric oxidase activity, an indicator of "cored" 
peroxisomes, was not systematically affected by 
administration of citral, (figure 8.14b).
The activity of mitochondrial -glycerophosphate 
dehydrogenase was estimated in the whole rat liver 
homogenate. Administration of citral at 2.4g/kg body 
weight, resulted in induced activity, with a maximum 
activity after 7 days (figure 8.15a); increased activity 
was sustained for up to 28 days. Total hepatic activity 
was not affected by citral administration at the lower 
and mid doses ( 0.096 and 0.48g citral/kg body weight). 
However, at 2.4g citral/kg body weight, the total hepatic 
activity of of -glycerophosphate dehydrogenase was 
increased with time to a maximum after 28 days (figure 
8.15b). Succinate dehydrogenase, a specific marker for 
mitochondria, was measured since the electron microscopy
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Figure 8.13
The Fffect of Oral Administration
albino Rats Upon Peroxisomal
Palmitoyl CoA p-Oxidation.
of Citral to Wistar 
Cyanide-Insensitive
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The figures presented are the mean ± SEM with 5 animals 
per group. Citral was administered by daily oral gastric 
intubation at 0.Ü96 (©), 0.48(A) and 2.4 ( A )  g/kg body
weight. Controls ( O ) received cornoil alone.
* P < 0.05, ** P < 0.01 and *** P < 0.001 compared to
controls. Results are expressed per mg protein (A) and 
per whole liver (B).
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Figure 8.14
The Effect of Oral Administration of Citral to Wistar 
albino Rats Upon A) Peroxisomal Catalase and B) 
Peroxisomal Uric Oxidase Activities.
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The figures presented are the mean ± SEM with 5 animals 
per group. Citral was administered by daily oral gastric 
intubation at 0.096 (©), 0.48(A) and 2.4 ( A) g/kg body
weight. Controls ( O ) received cornoil alone. * P < 0.05 
and ** P < 0.01 compared to controls.
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Figure 8.15
The Fttect of Oral Administration of Citral to Wistar 
albino Rats Upon Mitochondrial ex — Glycerophosphate 
Dehydrogenase Activity.
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The figures presented are the mean ± SEM with 5 animals
per group. Citral was administered by daily oral gastric
intubation at 0.096 ( # ), 0.4 8( A ) and 2.4 ( a ) g/kg body 
weight. Controls ( O ) received cornoil alone.
* P<0.05, ** P<0.0] and *** P <0.001. The results are
expressed per my protein (A) and per whole liver (B).
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indicated an increase in the number of mitochondria. 
However, the enzyme activity was not increased following 
administration of citral. In fact, the activity was 
decreased compared to controls following 28 days of 
citral administration (figure 8.16).
8.3.5 Plasma/Serum Biochemistry
Citral administration had no effect upon plasma 
triglycerides at any dose level. There was great 
variation in the results, and these gave high standard 
errors with consequently non-significant changes (table 
8.5). Similarly citral administration generally had no 
effect on plasma cholesterol although at the top dose 
level, after 3 days of citral administration, there was a 
significant decrease in total plasma cholesterol levels. 
This fall was transient and was not seen in the lower 
dose groups (table 8.6).
The total plasma protein and albumin concentrations 
were generally little affected by treatment (figure 8.17a 
and b), but Immunoelectrophoresis of serum proteins from 
control rats and animals from the top dose group (2.4 
g/kg body weight) did reveal changes in some components 
(figure 8.18). A tentative identification of some of the 
peaks was possible with reference to Emmett et al. , 
(1984) and Hinton et al., (1985) and the observations are 
summarized in table 8.7. From this table, it can be seen 
that Gc globulin ( ^ 1.8) showed a transient increase, 
being maximally increased after 7 days (figure 8.19). In
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Figure 8.16
The Fffect of Oral Administration of Citral to Wistar 
albino Rats Upon Mitochondrial Succinate Dehydrogenase 
Act ivi ty.
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The figures presented are the mean ± SEM with 5 animals 
per group. Citral was administered by daily oral gastric 
intubation at Ü . 096 { a ) , 0. 8 ( A ) and 2.4 ( A ) g/kg body 
weight. Controls ( O ) received cornoil alone.
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Table 8.5
Plasma Triglyceride Concentrations in Control and Citral- 
Treated Male Wistar albino rats.
Day
Dose (g Citral/lOOg body weight/day)
0(controls) 0.096 0.48 2.4
10
28
135.4 ± 43.9
154.5 ± 17.8
123.2 ± 28.3
158.8 ± 17.1
121.7 ± 30.3
7.5 ± 25.3
76.6 ± 19.4
74.9 ± 18.7
114.0 ± 18.6
141.0 1 6.3
146.1 ± 35.
147.0 ± 22.6
127.5 ± 17.0
94.4 ± 12.7
131.9 ± 27.7
126.8 ± 26.3
155.0 ± 57.9
160.4 ± 17.8
147.8 ± 2.3
155.3 ± 25.3
The figures presented are the mean ± SEM with five 
animals per group.
Units - mg triglycerides/100ml plasma.
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Table 8.6
Total Plasma Cholesterol in Male Wistar albino Rats 
Following Oral Administration of Citral.
Day
Dose (g Citral/lOOg body we ight/day
0(controls) 0.096 0.48 2.4
1 59.6 ± 10.2 55.0 ± 1.0 52.3 ± 6.1 52.9 ± 3.4 
* *
3 72.5 ± 3.6 66.1 ± 6.3 71.7 ± 15.8 51.1 4.3
7 68.7 ± 7.3 62.1 ± 2.7 64.0 ± 2.9 65.3 ± 5.2
10 67.3 ± 8.9 70.6 ± 5.2 6 6.0 ± 2.5 62.4 ± 1.4
28 69.3 ± 4.1 56.3 ± 5.8 65.7 ± 2.3 60.7 ± 3.8
Figures presented are the mean ± SEM with five 
animals per group.
Units - mg cholesterol/100ml plasma.
** P < 0.01.
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Figure 8.17
The Eftect of Oral Administration of Citral to Wistar
albino Rats Upon A) Total Plasma Protein and B) Plasma
Albumin Concentrations.
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The figures presented are the mean ± SEM with 5 animals 
per group. Citral was administered by daily oral gastric 
intubation at Ü.Ü96 ( # ), Ü.4 ( a ) and 2.4 ( a' ) g/kg
body weight. Controls ( O ) received cornoil alone. 
* * P<Ü.Ü1 compared to controls.
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Figure 8.18
Serum Protein Crossed Immunoelectrophoresis
/
11
10
The pattern obtained after crossed immunoelectrophoresis 
of control Wistar albino rat serum against anti (rat) 
serum in a gel containing 1% agarose and O.OSp barbitone, 
pH 8.6. Electrophoresis in the first dimension was with 
Ijjl of rat serum with a bromophenol blue external marker. 
Electrophoresis at 22 v/cm, continued until the 
bromophenol blue reached the edge of the plate. 
Electrophoresis in the second dimension was for IBh at 5 
v/cm against a gel containing 5% anti (rat) serum. Refer 
to table 8.7 for the identification of the individual 
proteins.
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Table 8.7
Summary of Changes in Serum Proteins in Rats Treated with 2.4g/kg citral.
Protein Time (Days)
A B C 1 3 7 10 28
1 Albumin Albumin 98.6 85.2 99.8 8 6 . 2 99.9
2 Of 2-antitrypsin or 1.5 94.2 89.7 102.3 83.3 98.7
3 inter- -trypsin-inhibitor - 109.9 87.9 69.2 52.7 35.2
4 0( 2-antichymotrypsin or 1 . 2 76.7 120.5 120.5 76.7 38.4
5 Gc globulin 0(1,8 1 1 0 . 0 105.8 145.6 123.5 114.7
6 Fibronectin - 2 0 0 . 0 66.7 173.3 1 2 2 . 2 80.0
7 Hemopexin 0(2,5 63.3 90.4 114.5 139.0 99.5
8 Transferrin - 6 8 . 0 50.1 87.0 70.2 80.2
9 C3 component - 50.0 69.4 156.0 97.2 1 0 0 . 0
10 IgG - 66.7 69.8 12.7 14.3 38.0
11 Haptoglobin £^2.4 88.4 73.5 88.4 1 1 0 . 0 97.3
12 — or 1.3 65.5 57.0 48.9 34.9 34.9
B -
C -
Protein identification as on figure 8.18 
Immunoelectrophoresis.
Protein identification from Emmett et al. ^ ( 1984) 
Protein identification from Hinton et al., (1985)
serum protein crossed
The concentrations for the individual proteins were estimated from the area 
under the curve from the rockets with one control and one test per time point and 
compared to albumin with figures presented as a percentage of the control.
Figure 8.19
The Effect of Oral Administration of Citral to Wistar
albino Rats Upon Specific Serum Proteins.
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One electrophoresis gel was run per time point with 
citral administered at 2.4 g/kg body weight. A
corresponding control was run at each time point. 
Results are expressed as percentage of control area under 
the curve for inter- (X -trypsin inhibitor (protein 3 on 
figure 8.18) ( A  ), Gc Globulin ( (Y 1.8 or protein 5)
( A ), transferrin (protein 8) ( □ ) and or 1.3 (protein 12)
( ■ ) .
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contrast, inter-cf-trypsin inhibitor and the glycoprotein 
( 1 .3 ) (figure 8.19) showed a progressive fall with
duration of treatment while IgG was consistently markedly 
depressed, most severely on days 7 and 10 of treatment; 
transferrin was also consistently depressed, but to a 
lesser degree. Hemopexin and C3 component were initially 
depressed in treated animals, but showed a rebound 
recovery "overshooting" on day 7 and 10 of treatment. In 
contrast, ^j-antichymotrypsin was markely lowered at the 
end of the exposure period.
8.3.6 [^H] Thymidine Incorporation into DNA
The results of the [^ H] thymidine incorporation 
study are summarized in table 8 .8 . Citral significantly 
reduced the final body weight after 3 days of citral 
administration; in addition, there was hepatomegaly with 
an increase in the total hepatic DNA. [^ H] thymidine 
incorporation into DNA was increased significantly 1 day 
after the start of citral administration, but the amount 
of radioactive label had fallen to below control levels 
after 3 days of citral administration.
Discussion
Interpretation of the results obtained in the top 
dose group (2.4 g/kg body weight/day) is complicated by 
the marked reduction in food intake over the first few 
days of the study relative to the other groups. It was 
concluded from Chapter 7 that the reduced body weight
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gain was a consequence of a toxic effect of the citral at 
this dose level as subsequently, the animals’ food intake 
was similar to controls on a body weight basis with food 
conversion being unaffected.
The transient fall in hepatic glycogen and
accummulation of lipid occurred most markedly during the 
period of reduced food intake. However, such hepatic 
changes only occur at dose levels which are associated 
with hepatomegaly (Grasso, 1985) and this suggests that 
the early changes in the top dose level were a
consequence of citral administration, followed by 
adaptation. Such transient changes are also seen with 
hypolipidaemic compounds and plasticizers (Price, 1985). 
This interpretation is supported by the transient, but 
non-significant, decrease in glucose-6-phosphatase 
activity and by the other results discussed below. Thus 
the glycogen depletion and lipid accumulation appear to 
be most probably a direct consequence of citral 
administration at high dose levels; similar changes have 
been reported for several hypolipidaemic compounds
(Barnard et al., 1980; Price et al., 1982; Price et al., 
1984, Mann et al., 1985).
A similar dose-related hepatomegaly to that caused 
by citral has been reported for many hypolipidaemic
compounds and other inducers of the microsomal mixed 
function oxidases as discussed in Chapter 7. The 
mechanism of hepatomegaly appeared to be early
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hyperplasia followed by hypertrophy. This mechanism may 
be inferred from the increased - thymidine
incorporation into DNA after 24 hours and the early 
mitotic burst seen in the top dose group. The specific 
hepatic DNA content was not increased, which is 
indicative of hypertrophy, with a population of normal 
cells and this is supported by histological observations 
which revealed only a transient increase in mitotic 
figures and no increase in polynucleated cells. The 
absence of necrosis during the first week of citral 
administration indicated that the wave of DNA replication 
and mitosis did not represent reparative hyperplasia, and 
thus the mitogenic effect was a primary effect of citral. 
Such a change has also been reported with Wy-14,643 
(Reddy et al., 1979). These observations are not unique 
since phénobarbital and other microsomal enzyme, inducers 
have also been shown to produce a wave of 
thymidine uptake prior to a wave of mitosis (Schulte - 
Hermann, 1974). Thus, peroxisome proliferators may 
produce liver enlargement in the same way as the 
microsomal - enzyme inducers.
Proliferation of peroxisomes and mitochondria was 
evident from both electron microscopy and enzyme markers. 
Such mitochondrial changes have been reported for a 
number of hypolipidaemic compounds (Hess et al., 1965; 
Kurup et al., 1970; Shindo et al., 1978; Osumi and 
Hashimoto, 1979a; Kristans et al., 1980). The sustained 
p-oxidation in the peroxisomes suggests that the
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mitochondrial p-oxidation is also sustained at a 
saturated level since it has been suggested that 
peroxisomal p-oxidation only becomes induced once the 
mitochondrial system is saturated (Berge, 1985).
Taken overall, the effects of high doses of citral 
appeared to follow the following course:
In the initial phase, citral may have competed with 
endogenous lipids for the mitochondrial p-oxidation 
pathway leading to impaired catabolism and the observed 
lipid accumulation. As an adaptive response, both 
p-oxidation and oo and ^  -1 oxidation of lipids were 
stimulated as indicated by the proliferation of 
peroxisomes and mitochondria with induction of cytochrome 
P-452, confirmed by enzyme assays and SDS gel 
electrophoresis. It should be noted that Hasumura e^ 
al. , ( 1983) showed that starvation induced -oxidation
of lauric acid. However, as discussed above, after 4 
days, food intake was essentially normal with persistent, 
all be it lower, induction of the -oxidation. This 
suggests that it was an effect of the citral and not 
initial reduction in food intake.
The increased capacity for lipid oxidation led to a 
resolution of the initial lipid accumulation. In later 
stages, cytochrome P-452 mediated oo and (&) -1 oxidation 
activity was reduced while cytochrome P-450 and 
p-oxidation were sustained at high levels, indicating
278
that, at this stage cytochrome P-450 was playing a more 
significant role in the metabolism of citral but that 
p-oxidation was also involved.
In support of this hypothesis, it is known that 
citral undergoes W  -oxidation (Kuhn and Livada, 1933; 
Licht and Coscia, 1978) and is ultimately oxidised to the 
dicarboxylic acid, Hildebrandt acid. The sustained
increase in p-oxidation may be explained by the continued 
requirement for oxidation of the initial metabolite of 
6D-oxidation to a dicarboxylic acid. This is in
agreement with the observations of Pettersen (1972) who 
reported the occurrence of urinary medium - and short - 
chain dicarboxylic acids following administration of 
hexadecanoic acid to normal and ketotic rats; More
recently, Vameque et al., (1985) demonstrated the 
existence in peroxisomes of some key enzymes involved in 
the catabolism of dicarboxylic acids.
Citral showed no significant hypolipidaemic
activity, despite the fact that the early histological 
and metabolic changes and SDS electrophoretic profiles 
showed many similarities to hypolipidaemic agents. This 
suggests that hypolipidaemic agents may have a more 
sustained effect on lipid metabolism, not compensated 
completely by peroxisome proliferation, increased 
mitochondrial p-oxidation or induction of cytochrome 
P-452 whereas with citral, the compensation is more 
complete.
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The results indicate that citral and hypolipidaemic 
agents may have a common mechanism in causing peroxisome 
proliferation and indeed, such a substrate theory was 
suggested by Reddy and Lalwani (1983). Berge (1985) 
suggested that induction of peroxisomal p-oxidation and 
palmitoyl-CoA hydrolase occurred via a common
induction mechanism regulated by an increased cellular 
level of long-chain acyl CoA. Such long-chain fatty 
acids undergo ^  -oxidation, form a mono-CoA ester and 
subsequently undergo partial p-oxidation and déacylation 
to medium chain dicarboxylic acids (Sherratt, 1985); this 
indicates an indirect mechanism of peroxisome
proliferation and induction of Co) - and 3 - oxidation.
Also worthy of note is that citral generally caused 
the induction/proliferation of "coreless" peroxisomes, 
deficient in uric oxidase. This was also evident from 
the lack of change in the uric oxidase activity following 
citral administration. Citral is like other peroxisome - 
proliferating compounds in this respect (Hess et al. ,
1965; Hruban et al., 1966; Svoboda et al., 1967; Mann et 
al., 1985). Recently however, proliferation of "cored"
peroxisomes has been reported with cholestyramine and 
nicotinic acid (Bakke and Berge, 1984). Generally,
periportal areas of the liver contained a greater
proportion of "cored" peroxisomes than centrilobular
areas, suggesting that the oxidase activity is related to 
the oxygen gradient across the hepatic lobules.
Induction of coreless peroxisomes suggests that the level
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of uric acid will be greater in these peroxisomes. It 
has been suggested that uric acid has antioxidant 
properties with consequential implications for protection 
against oxygen radical damage. This is discussed in more 
detail with regard to peroxisome proliferation and 
carcinogenesis.
Citral appears to belong to a novel group showing 
both microsomal enzyme induction and peroxisome 
proliferation. It is unknown whether citral is unique or 
whether other compounds react similarly.
A consequence of induction of the mixed - function 
oxidase system is depletion of vitamin A. This was 
evident after 28 days of citral administration at the top 
dose level. This agrees with Tuchweber et al.-, ( 1976)
and Leo et al., ( 1984). In turn, vitamin A deficiency 
has been reported to reduce the glutathione content of 
the liver and lung; in addition, glutathione - S - 
transferases are decreased (Dogra et al., 1982) in the 
lung, but increased in the liver (Siddik et al., 1980; 
Dogra et al., 1982). Chhabra et al., (1977) reported no 
increase in hepatic glutathione - S - transferase in 
vitamin A deficiency in rabbits or guinea pigs. 
Experimentally, vitamin A deficiency has been shown to 
result in lysosomal lesions in the liver of man (Leo e^ 
al. , 1983). During this study, lysosomal p-galactosidase 
activity was not affected suggesting that citral had no 
effect upon lysosomes after administration for up to 28
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days at a top dose of 2,4 g/kg body weight.
Peroxisome proliferating compounds are associated 
with tumour production in rodents (reviewed by Cohen and 
Grasso, 1981; Reddy and Lalwani, 1983). These compounds 
have been shown not to react with DNA directly (Blane and 
Pinaroli, 1980; von Danikan et al., 1981, 1984; Kornbrust 
et al., 1984; Goel et al., 1984) so separating them from 
classical carcinogens. Cohen and Grasso (1981)
classified rodent hepatocarcinogens according to their 
patterns of response, grouping microsomal - enzyme 
inducers and peroxisome proliferators together.
The mechanism of carcinogenicity of peroxisome 
proliferators is unclear. A free radical mechanism has 
been suggested by Reddy et al., (1980) and Reddy and 
Lalwani (1983) with H 2 O2 producing radical damage. This 
mechanism has been supported experimentally (Fahl et al.,
1984). The theory revolves around the disproportionate 
induction of H2 O2 - producing p-oxidation and the H 2 O2 - 
destroying catalase activity. Indeed, the results 
presented here show an inverse dose-relationship with 
catalase induction and a dose-dependent increase in 
p-oxidation. Thus, free radical damage is thought to 
result from inadequate catalase activity. However, there 
are several points that suggest that this hypothesis is 
incorrect or at least, incomplete. Firstly, catalase is 
not very effective at dealing with low H 2 O2 
concentrations or oxygen toxicity (Halliwell, 1978).
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This is due to the high Km of catalase; however, at high 
H 2 O2 concentrations, catalase is very effective at 
destroying H2 O2 . This suggests that catalase and H 2 O2 - 
producing pathways need not be induced in proportion. 
Secondly, the cell has the glutathione system to act as a 
radical scavenger. Indeed, recently, glutathione
peroxidase, the second line of defence after catalase 
(Aebi and Suter, 197 4 ) fwas shown to be increased by 30% 
following administration of 4-chloro-2-methylphenoxy- 
acetic acid to rats for 14 days (Hietanen et al., 1985) 
although peroxisomal p-oxidation was only induced 
2-fold. However, Reddy (1985) reported that glutathione 
peroxidase was generally inhibited by peroxisome 
proliferators. In addition, the cell has natural 
antioxidants, vitamin E and carotenes being the best 
documented. Recently, vitamin K has been shown to 
possess antioxidant properties (Canfield et al., 1985). 
Finally, proliferation of "coreless" peroxisomes may be 
very significant in this respect. These peroxisomes lack 
uric oxidase and will thus not lead to depletion of uric 
acid which has been suggested as playing a role in 
protecting the cell from radical damage (Ames et al., 
1981 and 1983). Thus, such proliferation of these 
peroxisomes may act as a natural defence against H 2 O2 
production. It is unlikely that citral acts as a 
carcinogen by this mechanism due to the relatively low 
degree of induction of the H 2 O2 producing p-oxidation 
system; also, after 28 days of citral administration, 
there was no histological evidence for lipofuscin or
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diastase-resistant granules indicative of radical species 
being present.
A second mechanism of carcinogenesis is persistent 
or transient hyperplasia (Grasso, 1985). It has been 
suggested that other non-hypolipidaemics which cause 
hyperplasia may potentiate carcinogens (BHT for example, 
Peraino et al., 1977; Würtzen et al., 1985). This 
mechanism only suggests that citral may potentiate 
carcinogens without being a complete carcinogen itself. 
Such promotion by citral has been reported with benzo [a] 
pyrene in vitro (Crocker and Sanders, 1970).
Although the total plasma protein concentration was 
not significantly altered following administration of 
citral, crossed Immunoelectrophoresis did show that 
specific proteins were changed. These changes were 
distinct from those which occur during the acute-phase 
response to inflammatory agents; two results suggest 
this, firstly no inflammatory changes were seen 
histologically and secondly, the haptoglobin 
concentration did not change and this is a sensitive 
indicator of acute-phase reactions in rats (Baumann et 
al. , 1983). This latter finding supports the results of 
Carmichael (1985). A similar result has recently been 
reported with hypolipidaemic drugs and the plasticizer 
di(2-ethylhexyl) phthalate (Hinton et al., 1985). It was 
also suggested that the fall in the two proteins ^  1.2 
and ^ 1.3 represented a generalized moderate-injury
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response. An increase in c^i.s was also reported with 
fenofibrate, clofibrate and dialkyl phthalates in rats 
(Hinton et al., 1985). Since all these compounds cause 
proliferation of peroxisomes and transient early 
hyperplasia following short-term administration to rats, 
^  1.8 may be associated with the hepatic changes.
Protein ^ 1 . 5  did not show any decrease with time, 
and it has been suggested that depression of this protein 
is a characteristic of hypolipidaemic compounds (Hinton, 
1985); this may be further evidence for citral not being 
a hypolipidaemic compound, although it should be noted 
that Wistar rats are poor responders to hypolipidaemic 
agents (Sirtori et al., 1980) and this may account for 
the lack in hypolipidaemic effect with citral.
Overall, there are significant differences between 
citral and the hypolipidaemics which have been reported 
to increase tumour incidence. However, no long term 
studies have been carried out on citral and these are 
needed to resolve whether peroxisome proliferators in 
general cause tumours and this may help elucidate the 
mechanism of tumour production.
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Section IV
General Discussion
In the foregoing chapters it was demonstrated that a 
number of the early changes caused by administration of 
citral to rats at high oral dose levels were similar to 
those reported for a number of hypolipidaemic drugs i.e. 
peroxisomal and smooth endoplasmic reticulum 
proliferation, fatty changes in the liver and 
hepatomegaly. Proliferation of peroxisomes has been 
correlated with hypolipidaemic activity (Cohen and 
Grasso, 1981) and plausible causal mechanisms involving 
increased levels of p-oxidation in peroxisomes may be put 
forward. However, citral did not exhibit any detectable 
hypolipidaemic activity; such activity is not always 
accompanied by proliferation of peroxisomes since a 
number of hypolipidaemic drugs appear not to cause 
proliferation of peroxisomes in man (Schwandt et al. , 
1978; Hanefeld et al., 1980 ; Bliimcke et al., 1983). This 
casts doubt on the hypothesis that increased peroxisomal 
enzyme activity is an obligatory requirement for 
hypolipidaemic activity.
While it was pointed out (Chapter 8) that Wistar 
rats are poor responders to hypolipidaemic drugs, the 
poor reproducibility of the assays for blood cholesterol 
and triglycerides may have masked any response to 
citral. Other work (Harrison, 1984) has demonstrated 
that the hypolipidaemic activity of clofibrate could be 
dissociated from peroxisomal proliferation. In addition, 
the increase in peroxisomal p-oxidation activity 
associated with hypolipidaemic agents is not invariably
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accompanied by hepatomegaly and peroxisome proliferation 
(Lazarow et al., 1982). Thus, peroxisome proliferation, 
peroxisomal p-oxidation, hepatomegaly and hypolipidaemic 
activity appear not to be simply, causally related.
The observation that citral did not cause 
hypolipaemia, while supporting these conclusions, is not 
definitive since the peroxisomal proliferation was not 
sustained and, as indicated earlier, there were marked 
variations in blood cholesterol and triglyceride levels 
which would mask any small and transient changes.
Some hypocholesterolaemic drugs, such as probucol 
and cynarin, are believed to exert their effect by a 
choleretic mechanism leading to increased faecal 
excretion of bile acids and reduced synthesis and 
absorption of cholesterol (Miettinen, 1972; Kritchevsky, 
1980). However, the mechanism of action of blood - 
triglyceride - lowering agents remains unclear. Masters 
and Holmes (1977) concluded that these compounds exerted 
a multivalent effect on intermediary metabolism.
The involvement of peroxisomal enzymes in some 
pathways of lipid metabolism and their increased activity 
following treatment with some hypolipidaemic drugs raises 
questions concerning their normal function and adaptive 
capacity. Peroxisomes contain only some of the enzymes 
involved in different pathways of lipid metabolism, for 
example, glycerolipid and glycerol-ether biosynthesis,.
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Thus, peroxisomes may act as regulators of lipid
metabolism via enzyme compartmentation. The peroxisomal 
P“Oxidation system may have a number of functions, chain 
shortening (and subsequent transport to mitochondria), 
heat production, production of acetyl groups for export to 
mitochondria or for biosynthetic purposes in the cytosol, 
or the pathway may modify fatty acids for use in 
glycerolipid and glycerol-ether lipid biosynthesis
(Alexson, 1985).
Since citral did not show any hypolipidaemic
activity, it is clearly different from many other 
peroxisome proliferators in rodents. Work with isolated 
peroxisomes and peroxisomal enzyme activities may help to 
elucidate the mechanisms of these differences. This will 
be particularly relevant with regard to the mechanism of 
action of hypolipidaemic compounds and the role of 
induction of peroxisomal p-oxidation.
The effect of citral upon the mixed function oxidase 
system and more precisely, the isoenzymes of cytochrome 
P-450 may help elucidate the role of ûû -oxidation and 
cytochrome P-452 in the mechanism of peroxisome 
proliferation by increased substrate load for p-oxidation 
(see Chapter 8). Since citral induces GaJ> and Q) -1 
oxidation and cytochrome P-452, it would suggest that 
these have no role in hypolipidaemia; however, the 
significance of induction of ou and Od -1 oxidation and 
cytochrome P-452 by hypolipidaemic compounds is unknown.
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Long-term studies examining the effect of prolonged 
exposure of citral upon cytochrome P-450 and its
isoenzymes may help elucidate the role of individual 
isoenzymes in the metabolism of citral and other 
peroxisome proliferating compounds. In addition, as 
discussed in Chapter 8 , such long-term administration of 
citral to rats would help elucidate the mechanism of 
carcinogenicity caused by some hepatic peroxisome 
proliferators. This may also clarify whether sustained 
proliferation of peroxisomes is a requirement for
hepatocarcinogenicity or whether it is caused by the 
sustained hepatomegaly also associated with peroxisome 
proliferating compounds.
It was originally proposed that the effects of 
hypolipidaemic compounds may be mediated via thyroxine 
(Thorp and Waring, 1962). Although this has been
disproved, hypolipidaemic compounds have been shown to 
depress serum thyroxine (Price et al., 1984; Price,
1985). Thus peroxisome proliferation may be dependent 
upon thyroid status. Since citral caused peroxisome 
prolif elation, it would be interesting to gauge the effects 
of citral upon the thyroid and the thyroid hormones.
Preliminary results (not presented in this thesis) showed 
that at the top dose level of citral used (2.4 g/kg body 
weight), the total serum thyroxine (T4 ) was reduced to 
approximately 60% of the control values at any one time 
point. However, these are only very early results and 
further work is needed. Thus, it may be possible to
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correlate changes in the thyroid with peroxisome 
proliferation and/or lipid metabolism.
Thyroxine status is also dependent upon vitamin A 
status and this may suggest an indirect effect of citral 
upon the thyroid gland. Sustained vitamin A deficiency 
increased the circulating thyroxine level (Garcin and 
Higueret, 1983); conversely, hypervitaminosis A decreased 
the thyroxine concentration (Garcin et al., 1984). 
Experimentally, citral depleted vitamin A (see Chapters 5 
and 8), but as mentioned above, citral depleted serum 
thyroxine, therefore the effects of citral upon the 
thyroxine concentration would appear not to be mediated by 
vitamin A depletion. Thus, citral may have a direct 
effect upon the synthesis of thyroxine or displace it from 
protein binding and so increase the rate of turnover of 
the hormone.
The increased levels of (3- and (e> -oxidation caused by 
citral (Chapter 8) may increase the metabolism of other 
compounds mediated by these pathways. Park and Leek
(1982) demonstrated p- and CsO - oxidation of vitamin K; 
thus induction of these pathways by citral and other 
peroxisome proliferating compounds may result in 
depression of vitamin K levels. This, in turn, may result 
in depletion of the four vitamin K- dependent clotting 
factors with prolonged blood clotting times. This
indirect mechanism may explain the erratic prolongation of 
thrombotest clotting times seen with citral administration
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to Long Evans hooded rats (Chapters 3, 4 and 5). This
strain of rat may have been particulary susceptible to 
vitamin K- deficiency since they were of Charles River 
origin and Mellette and Leone (1960) reported that CD rats 
also from Charles River were especially susceptible to 
vitamin K- deficiency. No such changes were detected in 
man following administration of clofibrate and three
related hypolipidaemic compounds (Beaumont et al., 1974). 
However, this does not preclude rodents from such an 
effect.
Recently, vitamin K has been reported to possess
antioxidant properties similar to vitamin E (Canfield e_t 
al., 1985). Vitamin E deficiency has been shown to cause 
proliferation of peroxisomes (Dabholkar, 1981; Reddy ejb 
al. , 1981) and it is possible that vitamin K deficiency
causes a similar change. However, the prolongations of 
thrombotest clotting time would be expected to be greater 
than those found experimentally if vitamin K deficiency
occurred in this instance.
Although citral caused proliferation of peroxisomes, 
it showed no detectable hypolipidaemic effect. In this 
respect, citral may be important in the elucidation of the 
mechanism of hypolipidaemia and the role of peroxisomes in 
normal and adaptive conditions.
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Appendix
Appendix 1
Serum Protein Crossed Immunoelectrophoresis.
Barbitone/Acetate Buffer (O.lp ionic strength).
4.52g diethylbarbituric acid (Barbitone) in a 2L flask. 
Add 1.5L of distilled water; stir and heat until it is 
dissolved and then cool. Add 35.5g of sodium diethyl 
barbiturate (barbitone sodium) and 26.Og of sodium 
acetate. Stir until dissolved and make the volume up to 
4.0L. Adjust the pH with sodium hydroxide or acetic 
acid.
Tank Buffer (0.56 jj ionic strength).
Dilute 3.0L of the barbitone/acetate buffer with 2.0L 
distilled water. Mix and add 2.5L to each side of the 
tank.
Agarose
Dissolve Ig agarose in 50ml of distilled water/50ml of 
O.lp barbitone/acetate buffer by heating. Store in 10ml 
aliquots in glass boiling tubes until required.
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Appendix 2
Serum Protein Crossed Immunoelectorophresis 
Stain and Destain.
Stain.
450ml 96% (v/v) ethanol 
450ml Distilled water 
100ml Acetic acid
5g Coomassie Brilliant Blue R.
Destain.
450ml 96% (v/v) ethanol
450ml Distilled water
100ml Acetic acid.
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